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Abstract 
The University of Manchster, Ling-I Su 
PhD in Biochemistry 
Thesis title: The effects of disease mutations on the transcription factor Interferon 
Regulatory Factor 6 
June 2011 
 
Van der Woude syndrome (VWS) and popliteal pterygium syndrome (PPS) are 
autosomal dominant disorders characterized by combinations of cleft lip and cleft palate 
(CLP), lip pits, skin-folds, syndactyly and oral adhesions. VWS and PPS are caused by 
mutations in the transcription factor Interferon regulatory factor 6 (IRF6). IRF6 belongs 
to a family of transcription factors that share a highly conserved DNA-binding domain 
(DBD) and a less conserved protein-binding domain. Mutation analysis reveals a general 
genotype-phenotype correlation between the distribution of mutations and the 
manifestation of either VWS or PPS. However, the molecular mechanisms by which 
these mutations affect IRF6 function are still unknown. Therefore the aim of this project 
was to characterize the molecular function and regulation of IRF6 and subsequently 
determine the effects of VWS and PPS mutations on IRF6 function. DNA binding site-
selection showed that the IRF6-DBD exhibited optimal binding site selectivity for the 
consensus sequence AACCGAAAC
C
/T. This sequence was used to investigate the effects 
of VWS and PPS mutations in the DBD. Almost all mutations abrogated DNA-binding. 
It was subsequently demonstrated that a VP16AD-IRF6-DBD fusion protein was able to 
activate transcription from a promoter containing the derived binding site. However, 
wildtype IRF6 was shown to be autoinhibited and compartmentalized in the cytoplasm. 
To determine what signals are involved in the nuclear translocation of IRF6, internal 
signals that facilitate nucleocytoplasmic trafficking were mapped. The cytoplasmic 
localization of IRF6 suggested that the identified nuclear export signal (NES) 
159
IQDTFPFLNI
168 
is constitutively active and dominant over the nuclear localization 
signal 
5
PRRVRLK
11
. Disruption of the NES leads to nuclear retention; however nuclear 
localization alone is insufficient for functional activation of IRF6. Therefore, the role of 
phosphorylation in the regulation of IRF6 was assessed. Five novel phosphorylation sites 
were identified in IRF6 at residues S47, S131, S153, S424 and T425. Phosphorylation at 
S424/S425 was necessary for combinatorial phosphorylation at the serine/threonine rich 
region to induce nuclear retention, whereas, phosphorylation in the DBD at S47 
abrogates DNA-binding. The understanding of IRF6 molecular function and mechanisms 
of regulation provides further insight into the pathways involved in the pathogenesis of 
VWS and PPS.  
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Chapter 1 
Introduction 
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1. Introduction 
Craniofacial malformations account for three quarters of all congenital birth defects in 
humans (Chai and Maxson, 2006). The prevalence of orofacial clefting (OFC) is 
approximately 1 in 700 live births (Kerrigan et al., 2000). In addition, the risk of 
developing cleft lip (CL), cleft palate (CP) and cleft lip and/or palate (CL/P) in stillbirths 
is three times more frequent compared to live births (Vanderas, 1987). OFC is also 
associated with an increased risk of mortality at all ages (Christensen et al., 2004), and 
the morbidity can be long-term for affected individuals and their families. Management 
of OFC can involve surgical approaches that include plastic surgery, anesthesiology and 
otolaryngology. Corrective surgery can be performed for the closure of CL and CP as 
well as secondary deformities. They are complex surgical procedures that may require 
multiple rounds over an extended period of time. These include preliminary lip and 
palate closure within the first year (Meijer, 1968), secondary correction of the lip and 
nose at age 4 and orthodontic treatment at age 12 (Muir, 1974). Children with CL/P have 
shown significant differences in cognition, communication, speech and hearing 
compared to children without CL/P, which can have an impact on their intellectual 
function (Richman and Eliason, 1982; Jocelyn et al., 1996). Individuals with CL/P have 
an elevated risk of psychological problems and difficulties with social interaction, and 
are more likely to suffer from low self-esteem, anxiety and depression (Bernstein and 
Kapp, 1981; Turner et al., 1998).  These problems may require nonsurgical approaches 
to manage, such as pediatrics, speech therapy and psychotherapy (Meijer, 1968).  
OFC is a major congenital abnormality that involves both genetic and 
environmental factors (Schutte and Murray, 1999). Extensive studies in developmental 
biology have contributed to our understanding of the genetic basis of craniofacial 
morphogenesis (Murray, 2002). Craniofacial abnormalities have been associated with 
mutations in numerous loci (Kerrigan et al., 2000). More than 400 genes have been 
associated with CL/P (Lidral and Murray, 2004). The most common form of syndromic 
orafacial clefting is Van der woude syndrome (VWS), which accounts for approximately 
2 percent of patients with CL/P. In addition, the phenotypic features of VWS are of 
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particular interest as they share high similarities with non-syndromic CL/P (Schutte and 
Murray, 1999). This makes VWS an ideal model for studying craniofacial development. 
Mutations in interferon regulatory factor 6 (IRF6) have been shown to underlie VWS and 
popliteal pterygium syndrome (PPS) (Kondo et al., 2002). Elucidation of the molecular 
function of IRF6 will provide better understanding of its role in palatogenesis. 
1.1. Normal development of the lip and palate 
The palate is formed from two primordia, the primary palate and the secondary palate. In 
the human embryo the face starts to develop in the fourth week of gestation (Stanier and 
Moore, 2004), and commences at embryonic day (E) 9.5 in mice (Dixon and Murray, 
2003). The neural crest cells that originate from the dorsal region of the anterior neural 
tube, called cranial neural crest cells (CNC), migrate and combine with mesoderm cells 
to form the facial primordia. The facial promordia is comprised of the frontonasal 
prominence, the paired maxillary processes and the paired mandibular processes that 
surround the primitive oral cavity. The frontonasal prominence is then separated by the 
nasal placode to form the paired medial nasal process and the lateral nasal processes (Fig 
1.1 A). The nasal placode subsequently develops into the nasal pit (Dixon and Murray, 
2003). The paired maxillary processes extend towards each other and towards the paired 
medial nasal processes. The paired maxillary processes then merge with the medial and 
lateral nasal processes to form the upper lip and the triangular primary palate (Fig 1.1 B) 
(Dixon and Murray, 2003; Stanier and Moore, 2004; Gritli-Linde, 2007).  
 The secondary palate makes up at least 90 percent of the palate and is composed 
of the hard and soft palate (Kerrigan et al., 2000). Development of the secondary palate 
involves the formation of the roof of the mouth and the nasal floor, which starts between 
the sixth and eighth week of gestation in humans (Lidral and Murray, 2004; Chai and 
Maxson, 2006) and stage E11.5 in mice (Dixon and Murray, 2003). The two palatal 
shelves from the maxillary processes initially grow bilaterally towards the oral cavity 
(Moxham, 2003). Palate shelf growth is attained by survival and proliferation of 
mesenchymal cells from neural crest (NC) cells and mesodermal cells of the
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Figure 1.1. Mouse facial development at embryonic day E10.5 and E12.5..5 and 
E12.5. (A to A”) Scanning electron microscopy and schematic representations of a 
murine head at embryonic day E10.5 showing medial nasal process and lateral nasal 
process separated by the nasal pit. The paired maximally process and mandibular 
process before fusion. (B to B”) Scanning electron microscopy and schematic 
representations of a murine head at embryonic day E12.5. The medial nasal process and 
lateral nasal process have fused. The paired maxillary process has fused to form the 
upper lip and primary palate. The paired mandibular processes have formed the lower 
jaw.  fnp, frontonasal prominence mnp, medial nasal process; lnp, lateral nasal process; 
mx, maxillary process; m, mandibular process; e, eye;. Adapted from (Dixon and 
Murray, 2003) and (Hovorakova et al., 2006).  
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first pharyngeal arch (Murray and Schutte, 2004). Meanwhile, the nasal septum grows 
down from the roof of the stomodeum dividing the nasal part of the oronasal cavity and 
the developing tongue fills the oral part of the oronasal cavity (Moxham, 2003). The 
palatal shelves then elevate to a horizontal position above the developing tongue. The 
directional change in the palate shelf growth is proposed to be the result of intrinsic shelf 
elevation forces by hydration of the extracellular matrix (ECM) components, such as 
glycosaminoglycans (hyalronan), in the shelf mesenchyme (Ferguson, 1988a). Rapid 
remodeling of the ECM is essential for maintaining the appropriate structural shape of 
the shelf (Morris-Wiman and Brinkley, 1992).  Following elevation, the medial edge 
epithelia (MEE) of the opposing palate shelves contact each other via the interactions of 
cell adhesion molecules and desmosomes to form a  midline epithelial seam (MES) 
(Tudela et al., 2002). Palatal fusion follows, as the MES then rapidly degenerates 
through a combination of apoptosis, epithelial cell migration and epithelial-mesenchymal 
transformation to establish mesenchymal continuity and form the secondary palate 
(Griffith and Hay, 1992; Cuervo and Covarrubias, 2004). The palate shelves also fuse 
with the primary palate anteriorly to divide the oronasal cavity into the oral and nasal 
cavities. Concurrently, palatal shelf fusion behind the secondary nasal septum forms the 
soft palate and uvula (Moxham, 2003). Palatal shelf elevation and fusion occurs in an 
anterior to posterior sequence (Chai and Maxson, 2006). Palatogenesis is normally 
complete by week 12 of development in humans and stage E15.5 in mice (Taya et al., 
1999; Moxham, 2003).  
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Figure 1.2. Secondary palate development in mice. (A and B) At embryonic day (E) 
E13 to E13.5 the palatal shelves project down the sides of the tongue. The palatal shelf is 
divided into three sections, the medial and lateral aspects and the tooth germ. The red 
line indicates the division between the medial and lateral aspects. (C) By stage E14.0 the 
tongue descends and the palatal shelves enlarge and grow horizontally above the tongue 
and towards each other along the midline. (D) The palatal shelves contact each other to 
form the midline epithelial seam, as indicated by the arrow and separates the nasal 
epithelium and oral epithelium. Palatal fusion starts to occur at E14.5. (E and F) From 
E15.5 to E16.5, palatal fusion continues to form a continuous palate and separates the 
nasal cavity and oral cavity. P, palatal shelves; T, tongue; m, medial aspect; l, lateral 
aspect; t, tooth germ; n, nasal epithelium ; o, oral epithelium. Adapted from (Chai and 
Maxson, 2006) and (Dryden, 2008).   
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1.2. Orofacial clefting 
1.2.1. Cleft lip and cleft palate  
There are over 300 syndromes that have OFC as associated features. CL/P are common 
congenital anomalies with a prevalence of 1/300-1/2500 for CL/P and approximately 
1/1500 births for CP (Stanier and Moore, 2004). Incidences of CL/P vary according to 
geographical variation, ethnicity and socio-economic status.  Ranking of incidences of 
CL/P among different populations show the highest in Asians (2/1000 live 
births),intermediate in Europeans (1/1000 live births) and lowest in Africans (0.4/1000 
live births) (Fraser, 1970; Lowry and Trimble, 1977; Vanderas, 1987). The variations in 
the structure of OFC are diverse. Clefts can occur as partial or complete clefts and can be 
either unilateral or bilateral. Facial features that are affected include the lips, alveolus, 
primary palate, and the hard and soft palate of the secondary palate, as isolated or in 
different combinations (Fig 1.3). The aetiology and pathogenesis of OFC may help 
unravel the intricate genetic and environmental network involved in developmental 
processes of normal craniofacial development and palatogenesis.  
1.2.2. Syndromic forms of orofacial clefting 
OFC disorders can be categorized as syndromic and non-syndromic based on their 
inheritance patterns. Syndromic OFC disorders exhibit additional characteristic features 
outside the region of clefting and account for ~30% of cases (Murray, 1995). Syndromic 
clefts are a result from chromosomal abnormalities, Mendelian single gene defects, 
teratogenic effects or have an unknown etiology (Fraser, 1970). Single gene disorders 
arise as a result of mutations in a specific gene, also referred as unifactorial or 
monogenic diseases. Most single gene disorders display characteristic Mendelian 
patterns of inheritance. The inheritance patterns can be based on whether the gene trait is 
autosomal, mitochondrial or X-linked and dominant or recessive. Many single gene 
disorders affect both sexes equally. However, if the defective gene is located in the 
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Figure.1.3. Spectrum of orofacial clefting. (A) Schematic representation of the mouth. 
Variations of orafacial clefting (B) unilateral cleft lip, (C) bilateral cleft lip (D) 
unilateral cleft lip and primary palate (E) bilateral cleft lip and primary palate (F) 
unilateral cleft lip and palate (G) bilateral cleft lip and primary palate, (H) isolated cleft 
of secondary palate (I) isolated cleft of the soft palate and (J) submucous cleft of the soft 
palate. 
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X-chromosome, there is a higher penetrance in males (Kalter and Warkany, 1983). 
Cytogenetic studies, which encompasses the study of chromosome biology, has led to 
the detection of chromosomal abnormalities in congenital malformations (Brewer et al., 
1998). A cytogenetic study by Azumi et al.  demonstrated that approximately 5% of 110 
patients with CL/P had chromosomal aberrations or alterations, which was 5.2 times 
higher than newborn babies (Azumi et al., 1978). 
1.2.3. Non-syndromic forms of orofacial clefting 
Non-syndromic clefting disorders account for ~70% of CL/P cases in humans (Murray, 
1995). Non-syndromic clefting disorders are distinguished by clefts that occur in the 
absence of other physical and developmental abnormalities (Mitchell, 1997; Wilkie and 
Morriss-Kay, 2001).  Non-syndromic CL/P follows multifactorial inheritance, which can 
be based on the combination of innate tendencies (which include susceptibility) and 
external circumstances to determine the risk of disease development (Falconer, 1965). 
The complexity of CL/P is due to the intricate molecular events that underlie 
embryogenesis, as it is modulated by a complex genetic cascade and environmental 
factors. This consequently makes it difficult to determine the aetiology (Cobourne, 2004; 
Jugessur and Murray, 2005). Although the inheritance of non-syndromic clefting 
disorders do not follow the simple Mendelian laws, many of the non-syndromic 
associated features tend to aggregate within families (Mitchell, 1997). In addition, genes 
associated with syndromic cleft disorders may also contribute to non-syndromic cleft 
incidences (Stanier and Moore, 2004). Evidence of genetic factors that influence CL/P 
was observed by examining familial recurrence patterns in CL/P twins. The familial 
aggregation for monozygote twins had a concordance rate of CL/P of 25-40%, signifying 
a strong genetic influence. In contrast, the dizygotic twins had a concordance rate of  3-
6%  (Mitchell and Risch, 1992).  The lack of complete concordance in the monozygote 
twins further implicates the contribution of environmental agents in the aetiology. 
Genetic and environmental factors are significant components in the aetiology of many 
 - 24 - 
malformations, and are thought to act either independently or in combination in OFC 
(Fraser, 1970).   
1.2.4. Environmental factors 
Environmental factors that could adversely affect the frequency of CL/P have been 
categorized into at least three classes: teratogens, infectious agents and nutrients. 
Exposures to teratogens such as retinoic acid, phenytoin, valproic acid, thalidomide, 
alcohol and herbicides may perturb metabolic and enzymatic pathways in palate 
development (Murray, 2002; Murray and Schutte, 2004). Endogenous retinoic acid (RA) 
is essential in the fusion of palatal shelves as it arrests palatal mesenchyme cells at the 
G1/S checkpoint, while promoting apoptosis in a dose-dependent manner in the MEE 
(Yu et al., 2005). However, RA can interfere with various steps of palatogenesis when it 
acts as a teratogen. High levels of RA affect NC survival and migration, causing severe 
hypoplasia of the branchial arches and facial clefting. Increased levels of RA also inhibit 
the expression of sonic hedgehog (Shh) and its receptor patched that hinders growth of 
the frontonasal prominence and maxillary processes leading to bilateral clefting of the lip 
and primary palate in the chick embryo. Exposure to RA also prevents growth and 
elevation of the palatal shelves. Disruption of  RA signalling pathway by the deletion of 
RA receptor (RAR) genes or expression of dominant-negative RAR mutants lead to cleft 
palate in mice (Young et al., 2000; Hilliard et al., 2005; Yu et al., 2005) 
1.2.5. Genetic factors  
CL and CP are birth defects that are caused by disturbances at any stage of palatal shelf 
growth, elevation, fusion between paired shelves, and disappearance of the MES 
(Ferguson, 1988b; Carinci et al., 2007). An array of genes encode a variety of factors 
such as polarizing signalling molecules, growth factors, receptors, transcription factors, 
cell adhesion molecules and extracellular matrix components involved in the multiple 
stages of palate development (Lidral and Murray, 2004; Stanier and Moore, 2004; Gritli-
Linde, 2007).  
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1.2.5.1. Polarizing signalling molecules 
Shh is a member of the hedgehog gene family that is important in craniofacial 
development as Shh signalling modulates the pattering and growth of facial primordia 
(Jeong et al., 2004). During secondary palate development in mice, Shh is predominantly 
expressed in the prospective palatal rugae, which arises prior to elevation of the palatal 
shelves, and the posterior palate region that forms the soft palate  (Sasaki et al., 2007). 
Mutations in Shh have been identified in patients with holoprosencephaly, the 
craniofacial disorder involving the development of the forebrain and midface. Other 
associated features include tooth abnormalities and CL/P (Belloni et al., 1996). 
 Some members of the bone morphogenetic proteins (BMP) gene family that 
belong to the transforming growth factor β (TGF-β) 3 superfamily have been implicated 
in palatogenesis (Zhang et al., 2002; Nie et al., 2006). Expression patterns of Bmp2 and 
Bmp4 in chick facial primordia indicate that BMP2 and BMP4 signalling plays a role in 
epithelial-mesenchymal signalling and are involved in the outgrowth of the facial 
primordia (Francis-West et al., 1994). In mice, Bmp2 and Bmp4 expression is localized 
within the epithelia and the mesenchyme of the palatal shelf during and after palate 
fusion and are only found in the anterior palate and not in the posterior palate (Zhang et 
al., 2002). Analysis of the pathogenesis of cleft palate caused by the exposure of RA in 
mice showed a reduction in BMP2 and BMP4 and BMP5 messenger ribonucleic acid 
(mRNA) levels, compared to the wildtype (Lu et al., 2000). BMPs trigger signalling 
cascades by binding and recruiting two types of receptor serine/threonine kinases to the 
cell surface, type I and type II receptors. The type II receptor phosphorylates the type I 
receptors to trigger a cascade of phosphorylation events which induce the activation of 
transcriptional co-regulators that regulate multiple developmental processes (Jiang et al., 
2006). In the nestin cre transgenic mice study, the conditional inactivation of the type I 
Bmp receptor Bmpr1a in the facial primordial lead to the development of bilateral CL/P, 
caused by the failure of horizontal growth of palate shelves and palatal fusion (Liu et al., 
2005). Conditional inactivation was necessary for this study as null mutants are 
embryonic lethal (Juriloff and Harris, 2008). 
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1.2.5.2. Growth factors and their receptors  
TGF-β isoforms have an overlapping and spatial sequence of expression during murine 
embryonic palate development (Fitzpatrick et al., 1990). TGF-β 1, TGF-β 2 and TGF-β 
3 have been implicated in transdifferentiation of MEE cells to mesenchymal cells. 
Furthermore, TGF-β 1 may be involved in the regulation of mesenchymal cell 
proliferation and ECM production (Pelton et al., 1990). TGF-β 3 plays an important role 
in the adhesion and disappearance of the MEE for normal palatal shelf fusion to 
generate a confluent palatal mesenchymal structure. TGF-β 3 can function by 
modulating the expression of cell adhesion and ECM molecules (Proetzel et al., 1995) 
and inducing cell cycle arrest, cell migration, and apoptosis in a chronological manner 
(Ahmed et al., 2007).  Mutations in TGF-β 3 have been identified in individuals with 
non-syndromic cleft palates (Lidral et al., 1998). Deletion of the TGF-β 3 gene results 
in the alteration of paired box 9 (Pax9) and Shh expression, suggesting that they are 
downstream effectors of TGF-β 3 signalling involved in the regulation of normal palatal 
fusion (Sasaki et al., 2007).  
Epidermal growth factor (EGF) stimulates glycosaminoglycan production within 
the palatal mesenchyme and epithelia and stimulates ECM biosynthesis (Bitgood and 
McMahon, 1995). EGF has been implicated in mesenchymal cell migration during 
degeneration of the MES. Furthermore, epidermal growth factor receptor (EGFR) was 
detected in degenerating MEE, suggesting that EGFR-mediated signalling is involved in 
MES degeneration. EGFR-mediated signalling is partly regulated by its downstream 
target matrix metalloproteinases (MMPs). Egfr 
-/-
 mice exhibit facial mediolateral defects 
and high incidence of cleft palate. Palate shelves showed adhesion but incomplete fusion, 
as residual epithelium in the medline was found (Miettinen et al., 1999).      
Some members of the fibroblast growth factor (FGF) and fibroblast growth factor 
receptor (FGFR) family are expressed during craniofacial development and are involved 
in signalling pathways (Jugessur and Murray, 2005; Riley et al., 2007a). In the presence 
of heparan sulfate proteoglycans,  FGF and FGFR1, a transmembrane receptor tyrosine 
kinase, can form heteromeric complexes to transduce signalling (Dode et al., 2007). 
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FGFR1 is expressed in the mesenchyme and epithelium of palatal shelves and is required 
in both primary and secondary palate development (Riley et al., 2007b). Targeted 
disruption of Fgfr1 in mice results in embryonic lethality, indicating their importance in 
embryonic development (Deng et al., 1994). Mutations in FGFR1, 2 and 3 have been 
associated with craniofacial disorders (Dailey et al., 2005). Loss-of-function mutations 
or deletions in FGFR1 causes autosomal dominant Kallmann syndrome, where CL and 
CP are associated features (Dode et al., 2003). Mutations in FGFR2 cause the Apert 
syndrome, where 76% of patients exhibit CP (Rice et al., 2004). Fgfr2b (IIIb isoform)–
null mice exhibited clefting of the secondary palate (Dailey et al., 2005). 
1.2.5.3. Cell adhesion molecules 
Poliovirus Receptor Like-1 (PVRL1) is a member of the immunoglobulin super family 
(Sozen et al., 2001). PVRL1 encodes nectin-1 which regulates the initiation and 
maintenance of epithelial adherens junctions. Nectin-1 functions in cooperation with 
cadherins in the formation of tight junctions on epithelial cells (Avila et al., 2006) 
PVRL1 is abundantly expressed in the MEE of the palatal shelves, the ectodermal 
component of tooth buds, the olfactory epithelium and the skin surface epithelium 
(Sozen et al., 2001). Loss-of-function mutations in PVRL1 are associated with the 
autosomal recessive CL/P-ectodermal dysplasia syndrome (Suzuki et al., 2000). Whereas, 
nonsense mutations in PVRL1 are linked to non-syndromic CL/P (Sozen et al., 2001).  
1.2.5.4. Extracellular matrix components 
Matrix metalloproteinase (MMP) are a family of proteolytic enzymes that can degrade 
components of the ECM, such as collagen. MMPs 2, 3, 9 and 13 have been detected in 
the medial mesenchyme during regression of the MES (Brown et al., 2002; Verstappen 
and Von den Hoff, 2006). Sequence analysis of individuals with CL/P revealed that 
polymorphisms in the promoter of MMP3 had positive association with CL/P (Letra et 
al., 2007). Similarly, tissue inhibitors of metalloproteinases (TIMPs)-1 and TIMP-2 
show enhanced expression in the medial mesenchyme as well. However, TIMP3 is only 
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expressed in the mesenchyme around the nasal epithelium. MMPs and TIMPs are 
involved in the control of tissue remodelling during palate fusion, and their activities are 
regulated by TGF-β 3 (Blavier et al., 2001; Letra et al., 2007). 
1.2.5.5. Transcription factors 
Members of the Msx homeobox gene family function as transcriptional repressors in the 
regulation of craniofacial, limb and nervous system development. Msh homeobox 1 
(Msx1) expression was observed in the anterior mesenchyme and is important in growth 
of the palate shelf horizontal apposition. Msx1
-/-
 homozygote mice develop clefts in the 
secondary palate, arrested tooth development and exhibited abnormal nasal and frontal 
bone development (Satokata and Maas, 1994). In another study, Msx1 null mutant 
embryos showed normal palatal shelves elevation but no contact or fusion of the paired 
palates due to reduced cell proliferation that consequently lead to growth impairment 
(Alappat et al., 2003). Association studies and sequence analysis confirm that mutations 
in MSX1 in humans are associated with non-syndromic clefting and tooth agenesis (van 
den Boogaard et al., 2000; Jezewski et al., 2003). Bead implantation experiments show 
that Msx1 directly regulates Bmp4 expression and functions upstream of Shh and Bmp2 
(Zhang et al., 2002; Alappat et al., 2003).  
LIM homeobox (Lhx) 8 (also known as L3) is a member of the LIM homeobox 
gene family. In situ-hybridization analysis revealed that Lhx8 is continuously expressed 
in the mesenchyme surrounding the oral cavity in mice (Matsumoto et al., 1996; Zhao et 
al., 1999). Targeted deletion of Lhx8 resulted in the development of secondary cleft 
palate in 60% of the mice. The Lhx8 knockout mice exhibited normal growth and 
elevation of the palatal shelves. However, palatal shelve contact and fusion at the MEE 
was impaired, suggesting that Lhx8 may be involved in the epithelia-mesenchyme 
interaction (Zhao et al., 1999) 
Pax9 is a member of the paired-box transcription factor gene family that is 
expressed predominantly in the palatal MEE during the vertical and horizontal growth of 
the palatal shelves. Pax9 may play a key role in palatal MEE fusion and mesenchymal 
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condensation of the secondary palate as it is expressed in MEE and mesenchyme.  It has 
been suggested that Pax9 is regulated predominantly by TGF-β3 during palatal fusion 
(Sasaki et al., 2007). Pax9 mutant mice exhibit CP due to abnormal morphology of the 
palatal shelves (Stanier and Moore, 2004). 
 The transcription factor p63 is a member of the p53 family that is involved in 
palatogenesis. Mutations in p63 have been linked to 5 developmental disorders that are 
characterized by facial clefting, abnormalities in the limb and ectodermal dysplasias.  
Embryos of p63
-/-
 mice exhibit bilateral CLs and clefting of the secondary palate. CPs are 
caused by the failure of palatal shelve growth. In situ hybridization of p63
-/-
 mice showed 
down-regulation of Fgf8 and Shh, in comparison to the expression pattern in wildtype 
mice (Thomason et al., 2008). Disruption of Fgf8 and Shh signalling corresponded to 
reduction in mesencymal cell proliferation and increased cell death. Thus, Fgf8 
expression in the maxillary processes was suggested to initiate palatal shelve outgrowth 
(Thomason et al., 2008). Whereas, Shh plays an important role in the survival and 
proliferation of mesenchyme cells (Jeong et al., 2004). 
Other transcription factors such as distal-less
 
(Dlx), Hoxa2, Gli2, Gli3 and T-box 
families form part of the gene network involved in CNC migration and differentiation 
and are modulated by Shh, BMPs
 
and FGF signalling (Stanier and Moore, 2004). Table 
1.1 shows a list of key genes involved in palatogenesis. 
 
 
Factors Genes 
Polarizing signals Shh,Bmp2, Bmp4 and Bmp7, Wnt5a, Smad2-4 
Growth factors and receptors Egf, Egfr, Tgfα, Tgfβ1-3, Fgd1, Fgf2, Fgf8, Fgfr1, Fgfr2 
Cell adhesion molecules  Pvrl1, Connexin43,E-cadherin 
Extracellular matrix Col2A1, Col11A1 and Col11A2, Mmp2, Mmp3, Mmp9, 
Mmp13, Timp1-3, Fibronectin 
Transcription factors  Ap2α, Dlx1-6, Gli2-3, Hoxa2, Irf6, Lhx8, p63, Pax9, 
Pitx1, Pitx2, Prx1, Msx1, Tbx1, Tbx22 
 
Table 1.1. Table of genetic factors involved in palatogenesis. Adapted from (Stanier 
and Moore, 2004)  
 
 - 30 - 
1.3. Van der Woude and Popliteal Pterygium syndromes   
Van der Woude syndrome (VWS) (OMIM no. 119300) and popliteal pterygium 
syndrome (PPS) (OMIM no. 119500) are autosomal dominant disorders caused by 
different mutations of the same gene (Ben et al., 2005). Genomic screens, phenotypic 
overlap and linkage data suggested that VWS and PPS were alleic (Kondo et al., 2002; 
Blanton et al., 2005). The locus for VWS and PPS was initially mapped to human 
chromosome 1q32-q41, by the identification of a deletion at 1q32-q41 in a patient with 
congential lower lip-pits (Bocian and Walker, 1987). In 2002, Kondo et al. uncovered 
the causative gene of VWS and PPS via the identification of a nonsense mutation in the 
gene encoding interferon regulatory factor 6 (IRF6) in an affected twin of a pair of 
monozygotic twins. VWS is characterized clinically by lip pits, CL/P and hypodontia, 
and is the most common syndromic form of CL and CP accounting for 2% of all cases 
(Fig 1.4) (Schutte et al., 2000; Du et al., 2006). A typical form of lower lip pits is the 
symmetrical bilateral paramedian sinuses of the lower lip. Other types include unilateral, 
medial or bilateral asymmetrical. Unilateral types mostly develop on the left side of the 
lip. Other associated features include missing teeth, club foot, thumb hypoplasia, 
tapering fingers and congenital heart disease (Rizos and Spyropoulos, 2004). VWS 
affects about 1 in 100,000-200,000 worldwide. Some studies show no significant 
difference between sexes (Rizos and Spyropoulos, 2004). There is very high penetrance 
of VWS which has been reported to be up to 96.7% (Janku et al., 1980; Shprintzen et al., 
1980). 
PPS shares similar orofacial phenotypes to VWS and has additional features 
including popliteal webbing, bands of mucous membrane between the jaw, syndactyly, 
and cutaneous, musculoskeletal and genital abnormalities (Fig 1.5) (Gorlin et al., 1968; 
Lees et al., 1999; Ben et al., 2005). PPS has a prevalence of approximately 1 in 300,000 
live births. 
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Van der Woude syndrome 
 
      
 
Figure 1.4. Characteristic orofacial deformities of van der Woude syndrome.  
Clinical appearances of twins that have (A) a unilateral lower lip sinus with unilateral 
cleft lip and (B) a bilateral symmetrical lower lip sinuses with soft palatal cleft, Adapted 
from (Tokat et al., 2005). Infants with VWS that have (C) a bilateral cleft lip and cleft 
palate, and (D) lip pits. Adapted from (Ghassibe et al., 2004; Tokat et al., 2005).  
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Popliteal Pterygium Syndrome 
 
        
 
 
Figure 1.5. Features associated with popliteal pterygium syndrome. (A) eyelid 
adhesions (B) bilateral popliteal webbing of the limbs, (C) two accessory nipples 
(polythelia) and (D) polydactyly, showing the growth of an extra digit. Adapted from 
(Gahm et al., 2007). 
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1.4. Interferon Regulatory Factor 6 
Interferon regulatory factor 6 (IRF6) is a member of the IRF family of transcription 
factors. The IRF family is characterized by a highly conserved, amino (N)-terminal 
deoxyribonucleic acid (DNA)-binding domain (DBD) containing a unique tryptophan 
cluster. IRF6 is a 467 amino acid transcription factor (Fig 1.6). Sequence alignment 
indicates that the IRF6 contains a winged-helix DBD (amino acids 13-113) and an 
interferon associated domain (IAD) protein-binding domain (amino acids 226-394). The 
function of IRF6 remains unknown, although mutations in the IRF6 have been identified 
to cause VWS and PPS (Kondo et al., 2002). 
1.4.1. Mutations in IRF6 cause VWS and PPS 
The IRF6 mutation spectrum has been investigated to identify possible inherited and de 
novo mutations in VWS and PPS patients (Kondo et al., 2002; Peyrard-Janvid et al., 
2005; Ye et al., 2005; Du et al., 2006; de Lima et al., 2009). 30-50% of VWS cases may 
arise de novo (Ye et al., 2005). More than 160 mutations have been identified within the 
IRF6 gene that contributes to disease manifestation (Fig 1.7). The variable clinical 
phenotypes are caused by different mutations that include deletions, missense mutations, 
terminations, insertions, splicing site mutations and chromosomal rearrangement (Ye et 
al., 2005). The mutations that lead to VWS and PPS are not randomly distributed in the 
IRF6 gene as a higher frequency of mutations reported to be located in the DBD and the 
IAD (Peyrard-Janvid et al., 2005; de Lima et al., 2009). Nonsense and frameshift 
mutations that encoded truncated IRF6 were significantly more common in VWS than in 
PPS (Schutte et al., 1999). Protein truncation mutations were observed to be evenly 
distributed throughout the gene (de Lima et al., 2009). For example, the F165fsX166 
frameshift introduces a premature stop signal and is predicted to eliminate the IAD 
caused VWS (Ye et al., 2005). In addition, six missense mutations mapped to exon 1 and 
2, which introduce new start codons in the 5‟ untranslated region that give rise to an 
altered IRF6 open reading frame were all associated with VWS families 
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MALHPRRVRLKPWLVAQVDSGLYPGLIWLHRDSKRFQIPWKHATRHSPQQEEENTIFKAW 60 
 
AVETGKYQEGVDDPDPAKWKAQLRCALNKSREFNLMYDGTKEVPMNPVKIYQVCDIPQPQ 120 
 
GSIINPGSTGSAPWDEKDNDVDEEDEEDELDQSQHHVPIQDTFPFLNINGSPMAPASVGN 180 
 
CSVGNCSPEAVWPKTEPLEMEVPQAPIQPFYSSPELWISSLPMTDLDIKFQYRGKEYGQT 240 
 
MTVSNPQGCRLFYGDLGPMPDQEELFGPVSLEQVKFPGPEHITNEKQKLFTSKLLDVMDR 300 
 
GLILEVSGHAIYAIRLCQCKVYWSGPCAPSLVAPNLIERQKKVKLFCLETFLSDLIAHQK 360 
 
GQIEKQPPFEIYLCFGEEWPDGKPLERKLILVQVIPVVARMIYEMFSGDFTRSFDSGSVR 420 
 
LQISTPDIKDNIVAQLKQLYRILQTQESWQPMQPTPSMQLPPALPPQ  467 
 
 
 
Figure 1.6. Amino acid sequence of IRF6 and its functional domains.  IRF6 contains 
two functional domains. The amino acid 13-113 constitute the conserved DNA-binding 
domain (green) and amino acid 226-394 represent the less conserved interferon 
association domain (pink). The signature penta-tryptophan residues are highlighted in red 
and the serine rich region is underlined. 
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 (de Lima et al., 2009). Truncation mutations that lead to haploinsufficiency of IRF6 
were found to cause VWS and not PPS (Schutte et al., 1999). 
Over 90 percent of IRF6 mutations are missense changes. Distribution analysis of 
these mutations indicated that they cluster in certain IRF6 coding domains (Ye et al., 
2005). Missense mutations provide an understanding of the relationship of the structure 
and function of the IRF6 gene product. In VWS missense mutation were almost evenly 
distributed between the DBD and the IAD and could result in the complete loss of IRF6 
function and dysfunction of the DBD and IAD (Kondo et al., 2002). The Y111H 
mutation within the IRF6-DBD is suggested to disrupt the IRF6 binding activity to its 
target sequences (Ye et al., 2005). Interestingly, Zucchero et al. used genotype 
transmission-disequilibrium analysis to investigate the risk of CL or CP that is associated 
with the single-nucleotide polymorphism V274I in IRF6.  The V/V homozygous was 
significantly associated with clefting, whereas the V/I heterozygous and I/I homozygous 
were not associated with clefting (Zucchero et al., 2004). 
Missense mutations in PPS were mainly located in the IRF6-DBD regions that 
had direct interaction with DNA, but not protein interaction. This was shown to be non-
random as 34 out of 36 families with PPS had mutations in exons 3,4 and 9. Exon 4 had 
the highest frequency of PPS mutations (de Lima et al., 2009). This suggests that 
different missense mutations in the DBD that cause VWS and PPS lead to different 
functional activity of IRF6 (Kondo et al., 2002). Thus PPS is principally associated with 
dominant-negative mutations as it forms inactive transcription complexes, but can also 
be caused by loss of function (Kondo et al., 2002).  
Mutations within the same exon can lead to different phenotypes, such as the 
R400W and the S407fsX436 in exon 9. The R400W missense mutation that encodes a 
full length protein has a milder phenotype. Whereas, the S407fsX436 frameshift 
mutation that encodes a truncated protein exhibits a more severe phenotype (Ye et al., 
2005). Intriguingly, the same mutation L22P, R84C, R84H and K89E were identified in 
individuals with VWS and PPS. This indicates that the genotype-phenotype other 
contributing factors such as the combination of causative mutations and genetic factors. 
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A      VWS mutations 
 
 
B          PPS mutations 
 
 
 
Figure 1.7. Lists of mutations in the IRF6 protein that cause VWS and PPS. (A) List 
of amino acid missense mutation, truncation (X) and frameshift (fs) within the IRF6 
DNA-binding domain (green) and interferon association domain (purple) and other 
regions, that have been identified in individuals with VWS and (B) PPS patients (Grant 
et al., 2000; Kondo et al., 2002; Kayano et al., 2003; Gatta et al., 2004; Ghassibe et al., 
2004; Matsuzawa et al., 2004; Peyrard-Janvid et al., 2005; Du et al., 2006; Matsuzawa et 
al., 2006; Brosch et al., 2007; de Lima et al., 2009).  
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Six out of ten coding variants identified by Peyrard-Janvid et al. were novel 
mutations, suggesting that new mutations often occur in the IRF6 gene. For example, the 
nonsense mutations Q120X and Q359X observed in the VWS patients were not present 
in any of the parents (Peyrard-Janvid et al., 2005). A study shows that imperfect mini-
repeat sequences, such as polypyrimidine tracts or dinucleotide repetitive units, are 
relatively abundant within the IRF6 coding sequence. These regions may be more 
susceptible to misalignment during DNA replication and thus become potential hot-spots 
for mutations (Ye et al., 2005). Five apparent hot-spots have been identified, R6, R84, 
R250, R400 and R412 all of which contain CpG dinucleotide (de Lima et al., 2009). 
1.4.2. Expression of Interferon Regulatory Factor 6 in mice 
Expression of Irf6 has been studied in mice by in-situ hybridization. Development of the 
lip and primary palate in mice is similar to that of humans. In mice the palatal shelves 
fuse and therefore is an ideal organism to study normal development of the secondary 
palate (Knight et al., 2006). During mouse primary palate development, expression of 
Irf6 was observed in the ectoderm covering the first and second pharyngeal arches and 
line of fusion between the mandibular processes. Irf6 was then expressed in the 
epithelium of the maxillary and mandibular processes of the first pharyngeal arch 
particularly at the epithelial fusion zone between the medial and lateral nasal processes 
and the maxillary process. Irf6 was still expressed after fusion at the medial and lateral 
nasal processes in the epithelium of the intermaxillary segment and the nasolacrimal 
groove (Knight et al., 2006). 
In the development of the secondary palate during the vertical growth of the 
palatal shelves Irf6 expression was detected in the epithelium lining the floor of the 
mouth. Irf6 expression profile changes during palatal shelf elevation, as Irf6 is expressed 
in the epithelium at the tip of the palatal shelf extending along the presumptive nasal 
palatal epithelium. As the paired palatal shelves interact, Irf6 was highly expressed in the 
MEE, the junction of the primary and secondary palate and along the base of the nasal 
septum. During fusion of the palate, Irf6 was strongly expressed in the MEE midline 
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seam. As the MES degenerated there was increasing levels of expression in the nasal and 
oral palatal epithelia (Knight et al., 2006). 
During palatal development, Irf6 expression was also detected in other regions, 
such as the ectoderm surrounding the developing eyes, epithelial components of the 
developing incisor and molar tooth germs, vibrissae, hair follicles (Knight et al., 2006) 
and in the apical ectodermal ridge of the limb buds (Washbourne and Cox, 2006).  
Mouse expression analysis reveals a considerable overlap between the expression 
pattern of Irf6 and Tgfβ 3 during development of the secondary palate. In the genetic 
hierarchy, Tgfβ 3 expression in mouse palatal shelves precedes Irf6 expression indicating 
that Irf6 may be downstream of Tgfβ 3. This was supported by studies with Tgfβ 3-/- 
embryos, which exhibit cleft palate, as Irf6 expression was not detected in the MEE of 
the palatal shelves of Tgfβ 3-/- embryos but was expressed in the tooth (Knight et al., 
2006). 
A study by Thomason et al. established a genetic link between IRF6. An epistatic 
approach was used by intercrossing p63
+/-
 and Irf6 
+/R84C
 heterozygous mice to establish 
genetic interaction between p63 and Irf6. 89% of compound heterozygous p63
+/-
Irf6 
+/R84C
 mice exhibited a cleft of the secondary palate. In comparison, the majority of 
heterozygous mice exhibited normal palate development. The expression pattern of Irf6 
and p63 were compared during stage E13.5 of secondary palate development by 
immunohistochemistry and quantified by quantitative PCR. In p63
-/-
 mice Irf6 was 
downregulated at the tips of the palates compared to wildtype. However, in Irf6 
R84C/R84C
 
mice p63 was not downregulated. Further analysis showed that small interfering RNA 
(siRNA) knockdown of p63 showed a decrease in Irf6 levels suggesting p63 modulates 
Irf6 expression. Two p63 enhancer elements upstream of Irf6 were identified by 
chromatin immunoprecipitation sequencing (ChIP-seq). In addition, chromatin 
immunoprecipitation quantitative PCR (ChIP-qPCR) of wildtype and mutant p63 showed 
that mutations in the DBD of p63 abolished p63 dependent expression of Irf6 (Thomason 
et al., 2010).  
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Figure 1.8. Irf6 expression profile in the mouse during lip and primary palate 
development. (A-D) In situ hybridization of sections of mouse during lip and palate 
development between stages E10.5 and E12.5. Irf6 is highly expressed in the ectoderm at 
fusion zones between the facial processes. mnp, medial nasal process; lnp, lateral nasal 
process; mx, maxillary process; m, mandibular process; n, nares; e, eye; v, vibrissae. The 
arrows in C indicate the nasolacrimal duct. Scale bar = 10 nm in A; 20 nm in B-D. 
Adapted from (Knight et al., 2006). 
 
 
 - 40 - 
 
      
Figure 1.9. Irf6 expression profile of in the mouse during secondary palate 
development. Irf6 expression analysis by in situ hybridisation of whole embryos (A-C) 
and sections (D-F) and immunohistochemistry between stage E13.5 and E14.5 show that 
Irf6 is expressed in secondary palate development. During palatal shelves enlargement 
and growth, Irf6 is expressed at the tips of the palatal shelves (D). After horizontal 
growth and contact of paired palatal shelves, Irf6 is also detected in the medial edge 
epithelia and the MES during palatal fusion (E,F). High levels of Irf6 is also observed in 
the tooth germs (A-D, F) and the base of the nasal septum (E). p, palatal shelf; tg, tooth 
germs; t, tongue. Scale bar = 10 nm in D-F; 20 nm in G-I. Adapted from (Knight et al., 
2006). 
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1.4.3. IRF6 function 
The function of most of the IRFs have been characterized, however the function of IRF6 
is still relatively unknown and does not seem to be related to the immune response 
(Blanton et al., 2005). To elucidate the function of Irf6, Richardson et al. generated mice 
carrying heterozygous and homozygous R84C missense mutation in the DBD using gene 
targeting. In Irf6
R84C/R84C 
homozygous mice, the disruption of the Irf6 leads to 
hyperproliferation of the epidermis with developmental arrest at early stages of 
differentiation. Furthermore the phenotype of Irf6
R84C/R84C 
mutant mice is highly similar 
to repeated epilation (Er) mice. Er is caused by mutation in the stratifin (Sfn), which is a 
phosphoserine-threonine binding protein found in differentiating keratinocytes that plays 
a role in cell cycle arrest. Irf6 and Sfn were shown to interact genetically to regulate 
epidermal development. Thus, Irf6 plays a key role in the keratinocyte proliferation-
differentiation switch (Richardson et al., 2006). 
In an Irf6 knockout study, Ingraham et al. generated Irf6 deficient mice (Irf6
gt1/gt1
) 
by inserting the gene trap vector into intron 1 of Irf6 to study the function of Irf6. The 
homozygous Irf6
gt1/gt1
 (null) embryos showed no detectable expression of Irf6 in skin. 
Histological analysis of the skin in wildtype embryos showed that the epidermis was 
composed of four stratified layers (basal, spinous, granular and cornified). In contrast, 
the Irf6 null mice exhibited taut and shiny skin, as only the basal layer and the spinous 
layer of the four stratified layers of the epidermis were present. However the spinous 
layer was greatly expanded, possibly due to proliferation and failure of keratinocytes to 
terminally differentiate. The granular and cornified outer layers appeared absent. This 
suggests that Irf6 plays a role in the regulation of keratinocytes proliferation and 
differentiation. In null mice desmosomes, which are structures important in epidermal 
adhesion between epithelial cells, were observed throughout the epidermis.  However, 
desmosomes are generally not observed in the superficial layers in wildtype embryos. 
The unusual presence of desmosomes was suggested to be due to the absence of the 
normal cornified layer. The Irf6 null mice also lacked external ears, visible digits, hind 
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limbs, tail and forelimbs. Skeletal analysis confirmed the presence of a shorter vertebrae, 
tail and sternum with delayed ossification. Other defects include craniofacial 
abnormalities, where skulls from null embryos exhibited shorter snouts and jaws. 
Furthermore, the palate shelves in null embryo were posteriorly and laterally displaced 
and had a cleft palate.  (Ingraham et al., 2006).  
Another study by Bailey et al. shows that IRF6 was identified as a mammary 
serine protease inhibitor (maspin) binding protein. Maspin is a tumour suppressor that 
promotes apoptosis and inhibits cell invasion and metastasis. IRF6 interacts with maspin 
via the protein association domain and its interaction is facilitated by IRF6 
phosphorylation. The interaction primarily occurs in the cytoplasmic compartment and 
may possibly regulate IRF6 nuclear translocation and block its function.  The maspin-
IRF6 interaction may be important in maintaining normal mammary epithelial cell 
phenotype (Bailey et al., 2005; Bailey et al., 2006).  
1.5. The Interferon Regulatory Factor family 
1.5.1. Members of the IRF family 
The IRF family of transcription factor consists of nine mammalian members as well as 
four viral members involved in interferon (IFN) induced signalling pathways to provide 
host resistance to pathogens (Fig 1.10) (Grant et al., 2000; Barnes et al., 2002; Ozato et 
al., 2007). However, the IRF family have additional functions including the regulation of 
the development of the immune system (Meraro et al., 1999) and differentiation of many 
cell types (Ozato et al., 2007). The IRF transcription factors are ubiquitously expressed, 
except for IRF4 and IRF8 whose expression is limited to hematopoietic cells  (Sato et al., 
2001). Furthermore their expression is either constitutive or induced upon viral infection 
or exposure to IFNs (Sharf et al., 1997). The IRFs exhibit diverse transcriptional activity 
and can function as transcriptional activators (IRF1, IRF3, IRF5 and IRF9), repressors 
(IRF8), or both (IRF2, IRF4 and IRF7) (Barnes et al., 2002).  
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Figure 1.10. Members of the IRF family. The Schematic diagram shows the IRF 
family and their functional domains. All IRF members have a DNA-binding domain 
(green) located at the N-terminal. IRF3, IRF4, IRF5, IRF8 and IRF9 have an interferon 
association domain (purple) and IRF2 has a repression domain.  
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1.5.1.1. IRF1 and IRF2 
IRF1 and IRF2 were the first IRFs discovered through their interaction with the positive 
regulatory domain (PRD1) in the virus inducible region of the IFN-β gene and can 
modulate the late stages of B cell differentiation. Other studies showed that IRF1 is 
involved in antiviral defense via IFN-γ. IRF1 also plays an important role in the 
development and activation of a number of immune cells, including CD8
+
 T cells, T 
helper 1 cells and natural killer (NK) cells. Furthermore, IRF1 functions in the inducible 
expression of major histocompatibility complex  (MHC) class I and in apoptosis (Paun 
and Pitha, 2007).  
IRF2 acts as both repressor and activator of transcription. IRF2 can function as a 
repressor as it contains a repression domain in its carboxyl (C)-terminus. However, upon 
proteolytic cleavage in the carboxyl (C)-terminal region IRF2 induced repression is 
reduced (Palombella and Maniatis, 1992). IRF2 recognizes the same binding site to IRF1 
and can suppress IRF1-induced transcription activity (Taniguchi et al., 2001). IRF2 can 
regulate the inhibition of IRF1 induced apoptosis and growth regulatory function. Thus, 
over expression of IRF2 can lead to oncogenic transformation, as observed in NIH/3T3 
cells (Paun and Pitha, 2007). As an activator, IRF2 can stimulate transcription of the cell-
cycle-regulated histone 4 and vascular cell adhesion molecule -1 genes (Taniguchi et al., 
2001). In the innate antiviral defense, IRF2 is required in the late stages of NK cells 
maturation and myeloid dendritic cells (DC) development. While in the adaptive 
immunity, IRF2 directly activates transcription of the transporter of antigenic peptides to 
MHC class I (Paun and Pitha, 2007). 
1.5.1.2. IRF3 and IRF7 
Pathogen recognition via cellular receptors and signalling pathways lead to activation of 
IRF3 and IRF7 that is essential for expression of type I IFN genes. IRF3 plays a pivotal 
role in the induction of antiviral response and production of IFN genes. Upon viral 
infection, ubiquitously expressed IRF3 becomes phosphorylated and results in 
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translocation to the nucleus. Phosphorylated IRF3 can interact with CREB-binding 
protein (CBP)/p300 coactivator and binds to the IFN-α and IFN-β promoter to up-
regulate IFN-α and IFN-β expression (Juang et al., 1998; Sato et al., 1998). Elevated 
levels of IFN-α and IFN-β can activate the ligand-dependent activator interferon-
stimulated gene factor (ISGF3) and subsequently stimulate expression of IRF7. IRF3 and 
IRF7 cooperate with each other to amplify IFN-α and IFN-β production and trigger the 
antiviral response (Sato et al., 2000). Specific toll-like receptors (TLR) signalling 
pathways have been implicated in the induction of type 1 IFNs. Activation of the TLR3 
and TLR4 signalling cascade can induce IRF3 nuclear translocation and stimulation of 
IFN-β (Doyle et al., 2002). Upon recognition of pathogen components, TLR9 can recruit 
the adaptor molecule MyD88. MyD88 can form a complex with IRF7 and the adaptor 
molecule tumor necrosis factor receptor–associated factor 6 (TRAF6) in a TRAF6-
dependent uniquitination dependent manner.  The MyD88/TRAF6/IRF7 complex can 
stimulate IFN-α production (Kawai et al., 2004). Studies in IRF7 deficient mice showed 
that virus induction of the MyD88-independent pathway markedly decreased the 
induction of IFN-α and IFN-β in Irf7-/- fibroblasts. This provided evidence that IRF7 acts 
as a master regulator of type I IFN expression (Honda et al., 2005). IRF7 is also 
implicated in regulation of monocyte differentiation. The over-expression of IRF7 was 
sufficient to drive monocyte differentiation to macrophages and induce cell cycle arrest 
(Lu and Pitha, 2001). 
1.5.1.3. IRF4 and IRF8 
IRF4 and IRF8 are highly homologous and are mainly expressed in lymphocytes, 
macrophages, B cells and DC (Marecki et al., 1999; Tsujimura et al., 2003a; Tailor et al., 
2006). Both IRF4 and IRF8 possess weak DNA-binding affinity. However, protein 
interaction with other members of the IRF family (IRF1 and IRF2) potentiates its DNA-
binding ability. IRF4 and IRF8 can form heterodimers with the E-twenty six (Ets)-family 
transcription factor PU.1 to enhance their binding activity and regulation of genes 
carrying IRF/Ets and Ets/IRF composite elements (Marecki et al., 1999). The IRF4/PU.1 
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heterodimer has been implicated in the transcriptional regulation of B cell-specific genes, 
which include immunoglobulin light chain (IgL) gene (Pongubala et al., 1992) and CD20 
gene (Himmelmann et al., 1997). Alternatively, IRF4 can form a dominant negative 
complex with IRF1 and IRF5 to antagonize their transcriptional activity. IRF4 is 
necessary for B cell and T cell maturation, such as the differentiation of B lymphocytes 
to plasma cells. IRF4 has also been suggested to be involved in CD4
+ 
DC development 
(Paun and Pitha, 2007). The hallmark of B cell development is the sequential expression 
and assembly of the B cell receptor (BCR). IRF-4,8
-/-
 compound mutants mice exhibited 
a lineage specific block in B cell development where it arrests at pre-BCR stage (Lu et 
al., 2003). IRF4 is involved in T cell cytokine production to coordinate immune 
responses. The cooperation of IRF4 with members of the nuclear factor of activated T 
cells (NFAT), such as NFAT1c (Hu et al., 2002) and NFATc2 has been shown to drive 
the expression of interleukin (IL)-4 (Rengarajan et al., 2002). In interleukin regulation, 
IRF4 can directly interact with the promoter region of IL-2 and induce expression. 
Furthermore, elevated levels of IRF4 can enhance the production of IL-10 and IL-13 (Hu 
et al., 2002). 
IRF8 directly regulates the transcriptional repression of PU.1 and the 
transcriptional expression of early B-cell Factor (EBF) activity in B-cell development 
and lineage commitment (Wang et al., 2008).  EBF is considered to be a „pioneer‟ factor 
as it plays an indispensable role in the direct activation of essential genes in B-cell 
differentiation and survival (Hagman and Lukin, 2005). IRF8 can form heterodimers 
with other IRF family members (IRF1 and IRF2) (Meraro et al., 1999). IRF8 and IRF1 
form heterodimers on the promoters of interleukin (IL)-12 p40 and IL-12 p35 genes to 
synergistically induce transcription for the increase of IL-12 levels. IL-12 plays a critical 
role in macrophage differentiation, macrophage-induced inflammation and the 
generation of T helper cells and cytotoxic T lymphocytes (Liu et al., 2004). IRF8 has 
also been implicated in the development of lymphoid and myeloid lineages (Taniguchi et 
al., 2001). IRF8 is essential for the early plasmocytoid DC development and the 
maturation of both plasmocytoid DC and myeloid DC (Tsujimura et al., 2003b). IRF8 is 
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involved in the induction of CD8α, IFN-α and IL-12 in DCs (Tsujimura et al., 2003a; 
Tsujimura et al., 2003b).  Irf8
-/-
 null mice were highly susceptible to viral infection, 
possibly due to impaired IFN-γ-dependent innate immune response. Irf8-/- null mice also 
displayed misregulation in the proliferation and differentiation of hematolymphoid cells 
(Holtschke et al., 1996). 
1.5.1.4. IRF5  
IRF5 plays a role in innate inflammatory response and antiviral response to specific virus. 
Upon virus infection, IRF5 can cooperatively interact with IRF3 to enhance IRF3-
mediated transactivation of IFN-α and IFN-β. In contrast, the formation of the 
IRF5/IRF7 hetero-dimer inhibits the expression of IFN-α. IRF5 interacts with the N-
terminus and C-terminus of IRF7 and as a result masks the DBD of both transcription 
factors (Barnes et al., 2003a). IRF5 is also involved in the induction of the early 
inflammatory cytokines and chemokines. Triggering TLR4 and TLR9-MyD88 dependent 
signalling induces IRF5 nuclear translocation and IRF5 binding to the Il-12 p40 cytokine 
gene. Irf5
-/-
 mice showed resistance to endotoxic shock induced by unmethylated DNA 
or lipopolysaccharide, and inhibition of cytokine IL-6, IL-12 and TNF-α production 
compared to wildtype mice (Takaoka et al., 2005). IRF5 is a direct target of the tumor 
suppressor p53 (Mori et al., 2002). Microarray and ribonuclease protection assay studies 
showed that IRF5 regulated a number of genes that are known targets of p53 such as p21, 
caspase 6 and B-cell lymphoma 2 (Bcl-2) suggesting an association with p53 induced 
proapoptotic pathways. In addition, IRF5 regulated a number of genes that are not p53 
targets, such Bcl-2 homologous antagonist/killer (Bak1) and caspase 8 indicating that 
IRF5 can still promote G2-M cell cycle arrest and apoptosis in a p53-independent manner 
(Barnes et al., 2003b).  
1.5.1.5. IRF9 
IRF9 is important in the antiviral effects of type I IFN. IRF9 can interact with signal 
transducer and activator of transcription (STAT) 1 and STAT2 to activate transcription. 
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In IFN-treated cells, the ISGF3 tertiary complex is formed that contains 
IRF9/STAT1/STAT2 which can bind the IFN stimulated response element (ISRE) of 
interferon stimulated gene (ISG) and activate the expression of IFN-α (Kraus et al., 2003) 
and IFN-γ (Bandyopadhyay et al., 1990). Studies in pristane-treated Irf9-/- and Stat-/- mice 
1 revealed that IRF9 and STAT1 are involved in the production of immunoglobulin G 
autoantibodies via TLR7 signalling. Irf9
-/-
 mice exhibited elevated levels of 
immunoglobulin M, implicating a role of IRF9 in isotype switching in response to self 
antigens (Thibault et al., 2008). 
1.5.2. Functional domains of IRFs 
The IRFs all share two conserved functional domains (Barnes et al., 2002). The IRF 
regions that share significant homology are the N-terminal DBD and the IAD, located 
near the C-terminal end. The first 115 amino acids encompassing the DBD contains a 
highly conserved winged typed helix-turn-helix motif with a characteristic penta-
tryptophan repeats spaced by 10-18 amino acids (Fig 1.11) (Fujii et al., 1999; Meraro et 
al., 1999; Kondo et al., 2002; Qin et al., 2003).  
DNA sequences recognized by IRFs have been found in promoters regions, 
termed as interferon regulatory factor elements (IRF-E) or IRF recognition sequence 
(IRS), in a variety of IFN-inducible genes (Harada et al., 1994; Xi and Blanck, 2003). 
All the IRF members are believed to bind to similar DNA binding motifs of 
AANNGAAANN due to their similarities in the secondary structure of the DBD (Tanaka 
et al., 1993). The IRF1-DBD has an alpha (α)/beta (β) architecture with a fold 
comprising of three α-helices (α1-α3) flanked by a mixed four-stranded β-sheet (β1-β4). 
The α-helices and β-sheet are linked by loops with three distinctive large loops (L1, L2 
and L3) located between β2-α2, α2-α3 and β3-β4. Loops L1 and L2 are characteristic 
features of the IRF family. Helices α2 and α3 form the helix-turn-helix conformation 
with α3 as the recognition helix that traverses the major groove perpendicular to the 
DNA axis (Escalante et al., 1998). Many IRF binding sites have been identified as either 
a single stretch of GAAA core sequence or show cooperative binding to tandem repeats 
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of GAAA (up to four) with one to three insertion bases induced by DNA structural 
distortions. Previous studies using polymerase chain reaction (PCR)-assisted DNA 
binding site selection identified the IRF-E to be G(A)AAA
G
/C
T
/CGAAA
G
/C
T
/C for IRF1 
and IRF2 (Tanaka et al., 1993), GAAA
C
/G
C
/GGAAAN
T
/C for IRF3 and GAA
A
/T
 
N
C
/TGAAAN
T
/C for IRF7 (Lin et al., 2000a). However IRF4 contains a lysine (L103) at 
the end of the recognition helix that is able to form a hydrogen bond with a guanine 
outside the core sequence (GAAAC) showing an extended IRF core sequence (Fig 1.12). 
The lysine residue is also found in the same location in IRF5, IRF6, IRF8 and IRF9 
(Escalante et al., 2002). 
 All the IRFs contain the less conserved IAD (Paun and Pitha, 2007). 
Similarities in the IAD suggests a similar function in regulating protein-protein 
interaction in this family of transcription factors (Sharf et al., 1997). The IAD is involved 
in protein-protein interaction with other transcription comodulators and can even form 
homo- and heterodimers with other IRF members (Qin et al., 2003). The diversity in the 
C-terminal sequences promotes interaction with specific transcription factors to regulate 
both unique and common target genes (Cheng et al., 2006). The IAD is also referred as 
Smad -interferon regulatory factor−binding domain (SMIR) as it has been shown to be 
related to the Smad family (Eroshkin and Mushegian, 1999). Smad proteins can be 
activated by TGF-β (Derynck and Zhang, 2003), and BMP ligands (Nohe et al., 2004), 
via type II and type I serine/threonine kinase receptors. This leads to the formation of 
Smad hetero-oligomeric complexes that can translocate to the nucleus, resulting in 
ligand-induced transcription of target genes by binding directly to DNA (Miyazono et al., 
2000). The formation of protein complexes may enhance IRFs ability to bind target DNA 
sequences known as IFN-stimulated response elements (ISREs) (Meraro et al., 1999). 
There are several factors that determine the function of each IRF including the cell type-
specific expression, transactivation potential (Barnes et al., 2002) and protein-protein 
interaction (Qin et al., 2003). 
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Figure 1.11. The IRF proteins share a high degree of homology in the DNA-binding 
domain with characteristic penta-tryptophan residues (blue). The secondary 
structures above the sequence are the relative locations of α-helices (orange) and β-sheet 
(purple) and loops of IRF1. The asterisks (*) denote identical amino acid residues among 
all aligned IRFs, double dots (:) indicate highly similar amino acids, and single dots (.) 
indicate less similar residues. Adapted from (Fujii et al., 1999).  
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Figure 1.12. Diagrams of IRF1 and IRF4 protein-DNA complexes and their 
interaction. (A) IRF1 DNA-binding domain consists of α helices and β sheets connected 
by multiple loops. The IRF1 helix-turn-helix (α2-α3) motif has high specificity for the 
major groove. (B)The Schematic diagram of IRF1-DNA complex shows that R82, C83, 
N85, and S86 residues interacts with the base pairs of the short IRF GAAA core 
sequence (grey). Two of the conserved penta-tryptophans, W38 and W58, straddle the 
major groove. Loops L1, L2 and L3 contact the DNA sugar-phosphate backbone, taken 
from (Escalante et al., 1998). (C) Ribbon representation of PU.1/IRF-4/DNA complex 
showing the fold of the DNA binding regions. The recognition helix (α3) is tilted in the 
major groove with its axis almost parallel to the DNA sugar-phosphate backbone. (D) 
The PU.1/IRF-4/DN sketch illustrates that the R98, C99, N102, and K103 residues of the 
IRF4 recognition helix interact with the extended core sequence GAAAC, taken from 
(Escalante et al., 2002). 
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1.5.3. Post-translational modifications of IRFs 
1.5.3.1. Phosphorylation  
IRF activity can be regulated by direct phosphorylation or phosphorylation through 
distinct signalling pathways (Panne et al., 2007b). Sequence alignments show that there 
is a serine/threonine (S/T) rich region that is conserved in the IRF family. 
Phosphorylation of one or multiple serine residues within the S/T rich region 
consequently leads to IRF dimerization. The dimers translocate to the nucleus and 
associate with other transcriptional factors to bind to their DNA targets (Lin et al., 1998). 
IRF3 is located in the cytoplasm in a closed conformation. Virus infection and double 
stranded RNA induces phosphorylation of IRF3 via the virus-activated kinase (VAK) 
components, IκB kinase (IKK)–related kinases IKKε and TANK-binding kinase 1 
(TBK1). Phosphorylation at the specific S/T residues at the S396 to S406 cluster leads to 
a conformational change that relieves the C-terminal autoinhibition to expose the DBD 
and IAD regions (Lin et al., 1998; Lin et al., 1999; Lin et al., 2000a). Phosphorylation of 
IRF3 increases its negative charge and leads to the formation of homodimers (Dragan et 
al., 2007) or heterodimers with IRF7 (Paun and Pitha, 2007). The dimers can then 
translocate to the nucleus and bind to specific DNA targets to regulate transcription. 
Phosphorylation of IRF3 at S385 and S386 controls phosphorylation at the adjacent S/T 
sites and modulates the association with CBP/p300 coactivators. The exposure of a 
nuclear export signal (NES) element signals for IRF3 to be exported from the nucleus 
and the initial activation of virus-responsive promoters is then terminated (Lin et al., 
1998; Lin et al., 1999; Lin et al., 2000a). Virus-induced phosphorylation by DNA-
dependent protein kinase (DNA-PK) at T135 caused nuclear retention and subsequently 
delayed its degradation by the ubiquitin-proteosome pathway. Interestingly the 
phosphorylation site is proximal to the NES (Karpova, 2001). Furthermore, in response 
to stress inducers and genotoxic stress IRF3 is phosphorylated at the N-terminus via the 
 - 53 - 
JNK pathway, which leads to nuclear translocation (Zhang et al., 2009). Therefore IRF3 
is activated in response to a variety of virus-induced signals. 
The crystal structure of IRF3 C-terminal transactivation domain provides an 
understanding of the spatial arrangement of the seven potential phosphorylation sites and 
underlines the functional consequence corresponding to their phosphorylation. The IRF3 
C-terminal transactivation domain contains N- and C-terminal autoinhibitory segments 
that interact to mask the hydrophobic surface of the IAD. The hydrophobic core 
stabilizes the autoinhibitory structure. The phosphorylation sites were grouped into three 
clusters. Cluster 1 contains S385 and S386. Phosphorylation of S385, which is found at 
the loop linking the IAD to the C-terminal autoinhibitory segment, is predicted to 
destabilize the local structure. S386 is exposed and therefore more accessible. Cluster 2 
contains S396 and S398, which are located in a loop that interacts with the N-terminal 
autoinhibitory segment, were postulated to disrupt the autoinhibitory structures. Cluster 3 
contains S402, T404 and S405 that are located in the hydrophobic core. Phosphorylation 
at these sites were proposed to induce structural rearrangement and expose the 
hydrophobic surface for protein-protein interaction. The accessibility of these 
phosphorylation sites implied that phosphorylation may occur sequentially. Here, an 
initial phosphorylation at cluster 1 is required to gain access to S/T residues in cluster 2 
and cluster 3 (Qin et al., 2003). Like IRF3, IRF7 C-terminal phosphorylation induces its 
transactivation activity. In murine IRF7, the phosphorylation sites S425 and S426 lead to 
the transactivation of IRF7 (Marie et al., 1998).  
The phosphorylation of individual IRF members by the same signalling pathway 
can have different functional effects. For example IRF5 and IRF7 are both 
phosphorylated by IKKα in a MyD88-dependent pathway. IKKα-mediated 
phosphorylation of IRF5 downregulates its transcriptional activity on type 1 IFN 
promoters and inhibits IRF5 ubiquitination. On the contrary, IKKα phosphorylation of 
IRF7 upregulates its transcriptional activation (Balkhi et al., 2009) 
In response to Newcastle disease virus (NDV) infection, IRF5 is phosphorylated 
at residues S477 and S480 leading to activation of IFNA promoters. However the triple 
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alanine mutant, IRF-5 3SA (S475A/S477A/S480A) still showed low levels of 
phosphorylation, indicating that IRF5 may have multiple phosphorylation sites (Barnes, 
2002). In a study by Chen et al, crystal structures showed that phosphomimetic mutation 
of S430D leads to the unfolding of the autoinhibited IRF5 monomer, enabling the 
assembly of homodimers. Whereas, phosphorylation at S436 is likely to stabilize the 
interaction of the homodimers (Chen et al., 2008b) 
IRF8 activity is also modulated by phosphorylation. IRF8 is a transcriptional 
repressor with restricted expression in hematopoietic cells. IRF8 interacts with IRF1 or 
IRF2 and PU.1 through its C-terminal domain. The protein association is regulated by 
phosphorylation on specific IRF8 tyrosine residues. Additionally, phosphorylation of 
other IRF8 tyrosine residues can hinder its DNA-binding (Sharf et al., 1997).  
1.5.3.2. Acetylation 
Acetylation of IRFs can alter their DNA-binding and transcriptional activities (Ozato et 
al., 2007).  GCN/PCAF and CBP/p300 are histone acetylases that are known to acetylate 
IRF2 and IRF7 on lysine resides in the DBD. IRF2 is selectively acetylated in a cell 
cycle-dependent manner to modulate cell cycle-dependent histone 4 transcription. In 
contrast, acetylation of IRF7 hinders DNA-binding (Ozato et al., 2007).     
1.5.3.3. Ubiquitination 
The ubiquitin proteasome pathway is an efficient cellular process that is important in 
many cellular processes including cell cycle control, signal transduction and apoptosis  
(Schwartz and Ciechanover, 1999). Ubiquitin-mediated regulation is involved in 
modulating IRF activity (Higgs and Jefferies, 2008). The phosphorylated form of IRF3 
can be negatively regulated as it signals for ubiquitination and proteasome-mediated 
degradation (Kawai et al., 2004). Phosphorylation of IRF6 also leads to its ubiquitination 
and subsequent degradation in a proteosome-dependent manner (Bailey et al., 2008). 
IRF7 is also subject to ubiquitination-dependent activation. The adaptor molecule 
TRAF6 binds to IRF7 and its ubiquitin ligase activity activates IRF7 (Kawai et al., 2004).    
 - 55 - 
1.5.4. Subcellular localization of IRFs  
The nuclear envelope consists of a double lipid bilayer which acts as a physical barrier 
that separates the nuclear and cytoplasmic compartments. The nuclear envelope is 
embedded with nuclear pore complexes (NPC) that provide aqueous channels to 
facilitate nucleocytoplasmic transport of molecules in an active, signal-mediated manner 
(Gorlich and Mattaj, 1996). Active nucleocytoplasmic transport primarily involves three 
components: the substrate, adaptor and receptors. Various transport substrates can bind 
to import or export receptors directly, or in the presence of adaptors, to form receptor-
substrate transport complexes. The transport complexes can associate with NPC and 
transport substrates via the NPC unidirectionally.  The receptors then dissociate from 
their respective substrates, and then recycle back to their original compartment (Mattaj 
and Englmeier, 1998). IRFs contain nuclear localization signals (NLSs) and NESs, 
whereby exposure of these signals determine the subcellular localization (Fig1.13).  
1.5.4.1 Nuclear localization signals in IRFs 
The NLS sequences identified in IRF family members are not highly conserved 
throughout the IRF family (Fig 1.13).  There are two classes of NLSs that have been 
identified in IRFs. The first is the monopartite basic NLS, which consists of a short 
sequence containing a single cluster of basic amino acids, often proceeded by an acidic 
amino acid or a proline. For example, IRF3 contains an intrinsic NLS of 
77
KR
78 
within 
the DBD (Kumar et al., 2000). The second is the bipartite basic NLS where two 
interdependent clusters of basic amino acids are separated by a flexible spacer and 
neutral and acidic residues flank the motif (Mattaj and Englmeier, 1998). The IRF1 NLS 
flanks the DBD C-terminally and includes two amino acid sequences that are rich in 
basic residues with a five amino acid spacer 
120
RKERKSKn5KSKTKRK
138
. In IRF2, 
there is a basic amino acid sequence at the retrospective position of IRF1 that shares ten 
of the 12 basic residues, which suggests a similar function (Schaper et al., 1998). The 
NLS that specifies IRF nuclear accumulation are generally contained within or flank the 
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DBD. With the exception of IRF5, which contains two NLS, a N-terminal NLS 
46
PRRVRLK
52
 and a C-terminal NLS 
448
PREKKLI
454
 (Barnes et al., 2002).  
1.5.4.2. Nuclear export signals in IRFs 
NES sequences were identified in IRF3, IRF5 and IRF7 (Lin et al., 2000b), all of which 
were shown to be predominantly cytoplasmic in uninfected cells. All the NES identified 
were shown to have a leucine-rich sequence.  Both IRF3 and IRF5 cytoplasmic 
localization was shown to be dependent on the NESs. Furthermore, chromosomal region 
maintenance (CRM1) is a shuttling receptor that binds to NESs to export target proteins 
from the nucleus to the cytoplasm. Previous studies show that IRF3 and IRF5 directly 
interact with CRM1 and their nuclear export is mediated by the CRM1 pathway (Kumar 
et al., 2000; Lin et al., 2005). This could present a common theme for controlling IRF 
function.  
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IRF family 
member 
Subcellular 
localization 
NLS sequence NES sequence 
IRF-1 nucleus 
120
RKERKSKn5KSKTKRK
138
  
IRF-2 nucleus 
120
KKGKKPKn5KVKnnKQ
138
  
IRF-3 cytoplasm 
77
KR
78
 
141
ILDELLG
147
 
IRF-4 nucleus 
66
KGKFRn10KTRLR
85
  
IRF-5 nucleus 
46
PRRVRLK
52       448
PREKKLI
454
 
150
LQRMLPSLSLT
161
 
IRF-6 cytoplasm   
IRF-7 cytoplasm  
448
LVLVKLEPWLCRVHL
462
 
IRF-8 nucleus 
66
KGKFKn10KTRLR
85
  
IRF-9 nucleus 
66
KGKYKn10KTRLR
85
  
 
Figure 1.13. Comparison of NLSs and NESs consensus sequences identified in IRF 
family members. Schematic representation of NLSs (orange) and NESs (yellow) in IRF 
family members. List of NLSs and NESs sequences identified in IRF family members. 
(Savitsky et al., ; Schaper et al., 1998; Kumar et al., 2000; Lau et al., 2000; Lin et al., 
2000b; Barnes et al., 2002)  
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1.6. Aims and Objectives 
Since the identification of mutations in IRF6 as the causative gene of the orofacial 
clefting disorders VWS and PPS (Kondo et al., 2002), there have been extensive studies 
conducted to identify novel mutations in IRF6 in VWS and PPS patients in different 
geographic populations. The analysis of the frequency and distribution of VWS and PPS 
mutations in IRF6 emphasize the importance of the DBD and the IAD (de Lima et al., 
2009). However, there has been little progress in establishing how variations in IRF6 
have a consequential effect on its functional role during palatal development that lead to 
the diverse VWS and PPS phenotypes. The aim of this study is to elucidate the molecular 
function of IRF6 and determine how the disease causing mutations affect IRF6 function. 
In this study the DNA-binding ability of IRF6 will be investigated and the relevance of 
subcellular localization and phosphorylation on the regulation of IRF6 function will be 
assessed.  
The transactivation mechanism of IRF6 is still poorly understood. To unravel the 
mechanistic role of IRF6 in transcriptional regulation, PCR-based site selection will be 
used to define the IRF6 recognition sequence. The IRF6 DNA-binding sequence can 
consequently be used in in vivo reporter assays to examine the effects of VWS and PPS 
causing mutations on the transcriptional activity of IRF6.  
An enhanced green fluorescent protein (EGFP) tagged IRF6 recombinant protein 
will be used to visualize the subcellular localization of IRF6 in vivo, by fluorescent 
microscopy. The effects of VWS and PPS missense mutations on IRF6 distribution will 
then be assessed. Various factors will then be screened to investigate if they may regulate 
the nuclear translocation and transcriptional activation of IRF6. Finally biochemical 
dissections of IRF6 will be carried out to identify the functional domains that are 
responsible for IRF6 subcellular localization. 
Studies are necessary to assess whether IRF6 functional activity is modulated by 
phosphorylation. Firstly, a phosphatase assay is important to confirm that IRF6 is indeed 
subject to phosphorylation. Mutational analysis of potential phosphorylation sites will 
then be carried out in order to identify regulatory phosphorylation sites. Finally, mass 
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spectrometry analysis of IRF6 protein will be used to help identify sites that are 
phosphorylated.  
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2.1. Protein purification of IRF6 proteins 
2.1.1. Nickel affinity chromatography   
Nickel Affinity chromatography under denaturing conditions was the first stage of 
protein purification for specific binding of hexahistidine-tagged IRF6-DBD (His-IRF6-
DBD) proteins. The His-IRF6-DBD was purified from BL21(DE3)-LysS cells 
harboring the pET-14b-IRF6-DBD.  The transformants were grown in a starter culture 
of 50 ml of luria broth (LB) containing 100 μg/ml ampicillin and 34 μg/ml 
chloramphenicol overnight at 37 °C in a shaker. The starter culture was then used to 
grow a 1 L culture of LB containing 100 μg/ml ampicillin and 34 μg/ml 
chloramphenicol at 37 °C in a shaker until the OD600nm reached between 0.6-0.8, 
indicating log phase growth. The IRF6 polypeptide was overexpressed by induction 
with 0.1 mM isopropyl-β-thiogalactopyranosid (IPTG) shaking at 37 °C for 3 hours. 1 L 
cultures were then centrifuged at 4000 revolutions per minute (rpm) for 10 mins. The 
cell pellet from 2 L cultures was resuspended in 10 ml buffer B (8 M urea, 0.1 M 
NaH2PO4, 0.01 M Tris-Cl pH 8) and incubated with agitation for 15 mins at room 
temperature. The cells were lysed by sonication at 40% amplitude with 5 cycles of 10 
seconds on and 10 seconds off on ice. The lysate was centrifuged at 17,000 rpm for 10 
mins to collect the supernatant containing the soluble proteins. 4 ml of 50% nickel-
nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) was added to the supernatant and 
incubated with agitation for 1 hour at room temperature to ensure specific binding of 
His-IRF6-DBD. The lysate-resin mixture was then transferred onto a Bio-rad column 
(BIO-RAD) for gravity-flow chromatography. The flow through was removed and the 
column was washed with 60 ml buffer C (8M urea, 0.1M NaH2PO4, 0.01M Tris-Cl pH 
6.5). The bound histidine tagged IRF6 polypeptide was eluted from the Ni-NTA column 
with 3 ml buffer E (8 M urea, 0.1 M NaH2PO4, 0.01 M Tris-Cl pH 4.5) for further 
refolding.  
To ensure the correct folding of the His-IRF6-DBD the eluate was dialyzed 
against HK200 buffer (50 mM N-2-hydroxyethylpiperazine-N‟-2ethanesulfonic acid 
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(HEPES), 200 mM KCl, 10% glycerol, pH 7.5). The eluate was transferred into a Slide-
A-Lyzer mini dialysis unit, 7 K MWCO (Pierce) with the base submerged in buffer for 
dialysis overnight at 4 °C and further dialyzed with fresh buffer HK200 buffer for 3 
hours at 4 °C.  
2.1.2. Heparin sulphate chromatography  
The second step of His-IRF6-DBD purification involved heparin sulphate 
chromatography. 5 ml HiTrap
TM
 Heparin HP column (GE Healthcare) was prepared by 
washing with 20 ml of dH20. The column was attached to the BioLogic HR System 
(BIO-RAD) and pre-equilibrated with HK200 buffer with 10 mM dithiothreitol (DTT) 
at 1 ml/min flow rate until baseline absorbance at 280 nm was stable.   
The purification was then performed with an isocratic flow of HK200 buffer 20 
ml at a flow rate of 1-2 ml/min to obtain a stable baseline. Then 8 ml of the dialysed 
elute containing soluble protein was injected with HK200 buffer at a flow rate of 0.5 
ml/min. The column was then washed with 15 ml of HK200 buffer to remove proteins 
with non-specific binding. The proteins bound to the column were eluted with a linear 
ascending gradient (20 ml) from 200 mM to 1000 mM KCl using HK1000 buffer (50 
mM HEPES, 1000 mM KCl, 10% glycerol, pH 7.5) and a final isocratic flow of 5 ml of 
HK1000 buffer. Fractions of the purification were collected. 
Finally, fractions containing His-IRF6-DBD were dialysed into HA500 (50 mM 
HEPES, 500 mM Ammonium acetate, 10% glycerol, pH 6.5) as previously described. 
The dialysates containing His-IRF6-DBD in HA500 were concentrated using a vivaspin 
5000 MW (Viva Science) and centrifuging at 4,000 rpm until the concentration was ~10 
mg/ml. 
2.1.3. In vitro translation of proteins  
TnT® T7/SP6 coupled reticulocyte lysate system (Promega) was used to synthesize in 
vitro translate proteins with a T7 promoter, in accordance with manufacturer‟s protocol. 
The translated proteins were labeled with L-[35S]-methionine (PerkinElmer). Protein 
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yields were analyzed by sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis (PAGE). The gel was immersed in fixing solution (20% methanol, 10% 
glacial acetic acid) for 20 mins, then dried on a Whatmann 3MM paper covered by cling 
film at 80 °C for 1 hour in a gel dryer (BioRad). Proteins were detected using a 
phosphorimager and Quantity One software (BioRad). 
2.1.4. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
The sequential steps of the protein expression and purification were monitored by SDS-
PAGE analysis. The protein samples were denatured by mixing protein sample at a ratio 
of 4:1 with a 5x loading buffer (0.625 M Tris-Cl (pH 6.8), 50% glycerol, 10% SDS, 
10% ß-mercaptoethanol, 0.05% bromophenol blue) and heating at 100 °C for 5 mins. 
The SeeBlue plus2 (Invitrogen) was used as a molecular marker. The samples were run 
on an 8-12% SDS gel at 250 volts with the time adjusted according to the percentage of 
polyacrylamide gel used and the protein molecular weights of interest.   
 To visualize protein bands, the gels were stained with coomassie blue (0.2% 
coomassie blue, 7.5% glacial acetic acid, 50% ethanol) and then destained with 
destaining solution (5% ethanol, 7.5% glacial acetic acid).    
2.2. Electrophoretic mobility shift assay  
2.2.1. Generation of double-stranded oligonucleotides  
To generate double stranded (ds) oligonucleotides of the desired sequence under 
investigation, two complementary single-stranded oligonucleotides were designed, each 
containing an additional CAGT sequence at the 5‟ end.  All oligonucleotides were 
purchased from Eurofins MWG Operon. The annealing reaction consisted of 1 μg of 
each single-stranded oligonucleotide in a total volume of 20 μl in TE buffer (10 mM  
tris HCl (pH 8.0) 1 mM ethylene diamine tetra-acetic acid (EDTA)). The annealing 
reaction was heated to 100 °C for 3 mins then immediately transferred into a beaker 
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containing 1.5 L of water at 80 °C which was then left to cool to room temperature. The 
annealed oligonucleotides were stored at -20 °C. 
2.2.2. Radiolabeling oligonucleotides 
Klenow reaction was used for radioactive labeling of ds oligonucleotides with 5‟ 
overhangs. The klenow reaction contained 2 μl of 0.1 μg/μl ds oligonucleotides, 1 μl 
Klenow enzyme (Roche), 1 μl of 2 U/μl Klenow buffer (Roche), 1 μl 2 mM 
deoxynucleotide-5‟-triphosphate (dNTP) without deoxyadenosine-5‟-triphosphate 
(dATP), 2 μl radiolabelled [α-32P] dATP made up to a total of 10 μl using distilled water. 
The Klenow mixture was incubated at 37 °C for 30 mins. To purify radiolabelled 
oligonucleotides, the 10 μl of Klenow reactions were resolved on a 10% non-denaturing 
polyacrylamide gel in 1x Tris Borate EDTA (TBE: 45 mM tris-borate, 1 mM EDTA) 
running buffer and run at 30 mA for 2 hours. The radiolabelled oligonucleotides were 
excised and the gel slice immersed in 300 μl TE buffer overnight. The 300 μl TE buffer 
containing ds oligonucleotides was mixed with 1 ml ethanol, 30 μl Miniprep III [3M 
potassium acetate; 11.5% acetic acid] and 1 μl 20 mg/ml glycogen. The mixture was 
incubated at -80 °C for 1 hour and then centrifuged at 13,000 rpm for 10 mins. The 
pellet was washed with 100 μl of 70% ethanol and centrifuged at 13,000 rpm for 10 
mins. The pellet was air dried for 10 mins and then dissolved in 50 μl TE buffer. 
2.2.3. Electrophoretic mobility shift assay  
The DNA-binding affinity of His-IRF6-DBD was examined by electrophoretic mobility 
shift assay (EMSA) using [α-32P] dATP radiolabelled DNA.  The binding reactions 
contained 2 μl DZ buffer (25 mM HEPES pH 7.9, 20% Glycerol, 2 mM MgCl2, 1 mM 
DTT, 0.1 μM ZnCl2, 0.2 mM EDTA), 2 μl 4xFPF (20 μM Spermidine, 23.5 μM EDTA), 
1 μl polydeoxyinosinic deoxycytidylic acid (dI/dC) (250 µg/ml), 1 μl Bovine Serum 
Albumin (BSA) (20 mg/ml), 1.5 μl KCl (1 M), and 4-6 μl His-IRF6-DBD protein which 
was adjusted with distilled water to a total volume of 15 μl. The binding reactions were 
pre-incubated at room temperature for 20 mins. 2 μl of 32P-labeled dsDNA was added 
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and mixed gently. 2 μl of loading dye 20% Ficoll, 0.25% xylene cyanol, 0.25% 
bromophenol blue, 70 mM ethylene diamine tetra-acetic acid (EDTA), 4.6 mM Tris-Cl 
pH 6.8 was added to each sample. The DNA-protein complexes were resolved on a 5% 
non-denaturing polyacrylamide gel in 1x TBE running buffer and run at 21 mA for 3-4 
hours.  Gels were fixed in fixing solution (70% water, 20% methanol, 10% acetic acid) 
for 20 mins and dried under vacuum for 1 hour at 80 °C, then visualized on a medical 
X-ray film (Fujifilm) or a phosphorimager screen.  
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Name Oligonucleotide  Sequence (5‟-3‟) Description  
S17-1 Sense: CAGTCGTCAACCGAAACTAGGGCG 
Anti sense: CAGTCGCCCTAGTTTCGGTTGACG 
IRF6 recognition sequence 
S17-2 Sense: CAGTCGTCAACCGATACTAGGGCG 
Anti sense: CAGTCGCCCTAGTATCGGTTGACG 
IRF6 recognition sequence containing 
alteration in GAAAC core sequence  A>T 
S17-3 Sense: CAGTCGTCAACCGACACTAGGGCG 
Anti sense: CAGTCGCCCTAGTGTCGGTTGACG 
IRF6 recognition sequence containing 
alteration in GAAAC core sequence  A>C 
S17-4 Sense: CAGTCGTCAACCGAAAGTAGGGCG 
Anti sense: CAGTCGCCCTACTTTCGGTTGACG 
IRF6 recognition sequence containing 
alteration in GAAAC core sequence C>G 
S17-5 Sense: CAGTCGTCAACGGAAACTAGGGCG 
Anti sense: CAGTCGCCCTAGTTTCCGTTGACG 
IRF6 recognition sequence containing 
alteration in the CC spacer C>G 
S17-dimer Sense: CAGTCGTCAACCGAAACCGAAACTAGGGCG 
Anti sense: CAGTCGCCCTAGTTTCGGTTTCGGTTGACG 
Two overlapping IRF6 recognition 
sequence 
GBP-dimer Sense: CAGTCGTCAATATGAAACTGAAAGTAGGGC 
Anti sense: CAGTCGCCCTACTTTCAGTTTCATATTGACG 
GBP- IRE containing two IRF recognition 
sequences 
ISG15-multi Sense:CAGTCTGGGGAAAGGGAAACCGAAACTAGGGCG  
Anti sense: CAGTCGCCCTAGTTTCGGTTTCCCTTTCCCCAG 
ISG15-IRE containing three IRF 
recognition sequences 
Table 2.1. List of oligonucleotides used for EMSA probes. 
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2.3. Cloning procedures 
2.3.1. Plasmid construction 
The mouse IRF6-DBD (1-113) encoding nucleotide sequence was amplified by PCR 
using forward and reverse primers
 
containing EcoRI and BamHI sites, respectively.
 
After EcoRI and BamHI digestion, the IRF6-DBD was inserted in the EcoRI and BamHI 
site of pVP16 vector. This
 
construct will be referred to as VP16AD-IRF6-DBD. The 
reporter gene contructs pGL3P-5IRF6S and pGL3P-5IRF6M were generated by 
annealing complementary oligonucleotides containing 5 multimerized IRF6 recognition 
sequences. 5IRF6S and 5IRF6M were digested with XhoI and SacI, and then ligated 
into pGL3-promoter luciferase reporter vectors. All enhanced green fluorescent protein 
(EGFP) tagged IRF6 C-terminal and N-terminal deletion mutants were generated by 
PCR and inserted into XhoI and PstI sites of pEGFP-C3, with the exception of IRF6-11-
467 in XhoI and XmaI. 
2.3.2. Polymerase Chain Reaction  
Polymerase chain reaction (PCR) was used for the amplification of specific DNA 
fragments. The PCR reaction mixture consisted of 20 ng of DNA template, 2 μl 5 mM 
dNTPs (New England Biolabs), 2 μl 5 mM forward primer, 2 μl 5 mM reverse primer, 5 
μl of 10x cloned Pfu buffer (Stratagene) and distilled water was added to make up a 
final volume of 50 μl. The PCR reaction mixture was preheated at 99 °C for 3 mins as 
an initial DNA denaturing step. 0.5 μl of cloned Pfu polymerase (2.5 U/μl, Stratagene) 
was then added. The PCR cycle parameters were set at: 95 °C for 30 secs for denaturing, 
55 °C to 63 °C for 60 secs for annealing the primers, and 72 °C for 90 secs for 
elongation for 29 consecutive cycles. Then a final extension step at 72 °C for 5 mins. 
The product of each PCR reaction was analyzed by electrophoresis on 1% (w/v) agarose 
gel. The complementary oligonucleotides were annealed as previously described. 
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Table 2.2. List of expression plasmids of IRF6 recombinant proteins. 
 
Plasmid  Description Reference  
peGFPC1-
IRF6  
Full length mouse IRF6  is fused to the C-
terminus of a CMV promoter driven 
expression vector encoding Enhanced 
Green Fluorescent Protein (peGFP-C1) 
Gift from Prof. M. Dixon 
Lab, Manchester 
FLAG-
IRF6  
Full length mouse IRF6  is fused to the C-
terminus of a T7 promoter driven 
expression vector encoding two FLAG 
epitopes (pSG5-KF2M1) 
Gift from Prof. M. Dixon 
Lab, Manchester 
PCDNA3-
IRF6-401 
 
a.a 1-401 of IRF6 inserted into CMV 
promoter driven pcDNA3.1 expression 
vector 
Gift from Prof. M. Dixon 
Lab, Manchester 
PCDNA3-
IRF6-225 
 
a.a 1-225 of IRF6 inserted into CMV 
promoter driven pcDNA3.1 expression 
vector 
Gift from Prof. M. Dixon 
Lab, Manchester 
PCDNA3-
IRF6-190 
 
a.a 1-190 of IRF6 inserted into CMV 
promoter driven pcDNA3.1 expression 
vector 
Gift from Prof. M. Dixon 
Lab, Manchester 
PCDNA3-
IRF6-152 
a.a 1-152 of IRF6 inserted into CMV 
promoter driven pcDNA3.1 expression 
vector 
Gift from Prof. M. Dixon 
Lab, Manchester 
PCDNA3-
IRF6-113 
a.a 1-113 of IRF6 inserted into CMV 
promoter driven pcDNA3.1 expression 
vector 
Gift from Prof. M. Dixon 
Lab, Manchester 
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Plasmid  Oligonucleotide Sequence (5’-3’) Description  
pGL3P-
5IRF6S 
Sense:CTCGTCAACCGAAACTAGGGCTCGTCAACCGAAACTAGGG
CTCGTCAACCGAAACTAGGGCTCGTCAACCGAAACTAGGGCTCG
TCAACCGAAACTAGGGCC 
Anti sense: 
TCGAGGCCCTAGTTTCGGTTGACGAGCCCTAGTTTCGGTTGACG
AGCCCTAGTTTCGGTTGACGAGCCCTAGTTTCGGTTGACGAGCC
CTAGTTTCGGTTGACGAGAGCT 
5 multimerized IRF6 consensus sequences 
incorporated in EcoRI and BamHI of the 
pGL3-promoter vector.  
pGL3P-
5IRF6M 
Sense: 
CTCGTCAACCGAGCGTAGGGCTCGTCAACCGAGCGTAGGGCTCG
TCAACCGAGCGTAGGGCTCGTCAACCGAGCGTAGGGCTCGTCAA
CCGAGCGTAGGGCC 
Anti sense: 
TCGAGGCCCTACGCTCGGTTGACGAGCCCTACGCTCGGTTGACG
AGCCCTACGCTCGGTTGACGAGCCCTACGCTCGGTTGACGAGCC
CTACGCTCGGTTGACGAGAGCT 
5 multimerized IRF6 consensus sequences 
with alterations at the GAAAC core sequence  
to GAGCG incorporated in EcoRI and 
BamHI of the pGL3-promoter vector. 
Table 2.3. List of oligonucleotides for the construction of plasmids. 
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Plasmid  Oligonucleotide Sequence (5’-3’) Description  
pVP16AD-
IRF6-DBD 
Sense: GATCGAATTCATGGCCCTCCACCCTCGAA                               
Anti sense: GATCGGATCCTCACACTTGATAGATCTTCACAGG 
IRF6-DBD- a.a 1-113 inserted into XhoI and SacI 
of the a N-terminal VP16 activation domain 
encoding vector pVP16AD 
pEGFPC3-
IRF6-60 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense:  
 CCGCCCTGCAGTCACCAAGCCTTAAAAATGGTGTTTTCTTC 
a.a 1-60 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding 
EGFP (pEGFP-C3) 
pEGFPC3-
IRF6-70 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
 CCGCCCTGCAGTCACCCTTCCTGGTACTTTCCGGTCTCCAC 
a.a 1-70 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding 
EGFP (pEGFP -C3) 
pEGFPC3-
IRF6-80 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
 CCGCCCTGCAGTCACTTCCATTTAGCTGGGTCAGGATCGTC 
a.a 1-80 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP (pEGFP-C3) 
pEGFPC3-
IRF6-90 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
 CCGCCCTGCAGTCAGCTTTTGTTGAGAGCACAGCGGAGCTG 
a.a 1-90 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP (pEGFP-C3) 
pEGFPC3-
IRF6-100 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
 CCGCCCTGCAGTCAGGTGCCATCGTACATCAAGTTGAACTCC 
a.a 1-100 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP (pEGFP-C3) 
pEGFPC3-
IRF6-113 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT                                  
Anti sense: 
 CCGCCCTGCAGTCACACTTGATAGATCTTCACAGGATTCAT                
a.a 1-113 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP (pEGFP-C3) 
pEGFPC3-
IRF6-120 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
 CCGCCCTGCAGTCACTGGGGCTGGGGGATGTCACACACTT 
a.a 1-120 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP (pEGFP-C3) 
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Plasmid  Oligonucleotide Sequence (5’-3’) Description  
pEGFPC3-
IRF6-130 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT  
Anti sense: 
CCGCCCTGCAGTCACCCTGTGGATCCTGGATTAATGACAGAGCC 
a.a 1-130 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP (pEGFP-C3) 
pEGFPC3-
IRF6-140 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT  
Anti sense: 
CCGCCCTGCAGTCAATCATTATCTTTCTCATCCCAAGGAGCAGA 
a.a 1-140 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-150 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT  
Anti sense: 
CCGCCCTGCAGTCAAAGTTCATCCTCCTCCTCATCTTCATCCAC 
a.a 1-150 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-160 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
CCGCCCTGCAGTCACTGGATGGGGACATGGTGCTGTGACT 
a.a 1-160 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-164 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: 
CGCCCTGCAGTCAGGGGAAGGTGTCCTGGATGGGGACATGG 
a.a 1-164 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-170 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT  
Anti sense: 
CCGCCCTGCAGTCAACCGTTGATGTTCAGGAAGGGGAAGGTGTC 
a.a 1-170 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-180 
Sense: GGCGGGCTCGAGATGGCCCTCCACCCTCGAAGAGT 
Anti sense: CCGCCCTGCAGTCAGTTGCCCACGCTGGCTGGC 
a.a 1-180 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-11-
467 
Sense: GCGGGCTCGAGATGAAGCCCTGGCTGGTGGCCCAG 
Anti sense: 
GATCCCCGGGTCACTGGGCAGGCAGAGCCTGTGGCAG 
a.a 11-467 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
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Table 2.4. List of PCR primers for the generation of IRF6 C-terminal and N-terminal deletion mutant. 
Plasmid  Oligonucleotide Sequence (5’-3’) Description  
pEGFPC3-
IRF6-11-
113 
Sense: GCGGGCTCGAGATGAAGCCCTGGCTGGTGGCCCAG 
Anti sense: 
CCGCCCTGCAGTCACACTTGATAGATCTTCACAGGATTCAT 
a.a 11-113 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-11-60 
Sense: GCGGGCTCGAGATGAAGCCCTGGCTGGTGGCCCAG 
Anti sense: 
CCGCCCTGCAGTCACCAAGCCTTAAAAATGGTGTTTTCTTC 
a.a 11-60 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-12-
113 
Sense: GCGGGCTCGAGATGCCCTGGCTGGTGGCCCAGG 
Anti sense: 
CCGCCCTGCAGTCACACTTGATAGATCTTCACAGGATTCAT 
a.a 12-113 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-12-60 
Sense: GCGGGCTCGAGATGCCCTGGCTGGTGGCCCAGG 
Anti sense: 
CCGCCCTGCAGTCACCAAGCCTTAAAAATGGTGTTTTCTTC 
a.a 12-60 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3) 
pEGFPC3-
IRF6-16-
113 
Sense: GCGGGCTCGAGATGGCCCAGGTGGACAGTGGCCTC    
Anti sense: 
CCGCCCTGCAGTCACACTTGATAGATCTTCACAGGATTCAT 
a.a 16-113 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3)) 
pEGFPC3-
IRF6-16-60 
Sense: GCGGGCTCGAGATGGCCCAGGTGGACAGTGGCCTC 
Anti sense: 
CCGCCCTGCAGTCACCAAGCCTTAAAAATGGTGTTTTCTTC 
a.a 16-60 of IRF6 is fused to the C-terminus of a 
CMV promoter driven expression vector encoding  
EGFP ( pEGFP -C3)) 
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2.3.3. Restriction digestion  
DNA was cleaved using the appropriate restriction enzyme and buffer in accordance 
with the manufacturer‟s recommendation (Fermentas, Roche or New England Biolabs). 
Restriction digestion reactions were incubated at 37 °C for 1-6 hours or overnight. 
Electrophoretic analysis was used to analyze the DNA fragments. 1-2 μl 
O‟GeneRulerTM DNA ladder (Fermentas) and the restriction digests were run on 1% 
agarose gel at 90 V for 30 mins in 1x tris acetate, EDTA (TAE) buffer (40 mM tris 
acetate, 1 mM EDTA). The DNA was stained with ethidium bromide and visualized 
under an ultraviolet source. DNA was excised and purified using the QIAquick gel 
extraction kit (Qiagen) following the manufacturer‟s protocol.  
2.3.4. Ligation  
Ligations were carried out using a 1:3 ratio or 1 μl:16 μl ratio of vector DNA:insert 
DNA, 1 μl of T4 ligase high concentration (5 U/μl, Invitrogen) and 3 μl of 5x T4 ligase 
buffer (Invitrogen), made up to a total of 15-22 μl using distilled water. A negative 
control was set up for each ligation reaction in which distilled water was used as a 
substitute for insert DNA. Samples were incubated at room temperature for 2-5 hours. 1 
μl of ligation reaction was used to transform Novablue competent cells (Novagen) 
following the manufacturer‟s instructions. Alternatively, 8 μl of ligation reaction was 
used to transform DH5α supercompetent cells (New England Biolabs) following the 
manufacturer‟s instructions. The bacteria were plated on selective LB plates and 
incubated at 37 °C overnight. Plasmids created from PCR products were ethanol 
precipitated and then confirmed by sequencing. 
2.3.5. Transformation of Bacteria 
To transform plasmid DNA, BL21(DE3) and BL21(DE3)-LysS were made competent 
using transformation & storage solution (TSS: 85 % LB medium 10% Polyethylene 
glycol (wt/vol, MW 8000), 5% Dimethyl Sulfoxide (DMSO) (vol/vol), 50 mM MgCl2 (pH 
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6.5). The cells were grown at 37ºC with shaking until the cells reach early log phase 
(OD600 = 0.25-0.4). 1 ml of early log-phase cells was centrifuged at 4 ºC for 1 min and 
the pellet was resuspended in 100 µl ice-cold 1x TSS. The TSS competent cells were 
frozen in liquid nitrogen and stored at -80 ºC. For transformation, approximately 10 ng 
of DNA was added to thawed TSS-competent cells and incubated on ice for 10 mins. 
The cells were then incubated at room temperature for 10 mins and then transferred 
back onto ice for 10 mins.  1 ml of LB media was added to the cells and the cells were 
incubated at 37 ºC for 1 hour shaking. The cells were plated onto LB agar plates 
containing selective antibiotic and incubated at 37 °C overnight. 
 For transformation of DH5α cells, DH5α high efficiency competent cells (New 
England BioLabs) and XL-1 Blue supercompetent cells (Stratagene), approximately 10 
ng of plasmid DNA was added to the bacteria, mixed gently and incubated in ice for 30 
mins. The DH5α cells were then heat-shocked at 42 °C for 45 secs, then transferred to 
ice.  250 ml of SOC media was added to the cells, which were then incubated at 37 ºC 
for 1 hour shaking. The cells were plated onto LB agar plates containing selective 
antibiotic at 37 °C overnight. 
2.3.6. Purification of plasmid DNA 
Small scale preparations of plasmid DNA, bacterial cells containing the desired 
plasmids were inoculated into 3 ml of LB media containing selective antibiotic and 
grown overnight at 37 °C with shaking. DNA was extracted from 3 ml overnight culture 
using the QIAprep® Spin Miniprep Kit (Qiagen) following the manufacturer‟s protocol. 
For larger quantities of DNA, transformants were inoculated into 100 ml of LB media 
containing selective antibiotic and grown overnight at 37 °C with shaking. The plasmid 
DNA was isolated by the QIAGEN Plasmid Midi Kit (Qiagen) in accordance with the 
manufacturer‟s protocol. 
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2.3.7. Ethanol precipitation of DNA and sequencing 
25 μl of miniprep DNA was mixed with 2 μl of Miniprep III and 70 μl of ethanol. The 
mixture was incubated at -80 °C for 1 hour and then centrifuged at 13,000 rpm for 10 
mins. The pellet was then washed with 50 μl of 70% ethanol and centrifuged at 13,000 
rpm for 10 mins. The supernatant was aspirated and the pellet was left to air-dry at room 
temperature. Plasmids requiring sequence analysis were ethanol precipitated and then 
sent for sequencing by Eurofin MWG Operon (London). 
2.3.8. Site directed mutagenesis 
The IRF6 point mutations were generated by site directed mutagenesis (SDM). The 
SDM reaction mixture consisted of 20 ng of DNA template, 1 μl 100 mM dNTPs (New 
England Biolabs), 1.25 μl of 100 ng/μl sense oligonucleotide, 1.25 μl of 100 ng/μl anti-
sense oligonucleotide, 5 μl of 10x Cloned Pfu DNA polymerase reaction buffer 
(Stratagene) and distilled water was added to make up a final volume of 50 μl. 1 μl of 
Pfu turbo DNA polymerase (2.5 U/μl, Stratagene) was then added to the SDM reaction 
mixture. The PCR cycle parameters were set at: 99 °C for 5 mins as an initial DNA 
denaturing step, 95 °C for 30 secs for denaturing, 60 °C for 1 min for annealing the 
primers, and 68 °C for 20 mins for elongation for 16 consecutive cycles. Then a final 
extension step at 68 °C for 40 mins. The reaction mixture was then treated with 1 μl 
DpnI restriction enzyme for 1 hour at 37 °C to digest the parental DNA template. 4 μl of 
Dpn1 treated reaction mixture was used to transform XL-1 Blue supercompetent cells 
(Stratagene), following the manufacturer‟s instructions.   
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Plasmid  Primer Sequence (5’-3’) 
EGFP-IRF6  
V18A 
Sense: GGCTGGTGGCCCAGGCGGACAGTGGCCTCTAC 
Anti sense: GTAGAGGCCACTGTCCGCCTGGGCCACCAGCC 
EGFP-IRF6  
V18M 
Sense: GGCTGGTGGCCCAGATGGACAGTGGCCTCTAC 
Anti sense: GTAGAGGCCACTGTCCATCTGGGCCACCAGCC 
EGFP-IRF6  
L22P 
Sense: CAGGTGGACAGTGGCCCCTACCCTGGTCTCATC 
Anti sense: GATGAGACCAGGGTAGGGGCCACTGTCCACCTG 
EGFP-IRF6  
W60G 
Sense: GAAAACACCATTTTTAAGGCTGGGGCTGTGGAGACCGGAAA 
Anti sense: CTTTCCGGTCTCCACAGCCCCAGCCTTAAAAATGGTGTTTTC 
EGFP-IRF6  
G70R 
Sense: CGGAAAGTACCAGGAACGGGTAGACGATCCTGACCC 
Anti sense: GGGTCAGGATCGTCTACCCGTTCCTGGTACTTTCCG 
EGFP-IRF6  
P76S 
Sense: GGTAGACGATCCTGACTCAGCTAAATGGAAGGCTCAGCTC 
Anti sense: GAGCTGAGCCTTCCATTTAGCTGAGTCAGGATCGTCTACC 
EGFP-IRF6  
R84C 
Sense: GCTAAATGGAAGGCTCAGCTCTGCTGTGCTCTCAACAAAAGC 
Anti sense: GCTTTTGTTGAGAGCACAGCAGAGCTGAGCCTTCCATTTAGC 
EGFP-IRF6  
R84G 
Sense: GCTAAATGGAAGGCTCAGCTCGGCTGTGCTCTCAACAAAAGC 
Anti sense: GCTTTTGTTGAGAGCACAGCCGAGCTGAGCCTTCCATTTAGC 
EGFP-IRF6  
R84H 
Sense: GCTAAATGGAAGGCTCAGCTCCACTGTGCTCTCAACAAAAGC 
Anti sense: GCTTTTGTTGAGAGCACAGTGGAGCTGAGCCTTCCATTTAGC 
EGFP-IRF6  
R84P 
Sense: GCTAAATGGAAGGCTCAGCTCCCCTGTGCTCTCAACAAAAGC 
Anti sense: GCTTTTGTTGAGAGCACAGGGGAGCTGAGCCTTCCATTTAGC 
EGFP-IRF6  
K89A 
Sense: CTCCGCTGTGCTCTCAACGCAAGCAGGGAGTTCAACTTG 
Anti sense: CAAGTTGAACTCCCTGCTTGCGTTGAGAGCACAGCGGAG 
EGFP-IRF6  
K89E 
Sense: CTCCGCTGTGCTCTCAACGAAAGCAGGGAGTTCAACTTG 
Anti sense: CAAGTTGAACTCCCTGCATTCGTTGAGAGCACAGCGGAG 
EGFP-IRF6  
D98H 
Sense: GAGTTCAACTTGATGTACCATGGCACCAAGGAAGTGCCC 
Anti sense: GGGCACTTCCTTGGTGCCATGGTACATCAAGTTGAACTC 
EGFP-IRF6  
D98V 
Sense: GAGTTCAACTTGATGTACGTGGGCACCAAGGAAGTGCCC 
Anti sense: GGGCACTTCCTTGGTGCCCACGTACATCAAGTTGAACTC 
EGFP-IRF6  
R250G 
Sense: CAACCCCCAGGGCTGCGGGCTCTTCTATGGGGACC 
Anti sense: GGTCCCCATAGAAGAGCCCGCAGCCCTGGGGGTTG 
EGFP-IRF6  
R250Q 
Sense: CAACCCCCAGGGCTGCCAGCTCTTCTATGGGGACC 
Anti sense: GGTCCCCATAGAAGAGCTGGCAGCCCTGGGGGTTG 
EGFP-IRF6  
V274I 
Sense: GTCAGCCTGGAGCAGATCAAGTTCCCAGGTCCAG 
Anti sense: CTGGACCTGGGAACTTGATCTGCTCCAGGCTGAC 
EGFP-IRF6  
L294P 
Sense: CTGTTCACCAGCAAGCCGTTGGATGTCATGGAC 
Anti sense: GTCCATGACATCCAACGGCTTGCTGGTGAACAG 
EGFP-IRF6  
K320E 
Sense: CAGGCTGTGCCAGTGCGAAGTGTACTGGTCAGGGC 
Anti sense: GCCCTGACCAGTACACTTCGCACTGGCACAGCCTG 
EGFP-IRF6  
C374R 
Sense: CTTTTGAGATCTACTTACGCTTTGGGGAAGAGTGGCC 
Anti sense: GGCCACTCTTCCCCAAAGCGTAAGTAGATCTCAAAAG 
EGFP-IRF6  
G376R 
Sense: GAGATCTACTTATGCTTTCGGGAAGAGTGGCCAGATGG 
Anti sense: CCATCTGGCCACTCTTCCCGAAAGCATAAGTAGATCTC 
EGFP-IRF6  
R400W 
Sense: GGTCATCCCAGTGGTGGCTTGGATGATCTATGAGATG 
Anti sense: CATCTCATAGATCATCCAAGCCACCACTGGGATGACC 
 
Table 2.5. List of primers used for site directed mutagenesis to generate disease 
causing EGFP-IRF6 and VP16AD-IRF6-DBD missense mutations. 
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Plasmid name Primer Sequence (5’-3’) Description 
EGFP-IRF6 
S407D 
Sense: GATCTATGAGATGTTTGATGGTGATTTTACCCGGTCC 
Anti sense: GGACCGGGTAAAATCACCATCAAACATCTCATAGATC 
pEGFPC1-IRF6 containing the aspartic acid 
mutation  S407D  
EGFP-IRF6 
T411D 
Sense: GTTTTCTGGTGATTTTGACCGGTCCTTTGACAGTGG 
Anti sense:  CCACTGTCAAAGGACCGGTCAAAATCACCAGAAAAC 
pEGFPC1-IRF6 containing the aspartic acid  
mutation T411D 
EGFP-IRF6 
S413D 
Sense: CTGGTGATTTTACCCGGGACTTTGACAGTGGCAGCG 
Anti sense: CGCTGCCACTGTCAAAGTCCCGGGTAAAATCACCA 
pEGFPC1-IRF6 containing the aspartic acid 
mutation S413D 
EGFP-IRF6 
S416D 
Sense: GATTTTACCCGGTCCTTTGACGATGGCAGCGTTCGCCTGCAG 
Anti sense: CTGCAGGCGAACGCTGCCATCGTCAAAGGACCGGGTAAAATC 
pEGFPC1-IRF6 containing the aspartic acid 
mutation S416D 
EGFP-IRF6 
S418D 
Sense: GGTCCTTTGACAGTGGCGACGTTCGCCTGCAGATCTCC 
Anti sense: GGAGATCTGCAGGCGAACGTCGCCACTGTCAAAGGACC 
pEGFPC1-IRF6 containing the aspartic acid 
mutation S418D 
EGFP-IRF6 
S424D 
Sense: GCGTTCGCCTGCAGATCGACACTCCAGACATCAAAG 
Anti sense: CTTTGATGTCTGGAGTGTCGATCTGCAGGCGAACGC 
pEGFPC1-IRF6 containing the aspartic acid 
mutation S242D 
EGFP-IRF6  
T411D/ S413D 
Sense: GTTTTCTGGTGATTTTGACCGGGACTTTGACAGTGGCAGCG 
Anti sense: CGCTGCCACTGTCAAAGTCCCGGTCAAAATCACCAGAAAAC 
pEGFPC1-IRF6 containing the aspartic acid  
mutation T411D/S413D 
EGFP-IRF6  
S416D/ S418D 
Sense: GATTTTACCCGGTCCTTTGACGATGGCGACGTTCGCCTGCAGATCTC 
Anti sense:GAGATCTGCAGGCGAACGTCGCCATCGTCAAAGGACCGGGTAAAATC 
pEGFPC1-IRF6 containing the aspartic acid 
mutation S416D /S418D 
EGFP-IRF6  4D Sense: GATTTTGACCGGGACTTTGACGATGGCGACGTTCGCCTGCAGATCTC 
Anti sense: GAGATCTGCAGGCGAACGTCGCCATCGTCAAAGTCCCGGTCAAAATC  
pEGFPC1-IRF6 containing the aspartic acid 
mutation T411D/S413D /S416D/S418D 
EGFP-IRF6 5D  
 
Sense:GATCTATGAGATGTTTGATGGTGATTTTGACCGGGAC 
Anti sense: GTCCCGGTCAAAATCACCATCAAACATCTCATAGATC 
pEGFPC1-IRF6 containing the  aspartic 
acid mutation S407D/T411D/S413D 
/S416D/S418D 
EGFP-IRF6 6D  Sense:  GACGTTCGCCTGCAGATCGACACTCCAGACATCAAAG 
Anti sense: CTTTGATGTCTGGAGTGTCGATCTGCAGGCGAACGTC 
pEGFPC1-IRF6 containing the aspartic acid  
mutation S407D/ T411D/S413D /S416D 
/S418D/S242D 
Table 2.6. List of primers used for site directed mutagenesis to generate EGFP-IRF6 phosphomimetic mutations in the S/T rich region  
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Table 2.7. List of primers used for site directed mutagenesis to generate EGFP-IRF6 phosphomimetic mutations in the N-terminal and C-
terminal region. 
 
 
Plasmid name Primer Sequence (5’-3’) Description 
EGFP-IRF6 
S47D 
Sense:  GGAAACATGCCACGCGGCACGACCCCCAACAAGAGGAAGAAAAC 
Anti sense: GTTTTCTTCCTCTTGTTGGGGGTCGTGCCGCGTGGCATGTTTCC 
pEGFPC1-IRF6 containing the  aspartic 
acid   mutation  S47D    
EGFP-IRF6 
S131D 
Sense:  CCAGGATCCACAGGGGATGCTCCTTGGGATGAG 
Anti sense:  CTCATCCCAAGGAGCATCCCCTGTGGATCCTGG 
pEGFPC1-IRF6 containing the  aspartic 
acid   mutation  S131D    
EGFP-IRF6 
S153D 
Sense:  GGATGAACTTGAGCAGGACCAGCACCATGTCCCCATC  
Anti sense:  GATGGGGACATGGTGCTGGTCCTGCTCAAGTTCATCC 
pEGFPC1-IRF6 containing the  aspartic 
acid p  mutation  S153D    
EGFP-IRF6 
S171D 
Sense: CCTGAACATCAACGGTGATCCCATGGCGCCAGCCAG 
Anti sense: CTGGCTGGCGCCATGGGATCACCGTTGATGTTCAGG 
pEGFPC1-IRF6 containing the  aspartic 
acid  mutation  S171D    
EGFP-IRF6 
S187D 
Sense:  TGCAGTGTGGGAAACTGCGACCCCGAATCAGTGTGGCC 
Anti sense:  GGCCACACTGATTCGGGGTCGCAGTTTCCCACACTGCA 
pEGFPC1-IRF6 containing the  aspartic 
acid  mutation  S187D    
EGFP-IRF6 
T425D 
Sense:  GTTCGCCTGCAGATCTCCGATCCAGACATCAAAGATAAC 
Anti sense:  GTTATCTTTGATGTCTGGATCGGAGATCTGCAGGCGAAC 
pEGFPC1-IRF6 containing the  aspartic 
acid mutation   T425D   
EGFP-IRF6 
T445D 
Sense:  CTGTACCGCATCCTTCAAGACCAGGAGAGCTGGCAGCCC 
Anti sense:  GGGCTGCCAGCTCTCCTGGTCTTGAAGGATGCGGTACAG 
pEGFPC1-IRF6 containing the  aspartic 
acid mutation  T445D 
EGFP-IRF6 
S448D 
Sense: GCATCCTTCAAACCCAGGAGGACTGGCAGCCCATGCAGCCTG 
Anti sense: CAGGCTGCATGGGCTGCCAGTCCTCCTGGGTTTGAAGGATGC 
pEGFPC1-IRF6 containing the  aspartic 
acid mutation  S448D 
EGFP-IRF6 
S457D 
Sense: CATGCAGCCTGCCCCCGACATGCAGCTGCCACAGGCTC 
Anti sense: GAGCCTGTGGCAGCTGCATGTCGGGGGCAGGCTGCATG 
pEGFPC1-IRF6 containing the  aspartic 
acid mutation   S457D 
EGFP-IRF6 
S424D/T425D 
Sense:  CAGCGTTCGCCTGCAGATCGACGATCCAGACATCAAAGATAACATC 
Anti sense: GATGTTATCTTTGATGTCTGGATCGTCGATCTGCAGGCGAACGCTG    
pEGFPC1-IRF6 containing the  aspartic 
acid mutation   S424D/T425D   
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Plasmid name Primer Sequence (5’-3’) Description 
EGFP-IRF6  
1A 
Sense: GTTTTCTGGTGATTTTGACCGGTCCTTTGACAGTGG 
Anti sense: CCACTGTCAAAGGACCGGTCAAAATCACCAGAAAAC 
pEGFPC1-IRF6 containing the  alanine  
mutation T411A 
EGFP-IRF6  
2A  
Sense: GTTTTCTGGTGATTTTGACCGGGACTTTGACAGTGGCAGCG 
Anti sense: CGCTGCCACTGTCAAAGTCCCGGTCAAAATCACCAGAAAAC 
pEGFPC1-IRF6 containing the  alanine   
mutation T411A/S413A 
EGFP-IRF6  
4A 
Sense: GATTTTGACCGGGACTTTGACGATGGCGACGTTCGCCTGCAGATCTC 
Anti sense: 
GAGATCTGCAGGCGAACGTCGCCATCGTCAAAGTCCCGGTCAAAATC  
pEGFPC1-IRF6 containing the  alanine  
mutation /T411A/S413A /S416A /S418A 
EGFP-IRF6 
5A  
Sense:GATCTATGAGATGTTTGATGGTGATTTTGACCGGGAC 
Anti sense: GTCCCGGTCAAAATCACCATCAAACATCTCATAGATC 
pEGFPC1-IRF6 containing the  alanine 
mutation S407A/T411A/S413A /S416A 
/S418A 
EGFP-IRF6 
6A  
Sense:  GACGTTCGCCTGCAGATCGACACTCCAGACATCAAAG 
Anti sense: CTTTGATGTCTGGAGTGTCGATCTGCAGGCGAACGTC 
pEGFPC1-IRF6 containing the alanine 
mutation S407A/T411A/S413A /S416A 
/S418A/ S242A 
EGFP-IRF6 
I159A 
Sense: GTCACAGCACCATGTCCCCGCCCAGGACACCTTCCCCTTC 
Anti sense: GAAGGGGAAGGTGTCCTGGGCGGGGACATGGTGCTGTGAC 
pEGFPC1-IRF6 containing the NES  alanine  
mutation I159A 
EGFP-IRF6 
NES 2.1A 
Sense: GTCCCCATCCAGGACACCGCCCCCGCCCTGAACATCAACGGTTC 
Anti sense: GAACCGTTGATGTTCAGGGCGGGGGCGGTGTCCTGGATGGGGAC 
pEGFPC1-IRF6 containing the NES  alanine 
mutations F163A/F165A 
EGFP-IRF6 
NES 2.2A 
Sense: GGACACCTTCCCCTTCGCGAACGCCAACGGTTCTCCCATGG 
Anti sense: CCATGGGAGAACCGTTGGCGTTCGCGAAGGGGAAGGTGTCC 
pEGFPC1-IRF6 containing the NES  alanine 
mutations  F166A/I168A 
EGFP-IRF6 
NES 4A 
Sense: GGACACCGCCCCCGCCGCGAACGCCAACGGTTCTCCCATGG 
Anti sense: CCATGGGAGAACCGTTGGCGTTCGCGGCGGGGGCGGTGTCC 
pEGFPC1-IRF6 containing the NES alanine  
mutations  F163A/F165A/F166A/I168A 
Table 2.8. List of primers used for site directed mutagenesis to generate EGFP-IRF6 alanine mutations in the serine/threonine rich region 
and the predicted nuclear export signal. 
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Plasmid name Primer Sequence (5’-3’) Description 
EGFP-IRF6 
S47A 
Sense:  GGAAACATGCCACGCGGCACGCCCCCCAACAAGAGGAAGAAAAC 
Anti sense:  GTTTTCTTCCTCTTGTTGGGGGGCGTGCCGCGTGGCATGTTTCC 
pEGFPC1-IRF6 containing the  alanine mutation 
S171A 
EGFP-IRF6 
S131A 
Sense:  CCAGGATCCACAGGGGCTGCTCCTTGGGATGAG 
Anti sense: CTCATCCCAAGGAGCAGCCCCTGTGGATCCTGG 
pEGFPC1-IRF6 containing the  alanine  mutation 
S131A 
EGFP-IRF6 
S153A 
Sense:  GGATGAACTTGAGCAGGCACAGCACCATGTCCCCATC  
Anti sense:  GATGGGGACATGGTGCTGTGCCTGCTCAAGTTCATCC   
pEGFPC1-IRF6 containing the  alanine   mutation 
S153A 
EGFP-IRF6 
S171A 
Sense: CCTGAACATCAACGGTGCTCCCATGGCGCCAGCCAG 
Anti sense: CTGGCTGGCGCCATGGGAGCACCGTTGATGTTCAGG 
pEGFPC1-IRF6 containing the  alanine   mutation 
S171A 
EGFP-IRF6 
S187A 
Sense:  TGCAGTGTGGGAAACTGCGCCCCCGAATCAGTGTGGCC 
Anti sense:  GGCCACACTGATTCGGGGGCGCAGTTTCCCACACTGCA 
pEGFPC1-IRF6 containing the  alanine   mutation 
S187A 
EGFP-IRF6 
S424A 
Sense: GCGTTCGCCTGCAGATCGCCACTCCAGACATCAAAG 
Anti sense: CTTTGATGTCTGGAGTGGCGATCTGCAGGCGAACGC 
pEGFPC1-IRF6 containing the  alanine   mutation  
S424A 
EGFP-IRF6 
T425A 
Sense:  GTTCGCCTGCAGATCTCCGCTCCAGACATCAAAGATAAC 
Anti sense:  GTTATCTTTGATGTCTGGAGCGGAGATCTGCAGGCGAAC 
pEGFPC1-IRF6 containing the  alanine   mutation  
T425A 
EGFP-IRF6 
S424A/T425A 
Sense:  CGTTCGCCTGCAGATCGCCGCTCCAGACATCAAAGATAAC 
Anti sense:  GTTATCTTTGATGTCTGGAGCGGCGATCTGCAGGCGAACG 
pEGFPC1-IRF6 containing the  alanine   mutation  
S424A/T425A 
Table 2.9. List of primers used for site directed mutagenesis to generate EGFP-IRF6 mutations in the N-terminal and C-terminal region. 
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2.4. Transfection Studies 
2.4.1. Cell culture 
Cell lines were maintained in culture media in 37˚C incubator with 5% CO2.  
 
Cell Line Culture Media 
Cos 7- African Green 
Monkey kidney 
fibroblast  
Dulbecco's modified Eagle's
 
medium (DMEM) (GibcoBRL), 
10% Foetal Bovine Serum (FBS) (GibcoBRL), 1% 
penicillin/streptomycin (GibcoBRL). 
HaCaT- Human 
keratinocyte 
DMEM, 10% Foetal Bovine Serum,1% non-essential amino 
acids (NEAA) 1% penicillin/streptomycin . 
MCF-10A - Human 
breast epithelial cells 
1:1 DMEM-F12 medium supplemented with 5% horse 
serum,
 
hydrocortisone (0.5 µg/ml), insulin (10 µg/ml), 
epidermal growth
 
factor (20 ng/ml), 0.1 µg/ml cholera toxin  
and 10% penicillin/streptomycin  
 
Table 2.10. List of cell lines and complete culture media. 
 
2.4.2. Transfection 
Cos 7 cells were cultivated on cover slips in 24-well plates containing DMEM medium, 
10% FBS at a concentration of 4x10
4
 cells/well at 37 °C and 5% CO2 atmosphere, 24 
hours before transfection. HaCaT cells were cultivated on cover slips in 24-well plates 
containing DMEM medium, 10% FBS and 1% NEAA at a concentration of 8x10
4
 
cells/well at 37 °C and 5% CO2 atmosphere, 48 hours before transfection. Transfections 
were performed by the jetPEI (polyplus transfection) method. 2 μ1 jetPEI reagent in 50 
μl 150 mM NaCl was mixed with 2 μg DNA in 50 μl 150 mM NaCl and incubate at 
room temperature for 30 mins. The 100 μl jetPEI/DNA solution was added to the cells 
and incubated at 37ºC, 5% CO2 for 24 hours. 
2.4.3. Luciferase assays 
Luciferase assays were carried out on extracts using the Luciferase® Reporter Assay 
(Promega) and Beta-Glo® Assay System (Promega). Cos 7 cells in 6 well plates were 
transfected by jetPEI method using 0.4 µg of
 
pGL3P-5IRF6M reporter or pGL3P-
5IRF6S firefly luciferase reporter,
 
and 3.5 µg or 4.5 µg of expression plasmids as 
indicated. In each experiment, 0.1 µg of SV40 βGal reporter was co-transfected as an 
internal control. At 24
 
hours after transfection, transfected cells were rinsed with 
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phosphate buffer saline (PBS) to remove residual debris. Cells were actively lysed by 
adding 250 µl passive lysis buffer (PLB) on ice, then scraped and gently mixed. The 
cells were incubated on ice for 10 mins and freeze-thawed at least once to ensure total 
lysis. 100 µl of Luciferase® Reporter Assay was added to 10 µl of each PLB lysate 
sample to measure the firefly luciferase activities. 50 µl of Beta-Glo reagent was added 
to 50 µl of PLB lysate sample, and then incubated for 30 mins at room temperature to 
measure the ß-galactosidase activities. Luminescence was measure using an Orion 
microplate luminometer (Berthold detection systems). All experiments were performed 
in triplicates.  
2.4.4. Statistical analysis  
Statistical significance was determined by performing ANOVA using GraphPad Prism 
(www.graphpad.com) with P values <0.05 were considered significant. 
2.4.5. Nuclei Isolation Assay 
Nuclei ez prep nuclei isolation kit (Sigma-Aldrich) was used to prepare cytoplasmic 
extracts and nuclear extracts. The preparation was done according to
 the manufacturer‟s 
instructions.  
2.4.6. Western Blotting  
The proteins resolved by SDS-PAGE were transferred onto a nitrocellulose membrane 
(Whatman) by equilibrating the gel and a nitrocellulose membrane in transfer buffer 
(250 mM Tris, 190 mM Glycine) to perform a semi-dry transfer using a BlotterTM 
(Bio-Rad) at 12 V for 75 mins. The blot was then blocked with 5% dried skimmed milk 
(Marvel) freshly made in TBS containing 0.05% TWEEN-20 (Sigma) for 1 hour.  
The membrane was then immunoblotted with the indicated primary antibody for 
1 hour at room temperature or 4 °C overnight on a rotating shaker. A rabbit polyclonal 
anti-IRF6 antibody, generously supplied by Prof. Brian Schutte, was used at 1/500 
dilution to detect IRF6. A rabbit polyclonal anti-GFP antibody A6455 (Invitrogen) was 
used at a 1/1000 dilution to detect EGFP. A mouse monoclonal anti-Flag antibody (M2, 
Sigma) was used at a 1/1000 dilution for the detection of Flag-tagged proteins. 
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Immunoblot analysis of beta () Tubulin (subcellular marker) and Lamin B1 (a nuclear 
envelope marker) was performed with rabbit polyclonal anti- Tubulin ab6046 (Abcam) 
and rabbit polyclonal anti-Lamin B1 ab16048 (Abcam), respectively, and were both 
used at a 1/1000 dilution. The blot was then rinsed 3 times in TBS-0.05% TWEEN 
(TBS-T) for 10 mins at room temperature. Goat anti-mouse IgG or goat anti-rabbit IgG, 
which are conjugated with horseradish peroxidase (Thermal Scientific Pierce), were 
used to probe the blot at a 1/1000 dilution in TBS-T/5% skimmed milk for 1 hour. The 
membrane was again rinsed 3 times with TBS-T for 10 mins to wash off excess 
secondary antibody. Immune complex were then detected by Supersignal West Dura 
Extended Duration Substrate (Pierce) following manufacturer recommendations. Bio-
Rad Fluor-S multi-imager with Quantity One software was used to detect the signal.  
2.4.7. Immunoprecipitation 
30 µl sepharose beads Protein G (Sigma) (for mouse monoclonal) or Protein A (Sigma) 
(for rabbit polyclonal) for a single reaction were washed twice with 500 µl PBS 
followed by centrifugation at 5000 rpm for 5 mins at 4 °C. The beads were resuspended 
in 500 µl PBS and incubated with 3 µl antibody or 3 µl mouse monoclonal or rabbit 
polyclonal IgG (Santa Cruz) as a non-specific control for up to 2 hours on a rotator at 4 
°C. The following antibodies were used for immunoprecipitation: mouse monoclonal 
anti-Flag antibody M2 (Sigma) and mouse monoclonal anti-CRM1 antibody (C-1) 
(Santa Cruz Biotechnology). The antibody bound beads were washed twice with 500 µl 
PBS for 4 mins on a rotator at 4 °C and then centrifuged at 5000 rpm for 5 mins at 4 °C.  
Cells grown in 100 mm culture dishes were washed with cold PBS three times. 
Cells were harvested and lysed by scraping the cells in 1 ml of lysis buffer (1% Triton, 
20 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% Glycerol) supplemented with 1 µM 
phenylmethylsulfonyl fluoride (PMSF) and 100 µl of Complete Protease Inhibitor 
Cocktail x7 (Roche) per ml of lysis buffer. The cell lysates were then sonicated at 35% 
amplitude for 10 secs and clarified by centrifugation at 13,000 rpm for 10 mins at 4 °C.  
950 µl of cell lysate was transferred to the pre-washed immune-sepharose beads and 
incubated on a rotator at 4 °C overnight. The beads were collected by centrifugation at 
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5000 rpm for 4 mins at 4 °C. The beads were washed five times with 1 ml PBS for 5 
mins on a rotator at 4 °C and then centrifuged at 5000 rpm for 5 mins at 4 °C.  The 
washed beads were boiled with 50 µl of Loading Buffer and samples were subject to 
SDS-PAGE and western blot analysis. 
2.4.8. Lambda Protein Phosphatase assay 
The lambda protein phosphatase assay was used to investigate the phosphorylation of 
IRF6 as lambda protein phosphatase releases phosphate groups from phosphorylated 
serine, threonine and tyrosine residues in proteins. Cos 7 cells were transiently 
transfected with 5 µg of FLAG-IRF6 expression plasmids by jetPEI method. At 24
 
hours after transfection, transfected cells were rinsed with PBS. Cells were actively 
lysed by adding 500 µl triton lysis buffer (TLB): 20 mM Tris–HCl, pH 7.4, 137 mM 
NaCl, 0.5 mM DTT, 10% glycerol, 1% Triton X-100 and 70 µl Complete Mini protease 
inhibitor cocktail 7x (Roche), supplemented with or without phosphatase inhibitors at 
25 mM sodium β-glycerophosphate, 2 mM sodium pyrophosphate, 2 mM EDTA, 1 mM 
sodium orthovanadate, 1 mM PMSF, 30 mM sodium fluoride λ. The cells were 
incubated on ice for 10 mins and then centrifuged at 13,000 rpm for 10 mins and the 
supernatant cell lysate was collected for lambda protein phosphatase (BioLabs) 
treatment. The lambda protein phosphatase reaction contained 7 µl 10x phosphatase 
buffer, 7 µl 20 mM MnCl2, 0.5 µl lambda phosphatase and 55.5 µl Cell lysate (~2 
µg/µl). The reactions were incubated at 30ºC for 30 mins. The lambda phosphatase 
reactions were stopped by the addition 20 µl 5x SDS loading buffer and heated at 95 ºC 
for 5 mins for SDS-PAGE analysis (Whitmarsh, 2002). 
2.5. Fluorescent microscopy 
2.5.1. Fluorescent microscopy  
Fluorescent microscopy was used to analyze the subcellular
 
localization of IRF6 and 
IRF6 mutants using EGFP tagged proteins. 1 µg of peGFP-IRF6, peGFP-IRF6 mutants, 
peGFP-C1 (negative control) and peGFP-C2-PC2 (positive control) expressing 
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plasmids. The DNA was transiently
 
transfected into Cos 7 cells, HaCatT cells or MCF-
10A cells by jetPEI method as mentioned previously. The subcellular distribution of 
EGFP-IRF6 and EGFP-IRF6 mutants was determined by counting the percentage of 
cells out of 100 cells that have a cytoplasmic (C), cytoplasmic and nuclear (C/N) or 
nuclear (N) localization. C cells were distinguished by more EGFP fluorescence in the 
cytoplasm than in the nucleus.  C/N cells exhibited similar intensity of EGFP 
fluorescence in the cytoplasm and the nucleus. N cells displayed more EGFP 
fluorescence in the nucleus than in the cytoplasm. All experiments were performed in 
triplicates.  
Subsequent experiments to examine the effects of different stimuli on the 
subcellular
 
localization of IRF6 were performed with peGFP-IRF6 transfection, as 
above, with the following modification. (i) In experiments performed with serum 
starvation, at 24 hours post-transfection, cells were serum starved with 0.5% FBS for 24 
hours. Serum was then added for 1 hour, 2 hours, 4 hours and 8 hours. (ii) For 
determining the effect of various stimuli on localization of IRF6, transfected cells were 
untreated or treated with 0.3 ng/ml epidermal growth factor (EGF) (Sigma), 0.4 µg/ml 
Phytohaemagglutinin (PHA), and 0.01 nM Phorbol-12 Myristate-13 Acetate (PMA), 10 
µg/ml polyinosinic:polycytidylic acid (Poly I:C) for the indicated times. (iii) For 
determining the effect of leptomycin B (LMB) (Sigma) on localization of IRF6, LMB 
was diluted to a final concentration of 10 ng/ml in complete medium and transfected 
cells were untreated or treated with LMB for 15 mins, 30 mins, 1 hour, 2 hours and 4 
hours.  
2.5.2. Fixation and Mounting  
Coverslips with adherent cells were rinsed three times in PBS. Cells were fixed 
with 4% paraformaldehyde (Electron Microscopy Sciences) for 30 mins in the dark, and 
then washed three times with PBS for 5 mins.  
The coverslips were mounted with a drop of Prolong gold with 4',6-diamidino-2-
phenylindole (DAPI) (Invitrogen) and left to dry in the dark at room temperature 
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overnight before examined under a fluorescence microscope. Microscopic images were 
captured with an Olympus widefield microsope at x100 magnification.  
2.6. Mass Spectrometry 
2.6.1. Colloidal Coomassie staining  
Cos 7 cells in 150 mm culture dishes and were transfected by jetPEI method using 1.5 
µg of
 
FLAG-IRF6 for 24 hours. FLAG-IRF6 was enriched and isolated by 
immunoprecipitation using mouse monoclonal anti-Flag antibody M2 (Sigma) as 
previously described. The proteins were resolved by SDS-PAGE. To visualize protein 
bands, the gels were stained with colloidal coomassie blue (0.1% coomassie G-250 
(Sigma), 10% ammonium sulphate, 3% ortho-phosphoric acid, and 20% ethanol) and 
then destained with distilled water. The samples were given to the Biomolecular 
Analysis Core Facility for liquid chromatography/tandem mass spectrometry 
(LC/MS/MS) analysis.  
2.6.2. Digestion 
Bands of interest were excised from the gel and dehydrated using acetonitrile followed 
by vacuum centrifugation.  Dried gel pieces were reduced with 10 mM DTT and 
alkylated with 55 mM iodoacetamide.  Gel pieces were then washed alternately with 25 
mM ammonium bicarbonate followed by acetonitrile.  This was repeated, and the gel 
pieces dried by vacuum centrifugation.  Samples were digested with trypsin, AspN & 
trypsin, GluC & trypsin enzymes overnight at 37 C. 
2.6.3. Mass Spectrometry 
Digested samples were analysed by LC/MS/MS using a NanoAcquity LC (Waters, 
Manchester, UK) coupled to a LTQ Velos (Thermo Fisher Scientific, Waltham, MA).   
Peptides were concentrated on a pre-column (20 mm x 180 μm i.d, Waters).  The 
peptides were then separated using a gradient from 99% A (0.1% FA in water) and 1% 
B (0.1% FA in acetonitrile) to 25% B, in 45 min at 200 nL min
-1
, using a 75 mm x 250 
  - 87 - 
μm i.d. 1.7 M BEH C18, analytical column (Waters).  Peptides were selected for 
fragmentation automatically by data dependant analysis. 
2.6.4. Data Analysis 
Data produced were searched using Mascot (Matrix Science UK), against the mouse IPI 
database.  Data were validated using Scaffold (Proteome Software, Portland, OR).  
Product ion spectra for the sites of phosphorylation described were further validated by 
manual inspection of the data. 
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Chapter 3 
Characterization of IRF6 DNA-binding activity 
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3. Introduction 
Specific mutations in IRF6 have been shown to cause VWS and PPS, the autosomal 
dominant CL and CP disorders (Kondo et al., 2002). Despite the functional relevance of 
IRF6 in palatal development, the functional properties of IRF6 have not yet been 
characterized. Identification of the IRF6 consensus DNA-binding sequence would 
enable the effects of mutations on the function of IRF6 to be determined. Members of 
IRF family are characterized by a well conserved DNA-binding domain (DBD). The 
IRF-DBD shares significant homology with other family members, suggesting it may 
recognize a similar consensus DNA sequence (AANNGAAA). To date, several IRF 
binding sites have been identified that contain single or tandem repeats of the GAAA 
core sequence separated by 1-3 variant base pairs (bp), highlighting the diverse binding 
properties of IRFs  (Fujii et al., 1999). Prior to my research in this chapter, experiments 
were carried out by Hayley Little to determine if IRF6 could bind to a subset of IRF1 
consensus sites. EMSA assays were performed to compare the binding affinity of in 
vitro translated IRF1-DBD and IRF6-DBD proteins to three double stranded 
oligonucleotides containing variations of the IRF1 IFN response elements. In 
comparison to IRF1-DBD, IRF6-DBD showed a weaker interaction to the three IRF1 
consensus sites, suggesting varying DNA sequence selectivity (Hayley Little, personal 
communication). I next sought to determine the consensus sequence of IRF6-DBD. To 
analyze the molecular function of the IRF6-DBD, the IRF6-DBD was first purified for 
PCR-based DNA-binding site selection in order to define the IRF6 consensus DNA-
binding sequence. The consensus sequence was subsequently used in promoter assays to 
examine the effects of the VWS and PPS mutations on the DNA-binding ability of the 
IRF6-DBD in vivo. 
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3.1. Expression and purification of the IRF6-DBD 
To determine the consensus DNA-binding site of the IRF6-DBD it was first necessary 
to develop a protocol to purify the isolated IRF6-DBD.  Purification of proteins can be 
achieved by fusing six histidine residues (His-tag) to the protein of interest. The His-tag 
has a high affinity for divalent metal ions, such as nickel (Ni
2+
), which can be utilized to 
separate His-tagged fusion protein from other proteins by using metal chelated affinity 
chromatography (Hengen, 1995). Therefore the sequence encoding the IRF6-DBD (1-
113 amino acid) was inserted into the pET-14b vector (pET-14b-IRF6-DBD) that 
carries an N-terminal hexa-histidine affinity tag regulated by an IPTG-inducible 
promoter. The pET-14b-IRF6-DBD encodes a hexa-histidine tag fused to the N-
terminus of IRF6-DBD (His-IRF6-DBD) protein. It had been previously demonstrated 
that the majority of His-IRF6-DBD expressed in bacterial cells is present in insoluble 
inclusion bodies (Hayley Little, personal communication), so it was necessary to purify 
His-IRF6-DBD under denaturing conditions using urea. Thus, the first step was to 
isolate the His-IRF6-DBD using nickel affinity chromatography. E.coli BL21(DE3)-
LysS was transformed with the expression plasmid pET14b-IRF6-DBD; the His-IRF6-
DBD protein was highly expressed after IPTG induction and a band was detected with a 
molecular weight of ~16 kDa (Fig 3.1 A, lane 1 and 2). All the buffers used in nickel 
affinity purification consisted of 8 M urea buffer for denaturing conditions. The cells 
were lysed with a high pH urea (pH8) buffer and incubated with nickel-nitrilotriacetic 
acid (Ni-NTA) agarose for high affinity binding of His-IRF6-DBD. Bound His-IRF6-
DBD was separated using a gravity flow column and the flow through was collected. 
The column was washed under stringent conditions using a urea buffer (pH 6.5) to 
remove non-specifically bound proteins. His-IRF6-DBD was then eluted with a low pH 
urea buffer (pH 4.5). Each purification step was visualized on a 10% SDS-PAGE gel 
(Fig 3.1 B). The SDS-PAGE analysis shows that there was excess His-IRF6-DBD 
protein lost in the flow through and the wash (Fig 3.1 B, lane 2 and 3). The purified 
protein was resolved as a single band by SDS-PAGE with a relative molecular mass of 
~16 kDa which corresponds to His-IRF6-DBD. As the purification was under 
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Figure 3.1. Purification of IRF6 recombinant protein. (A) Coomassie-stained SDS-
PAGE gel of BL21(DE3)-LysS cells expressing recombinant His-IRF6-DBD protein 
before and after 0.5 nM IPTG induction. Lane 2 shows a distinct band at ~16 kDa 
indicating an increased expression of His-IRF6-DBD upon IPTG induction. (B) SDS-
PAGE analysis of Nickel affinity chromatography His-IRF6-DBD purification from 
each purification step under denaturing conditions. Lane 1 shows a sample of the lysate. 
The flow through (lane 2) contained a mixture of bacterial proteins with no binding 
specificity for the nickel column as well as excess His-IRF6-DBD. The wash removed 
proteins with weak interaction to the column (lane 3). The eluate contained a protein 
with a size that corresponds to the molecular mass of ~16 kDa confirming presence of 
His-IRF6-DBD (lane 4). Abbreviations: M, Marker – SeeBlue® Plus 2.  
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denaturing conditions, the eluate was then dialyzed against low concentration KCl 
buffer (200 mM)  to remove urea and allow the refolding of His-IRF6-DBD. The yield 
from nickel-affinity chromatography was 1.38 mg His-IRF6-DBD per 1 L culture. The 
eluate containing His-IRF6-DBD recombinant protein still contained additional bands, 
indicating that there are still other proteins present and thus further purification was 
necessary for high purity. 
3.2. Heparin sulphate chromatography of IRF6-DBD protein 
Heparin sulphate chromatography was selected for the second step of purification as it 
is ideal for the isolation of DNA-binding proteins since the sulphate groups function as 
a high-capacity cation exchanger. The nickel affinity purified and dialyzed His-IRF6-
DBD was injected onto the heparin sulphate column. The DNA-binding protein His-
IRF6-DBD was then eluted using a potassium chloride (KCl) salt gradient for 
desorption of bound His-IRF6-DBD. The chromatogram profile shows that His-IRF6-
DBD eluted between ~700 mM to 1 M KCl which were collected in fraction 65 to 78 
(Fig 3.2 A). The fractions 65 to 78 containing purified His-IRF6-DBD was resolved by 
SDS-PAGE with a relative molecular weight of ~16 kDa corresponding to His-IRF6-
DBD (Fig 3.2, A and B). The His-IRF6-DBD was then dialyzed in 500 mM Ammonium 
acetate buffer and concentrated to 11.11 mg/ml using a vivaspin 5000 MW. The SDS-
PAGE analysis confirms that heparin sulphate chromatography improved the quality of 
the protein sample as only a single band was detected at ~16 kDa which corresponds to 
His-IRF6-DBD (Fig 3.3 A). To ensure that the purified His-IRF6-DBD is active, an 
EMSA was performed to examine its binding activity. 2 μl and 4 μl of the purified 
IRF6-DBD protein was incubated with 2 μl of radioactively labeled DNA containing the 
IRF1 consensus site previously shown to be bound by IRF6-DBD. The EMSA indicates 
that protein-DNA complexes were formed (Fig 3.3 B). Thus, the purified His-IRF6-
DBD is a competent DNA-binding protein, suggesting that it has refolded correctly. 
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Figure 3.2. Heparin Sulphate chromatography (HiTrap column) protein 
purification of His-IRF6-DBD. (A) The chromatogram of His-IRF6-DBD indicates 
that His-IRF6-DBD elutes between ~700 mM to 1 M Potassium Chloride (KCl) salt 
concentration. The blue line represents the absorbance at 280 nm which indicates 
protein concentration; black shows the percentage of Buffer B; the red line is the 
baseline.  (B) SDS-PAGE analysis of heparin sulphate chromatography purification of 
His-IRF6-DBD. Lane 1 is the Ni-affinity eluate. Lane 2-8 show F65-F71 that are 
successive fractions collected between 700 mM and 1 M KCl salt gradient. (C) Lane 2-8 
are successive fractions F72-F78 collected at 1 M KCl.  Lane 9 is 1 μg BSA. The 
protein band corresponds to a molecular mass of ~16 kDa confirming the presence of 
His-IRF6-DBD. Abbreviations: M, Marker – SeeBlue® Plus 2. 
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Figure 3.3. SDS-PAGE and EMSA analyses of heparin sulphate chromatography 
purified His-IRF6-DBD. (A) SDS-PAGE analysis of His-IRF6-DBD after dialysis in 
HA500 buffer and concentration. Lane 1 is 2 μg BSA, lane 2 is 2 μl of 11.11 mg/ml 
His-IRF6-DBD. (B) EMSA showing DNA-binding activity exhibited by purified His-
IRF6-DBD. DNA-binding activity of IRF6-DBD was assessed with purified IRF6 
recombinant protein incubated with 
32
P radiolabeled DNA containing an IRF binding 
sequence. Lane 1 and 2 contain DNA mixed with 2 μl and 4 μl His-IRF6-DBD 
respectively. The position of His-IRF6-DBD:DNA complex and free DNA probe is 
marked with arrows as indicated. Abbreviations: M, Marker – SeeBlue® Plus 2 
 
  - 95 - 
3.3. Defining the IRF6 consensus DNA-binding sequence 
Members of the IRF family of transcription factors have been shown to recognize and 
bind to a variety of consensus sequences in IFN-inducible genes. This was first shown in 
studies using the DBD of the IRF1 and IRF2 (Tanaka et al., 1993). As the IRF6-DBD 
consensus sequence has not been derived, a PCR-based binding site selection procedure 
was therefore used to define the IRF6 consensus DNA-binding sequence (Pollock and 
Treisman, 1990). One of the IRF1 consensus sites was selected to aid the isolation of 
protein-bound DNA. Random DNA were used as a substrate in a binding reaction with 
His-IRF6-DBD. Protein-bound and free DNA were separated by electrophoretic 
mobility shift assay (EMSA). Protein-DNA complexes were recovered for PCR 
amplification of the DNA and the PCR products were subsequently purified for a second 
round of selection. Four rounds of selection were carried out in total and binding was 
evaluated after each round by EMSA (Fig 3.4 A) (Su, 2007). The EMSA of the 
succeeding rounds of selection showed a clear enrichment in bound DNA by the third 
round of selection. There was a significant increase in the efficiency of specific DNA-
protein complex formation. EMSA analysis of the binding-site selection revealed that 
the His-IRF6-DBD had selected DNA sequences from the pool of random DNA.  
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Figure 3.4. Selection of a consensus DNA-binding site for His-IRF6-DBD. (A) 
EMSA analysis of the selected pools of binding sites by bacterially expressed His-IRF6-
DBD (lanes 2 to 5). The starting double stranded DNA is shown in lane 1. The free 
DNA represents the DNA pool after the indicated number of rounds of selection. The 
position of the protein-DNA complex is shown (arrow). The DNA from the complexes 
in lane 5 was amplified and cloned for sequence analysis. Adapted from (Su, 2007). 
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3.4. Sequence analysis of binding sites  
DNA obtained after the fourth round of selection was amplified by PCR. The PCR 
product was ligated into the T-tailed pDrive cloning vector for sequence analysis. 23 
different sequences of the sites selected by His-IRF6-DBD were compared (Fig 3.5 A). 
The consensus sequence derived after four rounds of selection is a 10 base-pair 
sequence AACCGAAAC
C
/T (Fig 3.5 B). The consensus sequence contains the 5‟-
flanking AA sequence and the GAAA core sequence separated by a spacer sequence. 
Nucleotides that make up the spacer sequence were predominantly CC. However, a TC 
variation of the spacer sequence was also tolerated. There was a strong selectivity for 
the nucleotide C at position 9 that gives an extended core sequence of GAAAC. The 
majority of the selected sites contain the GAAAC extended core sequence. In addition, 4 
of the 23 selected sites contain a GATAC core sequence. Furthermore, tandem repeats 
of the core sequence GAAA or GATA were selected by the His-IRF6-DBD in selected 
sites IRF6-S14 and IRF6-S22. The overall similarity in the selected sequence indicated 
that His-IRF6-DBD has selected a highly specific binding sequence.   
 To confirm that the DNA sequences recovered from the PCR-based site selection 
were true representations of the IRF6-DBD binding specificity, individual sequences 
were further tested by EMSA to verify if they bind efficiently and specifically (Fig 3.5 
B). The selected sequences that contained the core sequence with variations in positions 
1, 3 or 9 were S11, S15, S17, S18 and S19. To determine if the GATAC was a potential 
binding site, sequences S22 and S23 were also selected. There is apparent binding of 
His-IRF6-DBD to S11, S15, S17, S18 and S19 which contain the extended core 
sequence (Fig 3.5 C, Lane 2-6). All of the selected sites show a higher binding affinity 
to the IRF6-known sequence (Fig 3.5 C, Lane 1) which contains a GCCCGAAACT 
binding sequence. The distinct difference in the IRF6-known sequence compared to the 
His-IRF6-DBD selected sequences is the GC at the 5‟-flanking end. This indicates that 
the 5‟-flanking AA sequence does increase the binding affinity. 
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A 
  IRF6-known         tcgGGTACATGCCCGAAACTGATTGTGTAgag 
  IRF6-S1                  ctcAATCGAAACTAACTGACGCGTGTGAAcga  
  IRF6-S2      ctcCTCAACATGTTCAACCGAAACCCGCGcga  
  IRF6-S3          tcgTCATGTTTAACCGAAACCTAATCTCAgag  
  IRF6-S4       ctcTTAAGAGCTTTGACCGAAACCGTTAAcga  
  IRF6-S5               ctcTTTAACCGAAACCAAATGTCCGAGTAcga  
  IRF6-S6        ctcGCGCAAGCACAGACCGAAACTACTAGcga  
  IRF6-S7  ctcTTTTAGCCTTTTCCAAAACCGAAACTcga  
  IRF6-S8     tcgGCCTGCGTATGTCAACCGAAACTATTgag  
  IRF6-S9     ctcCAACTAGTACTTTAACCGATACCAAAcga  
  IRF6-S10                ctcTCAACCGATACTGTTGCGTTCTAAGGcga  
  IRF6-S11                  ctcTACCGAAACCGAGTGCAACACCTAAAcga  
  IRF6-S12               ctcCTAAACCGAAACCGAGGGTATGTTCCcga  
  IRF6-S13           ctcATCGAAAGACCGAAACTAAACTCGTCcga  
  IRF6-S14     ctcTACGAGACTGGGAAACCGAAACTAGAcga  
  IRF6-S15     ctcAGACAATAATTTAGACCGAAACCAGAcga  
  IRF6-S16                 ctcTAACCGAAACTCAAAATGAAGGAGTAcga  
  IRF6-S17                tcgTCAACCGAAACTAGGGCGGACATGGTgag  
  IRF6-S18                  ctcAATCGAAACTAAGTTAGTGCCACCAAcga  
  IRF6-S19          ctcGGAACCTCGATCGAAACCACCGTCATcga  
  IRF6-S20                 ctcCAACCGAAACCACGAATATTCGCTTCcga  
  IRF6-S21 ctcAGATAAAATTTCGCTTAGACCGAAACcga  
  IRF6-S22      ctcGCCCAAGTACGAAACCGATACTACTGcga  
  IRF6-S23    ctcACTTCAAAACTTTTAACCGATACCAAcga  
 
B 
                
 
 
 
   position        1     2    3     4    5    6    7    8   9 10 
 
C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Analysis of the His-IRF6-DBD DNA binding sequences selected by PCR 
based sites selection. (A) Sequence alignment of sequences of the DNA-binding sites 
selected by His-IRF6-DBD after four rounds of selection with respect to the 
AANNGAAANN core sequence. Nucleotides derived from the random sequence 
(uppercase) and the constant flanking primers (lowercase) are indicated. The IRF core 
sequence is underlined in each sequence. Sites are aligned and orientated according to 
this IRF core sequence. (B) A logo sequence representation for IRF6 binding sites after 
three rounds of selection with the allocated position numbers shown below. (C) 
Verification of His-IRF6-DBD binding to individual selected sites. EMSA of 4 μl His-
IRF6-DBD protein incubated with 76bp DNA of individual sites indicated above. The 
low mobility band corresponds to the protein:DNA complexes, as indicated by the 
arrow, and the higher mobility band corresponds to the free DNA probe. 
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The nucleotide at position 1 is predominantly A, although other nucleotides G and T are 
also present, suggesting flexibility in recognition of this nucleotide. Conversely, the 
nucleotide at position 2 of the 5‟-flanking AA sequence was always A. Unexpectedly, 
His-IRF6-DBD was shown to bind to GATAC containing sequences S22 and S23 (Fig 
3.5 C, lane 7 and 8), which differs to the GAAAC extended core sequence. This 
suggests that His-IRF6-DBD exhibits a unique sequence recognition compared to other 
members of the IRF family.  
 To examine the importance of individual base pairs within the identified 
consensus sequence AACCGAAAC
C
/T with regards to His-IRF6-DBD binding, single 
base pair changes in the S17 sequence TCAACCGAAACTAG were investigated by 
EMSA. Changes were introduced at position 7 (GAAAC) with A>T and A>C. The A>T 
substitution (GATAC) still permitted lower affinity binding to the sequence, showing 
that T in the core sequence can be tolerated. However disruption of the core sequence by 
A>C substitution (GACAC) ablated DNA-binding. This suggests that the core sequence 
is essential for His-IRF6-DBD binding. The spacer is predominantly CC. The C at 
position 4 (CC) in all the selected sites was conserved. To examine its significance the 
base pair was changed from C>G. No binding was observed (Fig 3.6 B, lane 4), 
implicating that there is no flexibility of the spacer sequence at position 4. Changes 
introduced to the extended core sequence at position 9 with C>G showed a reduced 
binding affinity (Fig 3.6 B, lane 5), showing that His-IRF6-DBD has preferential 
binding to the extended core sequence. Collectively, the data indicates that His-IRF6-
DBD has high affinity binding to the AACCGAAAC
C
/T consensus sequence in vitro.   
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A 
    S17-1    TCAACCGAAACTAG 
    S17-2    TCAACCGATACTAG 
    S17-3    TCAACCGACACTAG 
    S17-4    TCAACGGAAACTAG 
    S17-5    TCAACCGAAAGTAG 
 
 
 
 
 
 
B                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Analysis of His-IRF6-DBD binding to the defined IRF6 consensus 
sequence with various point mutations. (A) Nucleotide sequence of the radiolabeled 
14 bp S17 DNA and S17 with changes in individual base pairs (underlined). (B) EMSA 
showing the IRF6 binding affinity to S17 and S17 point mutations. The low mobility 
band corresponds to the protein:DNA complexes, as indicated by the arrow, and the 
higher mobility band corresponds to the free DNA probe. 
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3.5. His-IRF6-DBD can bind to overlapping tandem repeats 
The identification of the IRF6 consensus sequence can facilitate the search for cis-acting 
elements in promoter regions in potential target genes that may be involved in the same 
pathways. IRF responsive elements have been found in several genes containing various 
monomeric, dimeric and multimeric repeat sequences. Binding sites with single GAAA 
core sequences are always endowed with the 5‟-flanking AA sequence to give one 
complete interferon response sequence (IRS). IRF binding sites containing dimeric 
repeats of the core sequence have 1-3 spacer bases, with the majority of them possessing 
2 spacers. Some dimeric repeats possess the 5‟-flanking AA sequence to give two 
complete IRSs, while others lack the 5‟-flanking AA sequence. In addition, some IRF 
binding sites contain multiple repeats (Fujii et al., 1999). Tandem repeats of the core 
sequence GAAA was selected by the His-IRF6-DBD in sites IRF6-S14 
(GGGAAACCGAAACTA) and IRF6-S22 (ACGAAACCGATACTA) (Fig 3.5, B). 
This may suggest DNA-binding of dimeric IRF6. Furthermore, the gel retardation 
analysis of IRF6 bound to randomized DNA show two distinct bands in Fig 3.4, lane 4 
and 5. The higher band observed could possibly be (IRF6-DBD)2:DNA.  
Activation of type 1 IFN signalling leads to the transcriptional induction 
guanylate binding protein (GBP). Two ISREs were identified in the promoter that were 
both required for the maximal response of the GBP gene for IFN signalling (Lew et al., 
1991). Similarly, type 1 IFNs and virus infection can induce interferon stimulated gene 
15 (ISG15). The ISG15 contains multiple ISREs in the promoter and the deletion of the 
ISRE leads to the inability to respond to type 1 IFN signalling. IRF8/PU.1 and 
IRF4/PU.1 heterocomplex formation has been shown to activate the transcription of 
ISG15 (Meraro et al., 2002). To determine if IRF6 can bind to tandem repeats, EMSAs 
were used to verify if His-IRF6-DBD protein could bind specifically to radiolabelled 
DNA containing a single IRF6 binding site S17-1 and a S17-1 dimeric repeat. As the 
GBP and ISG15 genes contain a dimeric repeat and,multimeric repeats of the ISREs in 
their promoters respectively, they were selected to investigate His-IRF6-DBD binding to 
tandem repeats. The GBP gene contains a dimeric repeat with 2 bp spacer 
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AATATGAAACTGAAAGT at position (-113/-129). While, the ISG15 gene contains 
multiple repeats with 2 bp spacers CTGGGGAAAGGGAAACCGAAACT at position (-
117/-95). The ISG15 triplet repeat suggest a cooperative binding of three IRF molecules 
(Tanaka et al., 1993; Fujii et al., 1999). The EMSA analysis of His-IRF6-DBD bound to 
the IRF6 monomeric-sites show a single band indicating His-IRF6-DBD:DNA 
interaction (Fig 3.7, lane 2). Therefore, His-IRF6-DBD can be bound monomerically to 
the single IRF6 binding site. The His-IRF6-DBD binding to the IRF6 dimeric-sites and 
the ISG15 multimeric-sites exhibited two distinct bands in Fig 3.7 lane 3 and 5. The 
lower band was similar to the His-IRF6-DBD bound to the IRF6 monomeric-site. The 
higher band observed is likely to be two His-IRF6-DBD proteins bound to DNA. This 
indicates that two His-IRF6-DBDs were able to bind in tandem to DNA at the IRF6 
dimeric-sites. The intensities of the higher and lower bands indicate that there is a higher 
proportion of His-IRF6-DBD occupying one site than there is occupying two sites. His-
IRF6-DBD binding to the ISG15 multimeric-sites seemed to exhibit lower binding 
affinity compared to IRF6 dimeric-sites. Intriguingly, although there are three potential 
binding sites there are only two bands which demonstrate one and two monomerically 
bound His-IRF6-DBD molecules. It is not apparent which of the three sites have 
preferential binding or if one of the sites is not a binding site. Additionally, the His-
IRF6-DBD did not bind to the ISG15 multimeric-sites as effectively as to the IRF6 sites. 
In contrast, His-IRF6-DBD interaction with either of the GBP dimeric-sites is negligible. 
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A 
IRF6 S17-1     TCAACCGAAACTAG 
IRF6 S17 dimer CGTCAACCGAAACCGAAACTAGGGCG 
GBP dimer    CGTCAATATGAAACTGAAAGTAGGGC 
ISG15 multimer   CTGGGGAAAGGGAAACCGAAACTAGGGCG 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Analysis of His-IRF6-DBD binding to IRF recognition sequence 
containing tandem repeats. (A) Nucleotide sequence of the radiolabeled IRF6 S17, 
IRF6 S17 dimer, GBP dimer and ISG15 multimer DNA, with bases of the IRS core 
sequences underlined. These lines are overlapped for sites having tandem repeats of 
GAAA core sequence. (B) EMSA showing the His-IRF6-DBD binding affinity to S17, 
IRF6 S17 dimer, GBP dimer and ISG15 multimer DNA as indicated. The lowest 
mobility band corresponds to the His-IRF6-DBD2:DNA complexes, and the lower 
mobility band corresponds to the His-IRF6-DBD:DNA complexes, as shown by the 
arrows. The higher mobility band corresponds to the free DNA probe. 
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3.6. His-IRF6-DBD is autoinhibited by the C-terminal region 
To establish the relationship between the IRF6-DBD and the C-terminal region 
containing the IAD, this study investigated the effects of the C-terminal region on IRF6-
DBD DNA-binding function. EMSA studies were performed using in vitro translated 
wildtype IRF6 and IRF6 C-terminal deletions to residues 359, 225, 190, 152 and 113 
(Fig 3.8 A) to assess their DNA-binding ability to an IRF6 recognition sequence. The 
His-IRF6-DBD was also included to provide a reference point for positive His-IRF6-
DBD:DNA interaction (Fig 3.8 B). The EMSA shows that the full-length IRF6 was not 
able to bind DNA (Fig 3.8 B, lane 3). Similarly, C-terminal deletions IRF6-152, IRF6-
190, IRF6-225 and IRF6-401 were not able to bind to DNA containing an IRF binding 
sequence (S17 sequence TCAACCGAAACTAG) (Fig 3.8 B, lane 5-8).   Only the C-
terminal deletion of IRF6-113, containing the isolated DBD (Fig 3.8 B, lane 4 and 9), 
was able to bind DNA avidly. This suggests that the C-terminal region autoinhibits the 
DNA-binding ability of IRF6. Moreover, the deletion of the C-terminal domain up to 
amino acid 152 did not relieve the autoinhibition, suggesting an autoinhibitory domain 
between amino acid 113 to 152. Therefore IRF6 may pre-exist in a closed conformation, 
whereby the C-terminal region masks the DBD.  
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Figure 3.8. EMSA analysis of IRF6 C-terminal deletion mutants in DNA-binding. 
(A) A Schematic representation of a series of IRF6 C-terminal deletions. The DNA 
binding domain and the interferon association domain are indicated. (B) EMSA showing 
DNA-binding activity exhibited by in vitro translated wildtype IRF6, IRF6 C-terminal 
deleted proteins, and purified His-IRF6-DBD as indicated. DNA-binding activity of 
IRF6 proteins were assessed with 
32
P radiolabeled DNA containing an IRF binding 
sequence (S17 sequence TCAACCGAAACTAG). The position of free DNA probe 
complex and protein:DNA is marked with arrows as indicated. The C-terminal region 
autoinhibits IRF6 DNA-binding activity. 
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3.7. IRF6 regulation of transcription 
Mutation in IRF6 can lead to VWS and PPS (Kondo et al., 2002). Studies were 
therefore carried out to assess the DNA-binding ability of VWS and PPS mutants. 
Previous work in this laboratory showed that the majority of VWS and PPS missense 
mutations within the DBD inhibited DNA-binding in vivo tested by EMSA analysis. 21 
out of 22 missense mutations associated with VWS and PPS introduced in the DBD 
abrogated DNA-binding containing a complete IRF6 recognition sequence in vitro. 
Interestingly the G70R was the only mutation that exhibited similar DNA-binding 
affinities to the wildtype IRF6-DBD (experiments performed by Hayley Little). I next 
sought to examine if VWS and PPS mutations in the IRF6-DBD also inhibit DNA-
binding in vivo. By using the IRF6 consensus sequence AACCGAAAC
C
/T previously 
defined, we could establish a system to investigate if IRF6-DBD could bind to the 
recognition sequence in vivo and determine if the binding site could direct 
transcriptional activity of IRF6 in a promoter reporter assay. Subsequently, the system 
could then be used to assess the effects of VWS and PPS mutations on IRF6-DBD 
binding to the consensus sequence and transcriptional activation in vivo.  
 Due to the autoinhibition of the IRF6 C-terminal region on IRF6 DNA-binding 
(Fig 3.8 B), the full-length IRF6 is not active and could not be used to examine the 
transcriptional activity in a promoter reporter assay. The IRF6-DBD was therefore used 
in the subsequent study. However, sequence specific transcriptional activators are 
typically composed of 2 functional domains, namely the DBD and an activation domain. 
The activation domain of the herpes simplex virus protein (VP16AD) is highly acidic 
and can interact with components of the transcriptional machinery to regulate 
transcription. The VP16AD is frequently used to examine basic principles of 
transcription as it is a potent activator. The VP16AD is functionally autonomous and 
functions when it is fused to a DBD (Hall and Struhl, 2002). Thus, the IRF6-DBD 
sequence was inserted into the pVP16 vector to encode a VP16AD fused to the N-
terminus of IRF6-DBD (VP16AD-IRF6-DBD) protein. The integrity of the construct 
was confirmed by restriction digestion analysis and sequencing. In addition, two 
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artificial luciferase reporters were constructed to assess the transcription regulation of 
VP16AD-IRF6-DBD. The S17 sequence that was shown to be a high affinity binding 
sequence was used to generate 5 multimerized IRF6 consensus sites 
(CTCGTCAACCGAAACTAGGG)5 which was inserted into the promoter region of the 
pGL3-promoter (pGL3P) luciferase reporter vector (termed pGL3P-5IRF6S). The 
binding of the VP16-IRF6-DBD to the IRF6 consensus sites in the promoter of pGL3P-
5IRF6S should induce transcription, which can be quantitatively measured by firefly 
luciferase activity (Fig 3.9 A). As a negative control,  5 multimerized IRF6 consensus 
sites containing 3 substitutions in the GAAAC extended core sequence 
(CTCGTCAACCGAGCGTAGGG)5 was inserted into the promoter region of the 
pGL3P (termed pGL3P-5IRF6M) to abolish VP16AD-IRF6-DBD mediated DNA-
binding (Fig 3.9 A). All constructs were verified by sequence analysis.  These constructs 
were then used in initial luciferase assays to investigate whether VP16AD-IRF6-DBD 
can activate transcription in vivo and thus represent an indirect measure of DNA-binding.  
Luciferase assays were performed in Cos 7 cells which were co-transfected with the 
pGL3P-5IRF6M control plasmid or pGL3P-5IRF6S luciferase reporter plasmids and the 
expression plasmids encoding VP16AD only or the VP16AD-IRF6-DBD fusion protein. 
The luciferase activity did not show any significant difference between the 
transcriptional activities by VP16AD or VP16AD-IRF6-DBD fusion protein with 
pGL3P-5IRF6M control reporter (Fig 3.9 B lane 3-6). However, 4.5 µg of VP16AD-
IRF6-DBD exhibited a 1.56 fold increase with a significant difference of P<0.05, which 
is still a minor effect on the magnitude of transactivation comparatively. This shows that 
the IRF6-DBD was not able to recognize or bind to the mutated IRF6 consensus 
sequence. In contrast, there was a dose dependent increase in the VP16AD-IRF6-DBD 
induced activation of the pGL3P-5IRF6S reporter containing the IRF6 consensus 
sequence (Fig 3.9 B lane 9-12). 
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Figure 3.9. Transactivation of VP16-IRF6-DBD on a pGL3P-5IRF6M and pGL3P-
5IRF6S luciferase reporter. (A) Schematic representation of the VP16AD-IRF6-DBD 
protein transcription regulation of pGL3P-5IRF6M and pGL3P-5IRF6S. (B) luciferase 
assays to assess the regulation transcription of pGL3P-5IRF6M and pGL3P-5IRF6S 
reporter by VP16AD-IRF6-DBD fusion protein. Cos 7 cells were co-transfected with 
0.4 µg of
 
pGL3P-5IRF6M or pGL3P-5IRF6S reporter and 4.5 µg pCDNA3, 4.5 µg 
VP16AD or the indicted increasing amounts of 1.5 µg, 2.5 µg, 3.5 µg, 4.5 µg of 
VP16AD-IRF6-DBD expression plasmids. To control the transfection efficiency cells 
were additionally transfected with 0.1 µg ß-galactosidase plasmid pSV-ßGal. Cells were 
analyzed for luciferase and ß-galactosidase activities 24 h after transfection. The 
luciferase relative light units, normalized to the ß-galactosidase activity, of the relative-
fold change to VP16AD. Luciferase assays were performed in triplicate. Error bars 
represent standard error. Asterisks (*) indicates a statistically significant difference 
determined by ANOVA (P<0.05) when compared with VP16AD empty vector. 
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The maximum luciferase activity with a 6 fold increase was observed with 3.5 µg of 
VP16AD-IRF6-DBD expression plasmid. This indicates that the fusion of the IRF6-
DBD to the VP16AD is accountable for the increase in luciferase activity. This suggests 
that the VP16AD-IRF6-DBD fusion protein mediates transcriptional activation by 
directly binding to the IRF6 consensus sequences in the promoter.  The DNA interaction 
may be mediated by the IRF6-DBD, whilst transactivation of the reporter gene is 
mediated by the VP16AD. These results indicate that the constructs generated were 
functional and could be used as a system to investigate the effects of mutation in the 
IRF6-DBD on DNA-binding in vivo. 
3.8. VWS and PPS mutants reduce IRF6 transcriptional activity  
Sequence analyses of IRF6 in families with VWS and PPS revealed that there is a high 
prevalence of mutations in the DBD (Kondo et al., 2002; de Lima et al., 2009). This 
indicates that VWS and PPS associated mutations are likely to affect IRF6 function. To 
assess the effects of mutation in the IRF6-DBD on DNA-binding in vivo, the missense 
mutations were introduce in the VP16AD-IRF6-DBD fusion protein to test their ability 
to activate the pGL3P-5IRF6S reporter. The effects of V18A, L22P, W60G, G70R, 
R84C and K89A were investigated. The V18A, L22P and G70R missense mutations are 
associated with VWS. Whereas, the W60G and K89A missense mutations are associated 
with PPS. The R84C mutation has been identified in both VWS and PPS families 
(Kondo et al., 2002; Ghassibe et al., 2004; de Lima et al., 2009). The six different 
VWS/PPS point mutations were introduced in VP16AD-IRF6-DBD by site-directed 
mutagenesis and their ability to activate transcription was assessed. The amino acid 
sequence of the IRF6-DBD and the missense mutations that were introduced are shown 
in Fig 3.10 A. The wildtype and mutant forms of VP16AD-IRF6-DBD were analyzed 
for their ability to transactivate the pGL3P-5IRF6S reporter by transient transfection 
assays in Cos 7 cells. The wildtype VP16AD-IRF6-DBD showed increase in pGL3P-
5IRF6S reporter activity compared to VP16AD only (Fig 3.10 B lane 2). Notably, co-
transfection with all six VWS/PPS mutant VP16AD-IRF6-DBD expression vectors 
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displayed different activities at the multimerized IRF6 enhancer element (Fig 3.10 B 
lane 3-7). When comparing wildtype VP16AD-IRF6-DBD with the VWS/PPS mutants, 
a reduction in luciferase activity was exhibited ranging from 47% to 64%.  The data 
showed a significant difference of P<0.05 for V18M, L22P, W60G, G70R, R84C  and 
K89A missense mutants compared with wildtype. This confirms that introduction of 
VWS and PPS missense mutations impairs, but does not abolish, VP16AD-IRF6-DBD 
transcriptional activity.  The reduction in the transcriptional activation caused by VWS 
and PPS mutations in the IRF6-DBD correlates with the in vitro studies, which show 
that most VWS and PPS mutations in the IRF6-DBD disrupt DNA-binding. The 
changes in VP16-IRF6-DBD transactivation corroborates with the effects of mutations 
on the ability of IRF6-DBD to bind DNA.  
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A 
                 A   P                                     G 
MALHPRRVRLKPWLVAQVDSGLYPGLIWLHRDSKRFQIPWKHATRHSPQQEEENTIFKAW 60 
         R             C    A         
AVETGKYQEGVDDPDPAKWKAQLRCALNKSREFNLMYDGTKEVPMNPVKIYQV  113 
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Figure 3.10. Transactivation of VP16AD-IRF6-DBD wildtype and point mutants in 
the IRF6 reporter. (A) Amino acid sequence of IRF6-DBD protein with the residues 
chosen for site-directed mutagenesis in bold and the point mutation that cause VWS and 
PPS shown above in red. The conserved DBD amino acids 13-113 are highlighted in 
green. Amino acids that are predicted to directly interact with DNA based on IRF1 
structure are underlined (B) Luciferase assays to assess the activation of the pGL3P-
5IRF6S reporter by VP16AD-IRF6-DBD fusion protein or various point mutants as 
indicated. Cos 7 cells were co-transfected with 0.4 µg of
 
pGL3P-5IRF6S reporter with 
3.5 µg of VP16AD, wildtype or mutant VP16AD-IRF6-DBD expression plasmids. To 
control the transfection efficiency cells were additionally transfected with 0.1 µg ß-
galactosidase plasmid pSV-ßGal. Cells were analyzed for luciferase and ß-galactosidase 
activities 24 h after transfection. The luciferase relative light units, normalized to the ß-
galactosidase activity, of the relative-fold change to VP16AD-IRF6-DBD. Luciferase 
assays were performed in triplicate. Error bars represent standard error. Asterisks (*) 
indicates a statistically significant difference determined by ANOVA (P<0.05) when 
compared with wildtype VP16AD-IRF6-DBD. 
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3.9. Discussion 
3.9.1. Protein purification of His-IRF6-DBD 
IRF proteins are functionally diverse and can recognize different IRF-binding sites or 
same IRF-binding sites with different affinities despite the similarities in their DBD 
(Grant et al., 2000). We have successfully designed a purification protocol for His-
IRF6-DBD protein that can be used for EMSAs and other applications. The protein 
purification requires purification by nickel affinity chromatography (Fig 3.1 B) followed 
by heparin sulphate chromatography (Fig 3.2). The 2 step process was shown to be 
sufficient to produce high purity His-IRF6-DBD protein at 11.11 mg/ml. Purified His-
IRF6-DBD can be used for other experiments, such as initial crystallography trials. 
Determining the crystal structure of IRF6-DBD:DNA complex may reveal essential 
IRF6 residues involved in direct interaction with its DNA recognition sequence and 
solve the three dimensional structure of IRF6-DBD. Members of the IRF family can 
recognize variants of the IRF recognition sequence. The ability to bind to variants is due 
to the subtle differences in the tertiary structure of DBD. In addition, this is also 
partially contributed by the differences in the framework of hydrogen bonds and van der 
Waals contact between residues in the recognition helix and the core sequence. These 
differences are influenced by an extensive network of water molecules located in the 
interface (Dragan et al., 2007). Thus, establishing the crystal structure of His-IRF6-
DBD bound to DNA may reveal essential residues and structural motifs that may be 
involved in direct interaction with specific DNA sequences to regulate transcription.  
3.9.2. IRF6 consensus sequence 
Non-coding genomic regulatory regions that modulate the expression of genes tend to 
have conserved DNA consensus sequences that are highly specific for certain 
transcription factor binding. To gain an insight to the IRF6 consensus sequence we used 
PCR based site selection using a pool of random DNA. The random DNA comprised of 
26 random nucleotides flanked by 20 bp of known DNA sequences. The results in Fig 
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3.4 show that after three successive rounds of selection there was an increasing yield of 
DNA-protein complexes, which suggests that IRF6 selected for increasingly specific 
DNA sequences. The selected sites were all located in the randomized portion of the 
DNA, showing that there is no overlap with the known flanking primer and therefore 
were not biased in the selection.  
Alignment of 23 sequences was used to define the IRF6 consensus sequence (Fig 
3.5 A). 23 independently sequenced clones were considered sufficient and accepted for 
determining the IRF6 consensus sequence as the IRF1 and SAP-1 consensus sequence 
were derived by aligning 21 sequences (Tanaka et al., 1993) and 20 sequences (Shore 
and Sharrocks, 1995) respectively. The results show the IRF6 recognition site for an 
IRF6 monomer to be AACCGAAAC
C
/T (Fig 3.5 B). All of the binding sites selected 
are very similar and therefore may show the optimal binding specificity for IRF6. This 
is consistent with other findings that members of the IRF family are believed to bind to 
similar DNA-binding motifs of AANNGAAA as they have extensive homology among 
their DNA-binding domain. In general, IRFs recognize DNA sequences that span 11 to 
13 nucleotides and do not appear to be palindromic (Tanaka et al., 1993).  
The important residues that contact the core sequence in IRF1 are R82, C83, 
N85, and S86 (Tanaka et al., 1993). The R84, C85 and N88 residues are also found in 
the recognition helix (α3) in IRF6 that bind to the GAAA core sequence. However, due 
to the amino acid sequence homology to IRF4 that contains a lysine residue K103 at the 
end of the recognition helix (Escalante et al., 2002), IRF6 also contains a critical lysine 
residue K89 that shares the affinity to an extended IRF core sequence, GAAAC. 
Therefore the selected GAAAC core sequence is likely to be an authentic binding site. 
Further analysis showed that changes in the extended core sequence of C>G 
dramatically reduced IRF6-DBD binding, proving its significance (Fig 3.6 B, lane 5). 
In the motif the 5‟-flanking AA sequence was identified to be essential for the 
recognition of the GAAA core sequence as all the selected sites had at least one A. This 
also supports the findings that the 5‟-flanking AA sequence produces a complete IRS. 
However, the variability in the 5‟-flanking AA sequence at position 1 indicates that 
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IRF6 binding to the 5‟-flanking sequence is weaker than the 3‟- core sequence (Fujii et 
al., 1999). In the IRF6 recognition sequence, the spacer nucleotides between the 5‟-
flanking AA sequence and the core sequences always consists of 2 bp. Studies by 
Tanaka et al. also show >80% preference for a two nucleotide spacer (Tanaka et al., 
1993). In the spacer sequence CC were the predominant bases. Changes from C>G in 
position 4 (Fig 3.6 B, lane 4) prevented IRF6-DBD binding.  
3.9.3. His-IRF6-DBD binding to multimeric repeats 
PCR based site selection for IRF1 and IRF2 selected the consensus sequence 
G(A)AAA
C
/C
T
/CGAAA
G
/C
T
/C . IRF1 and IRF2 have a mutually antagonistic function by 
competing for the same target gene. Initial studies showed evidence that IRF1 bound to 
the recognition sites as monomers (Tanaka et al., 1993). It was later shown that IRF1 
could also form homodimers (Kirchhoff et al., 1998). A DNA-binding feature of IRF 
family members is the ability to bind to the single and tandemly repeated sequence of 
the GAAA core sequence with mostly two spacer sequence, but one to three spacer 
sequences have also been identified.  
At present, it is not known if IRF6 functions as a monomer or requires the 
formation of homo- or heterodimer to exert physiological function in vivo. We first 
investigated the tandem binding of His-IRF6-DBD to monomeric, dimeric and 
multimeric repeats of the GAAA core sequence (Fig 3.7). The His-IRF6-DBD protein 
bound to the s17-1 monomer site, containing a complete single IRF6 consensus 
sequence gives a single bandshift. This shows that His-IRF6-DBD bound to the s17-1 
monomer site monomerically and not as a His-IRF6-DBD2 dimeric complex. For both 
S17 dimer and ISG15 multimer, the His-IRF6-DBD monomeric binding
 
greatly exceeds 
two monomeric His-IRF6-DBD proteins binding to the DNA. The IRF6 dimeric site 
contains two copies of the IRF6 consensus sequence with a 4 bp overlap in sequence of 
the first site and the second site. There is a 2 bp spacer DNA between the 5‟-AA 
flanking and 3‟-GAAA core sequences. Model building studies reveal that 2 bp spacers 
produce no direct contact between two adjacent DBDs. This also implies the lack of 
protein-protein interaction that may restrict the position and orientations of two adjacent 
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DBDs (Fujii et al., 1999). The ISG15 multimer contained three GAAA core sequences 
(Fig 3.7 B, lane 5); however it only yields two complete IRS sequences. This may 
reflect why there was binding of one or two His-IRF6-DBD proteins to the ISG15 
multimer, but not three His-IRF6-DBD proteins. Given that His-IRF6-DBD was able to 
bind to the ISG15 multimer, it signifies that the DNA-binding sites for His-IRF6-DBD 
can be less stringent than the identified IRF6 consensus sequence.  
For both S17 dimer and ISG15 multimer, there was a higher proportion of His-
IRF6-DBD occupying one binding site than occupying two sites. Previous studies by 
Fujii et al. using quantitative analysis of EMSAs show that DBDs and/or their 
interactions with DNA partly contribute to cooperativity. The binding of a single IRF2-
DBD induces DNA distortion and subsequently prepares a template for the enhancement 
and cooperative interaction of the second IRF-DBD. The cooperative DNA-binding by 
DNA distortion is not facilitated by protein-protein interaction of the adjacent IRF-
DBDs.  This was shown using two-fold serial dilutions of IRF2-DBD protein bound to 
DNA containing two copies of the IRS sequence (Fujii et al., 1999). In this study a fixed 
amount of His-IRF6-DBD protein was used and the DNA was in excess. Thus we were 
not able to establish if cooperative binding to tandem repeats is achieved by the 
distortion of DNA structure with IRF6-DBD. 
His-IRF6-DBD was unable to bind to the GBP dimer (Fig 3.7 B, lane 4). A 
possible explanation for the inability of His-IRF6-DBD to recognize the GBP dimer 
could be due to an incompatible DNA sequence. Although there were two GAAA core 
sequences it only yields a single complete IRS sequence. The IRS also lacks the 
extended core sequence GAAAC, which dramatically reduces His-IRF6-DBD binding 
as shown in Fig 3.6, B lane 5. This is due to the K89 interaction with the guanine of the 
C:G base pair. Moreover, the 2 bp spacer of CT at position 3 and 4 may also have an 
impact on protein binding as PCR based site selection and mutational analysis of the 
IRF6 consensus sequence show that the C is always conserved at position 4. 
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3.9.4. IRF6-DBD is autoinhibited by the C-terminal region 
EMSA studies were carried out to assess the DNA-binding ability of in vitro translated 
wildtype IRF6 and C-terminal deletions of IRF6. The results showed that wildtype IRF6 
and C-terminal deletion up to amino acid 152 do not bind DNA (Fig 3.8 B). Only the C-
terminal deletions IRF6-113, containing the DBD alone, could bind DNA (Fig 3.10, 
lane 4). This demonstrates that the C-terminal region autoinhibits the DNA-binding 
ability of IRF6. IRF6 may exist in a transcriptionally inactive closed conformation. This 
shows that the C-terminal region of IRF6 has a significant influence on IRF6 functional 
activity. The C-terminal region contains the IAD that is involved in protein:protein 
interactions that determine their functional activity. There is a significant occurrence of 
VWS and PPS missense mutations in the DBD and the IAD which is indicative of their 
biological importance (de Lima et al., 2009). Therefore it is necessary to investigate the 
precise function of the full-length IRF6 and not only of the isolated DBD. For example, 
IRF4 and IRF8 required the DBD and IAD for functional activity at target ISREs. IRF4 
and IRF8 can act as both transcriptional activator and repressors depending on their 
interacting partners (Holland et al., 2010). 
Taking into consideration that a truncated variant of the IRF6 protein containing 
the DBD was used in these studies, this may have altered the true conformation of the 
DBD and thus its binding affinity and specificity (Grant et al., 2000). The isolated IRF3 
N-terminal domain bound to DNA stronger, possibly due to its greater net positive 
charge. However, the stability of both the NTD and CTD of IRF3 decreases with 
increasing negative charge on the CTD. This indicates that full-length IRF protein as a 
whole will affect its overall function. For instance, the increase in negative charge 
induces restructuring and subsequently the formation of stable dimers (Dragan et al., 
2007). The DBD is not the only determinant in the regulation of transcription. 
Cooperation with other IRFs or transcription factors may play a significant role too.  
The full-length IRF6 protein may adopt different conformations and hence a more 
diverse binding site specificity through the IAD. For example, binding studies of IRF3 
used a 26 bp DNA containing two IRF-binding sites, PRDI and PRDIII, from the human 
  - 117 - 
IFN-β enhanceosome. The PRDI and PRDIII sites both consisted of 8 bp and contained 
the 5‟-flanking AA sequence and the core sequence. The spacer DNA between the 
binding sites contained 5 bp. Dragan et al. carried out fluorescence anthisotrophy 
titrations of DNA containing both PRDIII and PRDI binding sites (from the human IFN 
enhanceosome) and DNA containing PRDI binding site only with IRF3-WT or 
phosphomimetic mutants 2D (S396D, S398D) or 5D (S396D, S398D, S402D, T404D 
and S405D). Binding of the 2D mutant was similar to the wildtype to both single and 
double binding sites and as monomeric protein. However the 5D mutant binds to the 
double binding site avidly as a direct consequence of dimerization and it also results in 
either DNA distortion or interdomain linker distortion (Dragan et al., 2007).  
3.9.5. VWS and PPS missense mutations in the IRF6-DBD reduce 
transcriptional activity 
Defining the IRF6 consensus sequence has provided the opportunity to assess the DNA-
binding activity of wildtype IRF6-DBD and determine the causative effects of VWS and 
PPS mutant on its function in vivo. To begin to characterize whether IRF6-DBD is able 
to recognize the IRF6 consensus sequence in vivo luciferase assays were conducted. 
Three constructs were generated; VP16AD-IRF6-DBD fusion protein and pGL3P-
5IRF6S and pGL3P-5IRF6M luciferase reporters. Assessment of the effects of 
VP16AD-IRF6-DBD on the transcriptional activation of the pGL3P-5IRF6M and 
pGL3P-5IRF6S luciferase reporters revealed that VP16AD-IRF6-DBD potentiated 
transcription from the pGL3P-5IRF6S reporter, but showed minimal activation of the 
pGL3P-5IRF6M luciferase control reporters (Fig 3.9). This suggests that the VP16AD-
IRF6-DBD fusion protein and the multimerized IRF6 enhancer element are both 
necessary for transactivation of the luciferase reporter gene.  
Previous EMSA studies showed that in vitro translated IRF6-DBD was able to 
bind to the recognition sequence, and that VWS/PPS mutations in the DBD abrogated 
DNA-binding with the exception of the G70R mutation (Little et al., 2009; experiments 
performed by Hayley Little). Luciferase studies were conducted to replicate and verify 
the previous finding in vivo. Six VWS/PPS mutations (V18A, L22P, W60G, G70R, 
  - 118 - 
R84C and K89A) were introduced in the VP16AD-IRF6-DBD to investigate their 
ability to bind to the IRF6 consensus sequence and subsequently activate transcription 
of the luciferase reporter in vivo. All six VWS/PPS missense mutations showed a 
reduction in luciferase activity by at least 35%, in comparison to the wildtype (Fig 3.10). 
However there was not a complete inhibition of transactivation. This apparent 
discrepancy, in comparison to the complete abrogation in in vitro studies, may reflect 
the possible formation of weak protein-DNA interactions which are not sustained in 
EMSA studies due to the high stringency conditions. Crystal structures of protein-DNA 
interaction in IRFs clearly show the formation of a combination of electrostatic 
interactions, van der Waals, hydrogen bonds at multiple regions for optimal interaction. 
The C-terminal of the α3 recognition helix sits in the major groove and recognizes the 
GAAA core sequence (Fujii et al., 1999). However, other residues aside from the 
residues in the α3 recognition helix are also important for binding specific DNA 
sequences (Grant et al., 2000). Two of the five conserved tryptophan residues in loop L1 
and α2-helix contact the phosphate backbone and act as “anchors”. The conserved 
histidine residues in loop 1 recognize the 5‟-AA flanking sequence in the minor groove 
(Escalante et al., 2007). The single missense mutation may have a significant impact as 
a result of steric hindrance, charge repulsion or conformational change to abolish the 
surrounding direct interactions. However, as there are several points of contact the 
single missense mutations may not in effect abolish all protein-DNA interactions. The 
weakened interactions may still bring lower levels of VP16AD-IRF6-DBD into close 
proximity and thus there is reduced induction of the luciferase gene.    
A more detailed observation of the location of these mutations may provide an 
insight of how they specifically affect DNA-binding. The L22P mutation was identified 
to be a PPS causing mutation (Ghassibe et al., 2004). Leucine residues have high helix-
forming propensities, and in IRF6 residue L22 is predicted to be located in α1 helix. If 
L22 facilitates helix formation, the proline introduces a kink in the α helix due to its 
rigid, cyclic side chain that lacks an amide group to form H-bonds. For example, the 
comparison of circular dichroism (CD) spectra of wildtype and R84P mutant IRF6-DBD 
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showed that the proline mutation severely disrupted IRF6-DBD structure (Little et al., 
2009; experiments performed by Tom Jowitt). Thus, it is possible that the L22P 
mutation could destabilize the α-helix and affect the DBD tertiary structure. The V18A 
mutation leads to VWS development, and is also located in α1 helix (Kondo et al., 
2002). In IRF1, L12 is located at the N-terminal of α1 helix and has direct interaction 
with cytosine in the G:C base pair after the core sequence GAAAGT. Sequence 
alignment of IRF1 
12
LE
13 
corresponds with IRF6 
17
LV
18
. This may indicate that the N-
terminal of the α1 helix is in close proximity to DNA. It could be possible that mutation 
of the adjacent residues V18 may have an impact on the stability of leucine interaction 
with DNA.  
 The G70R CD spectra was similar to the wildtype and homology modeling 
based on IRF4 structure predict that G70 is located in loop L2 between helix α2 and α3  
and is not involved in the DNA-binding interface. Furthermore, G70R mutant was 
shown to interact with DNA by EMSA, in vitro (Little et al., 2009; CD, EMSA and 
modeling experiments performed by Tom Jowitt, Claire Baldock and Hayley Little 
respectively). In contrast to these findings, luciferase assays showed that the G70R was 
able to reduce transcription in vivo.  
Interestingly, the three mutants W60G, R84C and K89A were identified in PPS 
patients all have a direct interaction with the GAAA core sequence (Kondo et al., 2002). 
The IRF-DBD is characterized by penta-tryptophan repeats. The crystal structure shows 
that the W54 and W74 of IRF4 form H-bonds with the DNA backbone between the GT 
spacer and guanine AC:TG bps outside of the AAGTGAAAC extended core sequence 
respectively  (Escalante et al., 2002). Similarly, crystal structures show that residues 
W38 and W57 in IRF3 (Panne et al., 2004) and W38 and W58 in IRF1 formed H-bonds 
at the same sites (Escalante et al., 2002). The conserved W60 in IRF6 is homologous to 
W74, W58 and W57 in IRF4, IRF1 and IRF3 respectively. Thus, W60G mutation could 
therefore diminish protein-DNA interaction as H-bonding would be altered at the DNA 
backbone of the extended core sequence GAAAC. The rigidity of the tryptophan 
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provided by hydrophobic contacts has been proposed to minimize entropy loss to 
enhance protein-DNA interaction (Escalante et al., 2002). 
The specificity of binding between a protein and DNA is provided by protein 
side chains such as arginine, asparagine, glutamine or histidine. The arginine side chain 
consists of a 3-carbon aliphatic straight chain capped by a guanidinium group. The 
guanidinium group contains nitrogen lone pairs, which gives five possible proton donor 
groups for hydrogen bond formation (Shimoni and Glusker, 1995). Crystal structures of 
IRF family members IRF1, IRF2, IRF3 and IRF4 contain arginine residues R82, R82, 
R86 and R98 respectively which are key residues for base recognition of the GAAA 
core sequence. For example, in IRF1 R82 forms two H-bonds with guanine in the 
GAAA core sequence and a salt bridge with the preceding phosphate group (Escalante 
et al., 2002). Like IRF1, the R82 in IRF2 also forms two H-bonds with guanine, 
however one is mediated by a water molecule (Fujii et al., 1999). The arginines are 
conserved in the α3 recognition helix, and are comparable to R84 in IRF6. The missense 
mutation R84C results in a change from a positively charged group to a short, non-polar 
thiol group which may result in insufficient directional contact with DNA. Furthermore, 
the comparison of the CD analysis of wildtype and R84C IRF6-DBD show a similar 
spectrum (Little et al., 2009; experiments performed by Tom Jowitt). This indicates that 
the interference in protein-DNA interaction is not due to changes in the tertiary structure.  
Finally, K103 in IRF4 is involved in the DNA-binding interface as it forms 
direct H-bonds with the third adenine of GAAAC and guanine C:G base pair outside of 
the GAAAC extended core sequence (Escalante et al., 2002). This indicates that K103 is 
important for the specificity of the GAAAC extended core sequence. The K103 is 
homologous to K89 in IRF6, and we have previously shown that IRF6 showed 100% 
recognition of the extended cytosine in the PCR based site selection. In addition the 
alteration C>G in the S17-5 DNA sequence TCAACCGAAAGTAG of the IRF6 
consensus sequence showed a dramatic reduction in protein-DNA-binding (Fig 3.6 B, 
Lane 5), indicating the relevance of that interaction. However the protein-DNA binding 
was not abolished. 
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Missense mutations introduced in the IRF6-DBD can disrupt IRF6 DNA-binding 
and potentially modify gene expression. The luciferase assays show that both VWS and 
PPS mutations reduced transcriptional activity to a similar extent in vivo. However, the 
results here with regards to the PPS phenotypic consequence do not have a strong 
correlation with their relative levels of impaired transactivation. The same missense 
mutation can cause either VWS or PPS, such as R84C, R84H and L98E. In addition, 
different missense mutation of the same residue can cause VWS or PPS.  For example 
W60C and W60G were found in a patient diagnosed with VWS and PPS respectively, 
signifying that they are not mutually exclusive (de Lima et al., 2009). Furthermore, 
there is the interplay of genetic factors and environmental factors that underlie the 
diverse variations of disease progression in individuals (Stanier and Moore, 2004). 
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Chapter 4 
Characterization of IRF6 subcellular localization 
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4. Introduction  
 
The subcellular localization of transcription factors is important for their functional 
activity. The nuclear envelope is a double lipid bilayer that functions to enclose all 
genetic material in the nucleus and partitions the nucleus from the cytoplasm (Wente 
and Rout, 2010). This compartmentalization provides the advantage of functional 
regulation as the barrier can restrict access to DNA (Strambio-De-Castillia et al., 2010). 
The subcellular localization of different members of the IRF family vary, being mainly 
in the nucleus (IRF1, IRF4, IRF8 and IRF9) or mainly in the cytoplasm (IRF3, IRF5 
and IRF7) (Tamura et al., 2008). IRF3, IRF5 and IRF7 exist in a closed conformation in 
the cytoplasm, but translocate into the nucleus upon activation (Lin et al., 2000b; Cheng 
et al., 2006).  
In this study, the subcellular localization of IRF6 and the effects of VWS and 
PPS mutations on its distribution were investigated. Initial experiments demonstrated 
that IRF6 is predominantly cytoplasmic. The subcellular localization of IRFs can be 
modulated by the activation of multiple signalling pathways (Servant et al., 2002). 
Investigations were therefore undertaken to identify stimulants that may induce IRF6 
nuclear translocation and activation. Finally, the directionality of transport can be driven 
by the exposure of NLS and NES internal signals in IRFs. Studies were conducted to 
identify internal signals in IRF6 that influence its subcellular localization.  
4.1. IRF6 is predominantly cytoplasmic  
IRF6 tissue expression is tightly regulated in a spatial and temporal manner. Extended 
studies in Irf6 mutant mice showed that IRF6 plays a vital role in the keratinocyte 
proliferation-differentiation switch (Richardson et al., 2006). Human keratinocyte 
HaCaT cells express endogenous IRF6, and were therefore used to investigate the 
subcellular distribution of IRF6. A plasmid which encodes the full-length mouse IRF6 
fused to the C-terminus of Enhanced Green Fluorescent Protein (EGFP-IRF6) was used 
for detection by fluorescent microscopy. Transient transfections with plasmids 
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expressing EGFP alone, EGFP-IRF6 and EGFP-PC2 were carried out in HaCaT cells 
and were monitored by fluorescent microscopy at 24 hours post-transfection. The 
subcellular distribution is summarized by the percentage of cells that are cytoplasmic 
(C), cytoplasmic and nuclear (C/N) or nuclear (N). The localization of EGFP-IRF6 was 
assessed by the comparison with EGFP which was used as a negative control where it 
was mainly distributed in both the cytoplasm and nucleus (Fig 4.1 panel A) and EGFP-
PC2 as a positive control as it is a transcription factor that is constitutively resident in 
the nucleus (Fig panel C). EGFP-IRF6 was shown to be located predominantly in the 
cytoplasm (Fig 4.1 panel B).  The EGFP-IRF6 distribution is distinct from that of EGFP 
alone and EGFP-PC2, indicating that the EGFP tag does not prevent nuclear 
translocation.  
Having demonstrated that transfected EGFP-IRF6 is cytoplasmic we next 
determined whether the endogenous protein was also cytoplasmic. HaCaT cells express 
endogenous IRF6, therefore cytoplasmic and nuclear extracts were prepared to examine 
the subcellular distribution of endogenous IRF6. A western blot analysis of whole cell, 
cytoplasmic and nuclear extracts of HaCaT cells was performed. An anti-IRF6 antibody 
was used to detect endogenous IRF6 (Fig 4.1 B). In whole extracts of HaCaT cells the 
endogenous IRF6 was detected as two bands. This suggests that IRF6 exists in two 
forms, which could either be different isoforms or post translationally modified (Fig 4.1 
B, lane 1). The endogenous IRF6 was mainly detected in the cytoplasmic fraction and 
not in the nuclear fraction, which further confirm that IRF6 is predominantly 
cytoplasmic (Fig 4.1 B, lane 2 and 3). These data are consistent with the fluorescent 
microscopy using EGFP-IRF6. Thus, in HaCaT cells IRF6 is predominantly 
cytoplasmic.
  - 125 - 
 
A          
 
 
 
 
 
 
 
  
 
 
 
B                                                                     
 
 
 
 
 
      
 
 
Figure 4.1. The subcellular localisation of EGFP-IRF6 in HaCaT cells. (A) HaCaT 
cells were transiently transfected with constructs expressing EGFP only, EGFP-IRF6 
and EGFP-PC2. The subcellular localization was determined 24 hours post-transfection. 
A to C: EGFP fluorescence (green); A‟ to C‟: The nucleus is stained with DAPI 
fluorescence (blue); A‟‟ to C‟‟ Merged images of EGFP and DAPI fluorescence. Images 
were acquired with an Olympus widefield microscope using a x100 objective. Scale bar 
represents 10 µm. The graph below shows the percentage of cytoplasmic (C), 
cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing EGFP only, EGFP-IRF6 and EGFP-PC2 proteins as indicated. Statistically 
significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for C/N and (#) for N 
localization when compared with wildtype EGFP-IRF6. Percentages are representative 
of 100 cell counts each from three independent experiments. (B) Cytoplasmic and 
nuclear extracts prepared from HaCaT cells were analysed by SDS-PAGE and western 
blotting using a polyclonal anti-IRF6 antibody to detect endogenous IRF6. The blot was 
also probed with anti-β tubulin and anti-lamin B to confirm the purity of the 
cytoplasmic and nuclear cell fractions respectively. Lane 1, Whole extract (WE); lane 2, 
Cytoplasmic extract (CE); lane 3, Nuclear extract (NE).  
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4.2. The effects of VWS and PPS-associated mutations on IRF6 
subcellular localization  
Missense mutations account for a large percentage of VWS and PPS causing mutation 
(Ye et al., 2005). The distribution of VWS and PPS differ in that VWS mutations are 
mainly located in the DBD and the IAD, while mutations in PPS are frequently found in 
the DBD (Kondo et al., 2002; de Lima et al., 2009). However, the effects of missense 
mutations in the DBD and IAD on IRF6 subcellular distribution have not been studied. 
Twenty two VWS and PPS causing IRF6 missense mutations were selected, with 
particular emphasis on the DBD and the IAD (Fig 4.2 A). The introduction of VWS and 
PPS missense mutations in EGFP-IRF6 may provide an insight into the potential effects 
of missense mutations on IRF6 subcellular distribution. The plasmid constructs were 
generated by site-directed mutagenesis and were all confirmed by sequence analysis. 
Subsequently, the subcellular localization of each missense mutant was examined in 
HaCaT cells. HaCaT cells were transfected with EGFP-IRF6 missense mutants. 
Fluorescent microscopy was used to analyze the subcellular distribution and the 
percentage of cells that are C, C/N or N were calculated. The subcellular localization of 
EGFP-IRF6 missense mutations in the DBD were first analyzed (Fig 4.3). The results 
indicated that the fifteen VWS and PPS missense mutation introduced in the DBD 
showed a similar subcellular distribution to the wildtype EGFP-IRF6. Only L22P 
showed a considerably lower cytoplasmic localization, however the subcellular 
distribution pattern is still similar to wildtype EGFP-IRF6. There was no difference in 
the subcellular distribution between the VWS and PPS missense mutations in the DBD. 
For example, missense mutations found in VWS and PPS patients R84C and R84H and 
VWS missense mutations R84G and R84P all share a similar subcellular distribution. 
Furthermore, missense mutations in conserved residues W60, R84 and K89 that are 
predicted to directly interact with DNA, also had little effect on the subcellular 
distribution. These data demonstrate that disease causing mutations in the DBD of 
EGFP-IRF6 do not affect its subcellular subcellular distribution, at least in the cases 
studied in unstimulated cells.     
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Figure 4.2. Selected residues for IRF6 site-directed mutagenesis and the 
subcellular localization of VWS and PPS point mutants in the IRF6-DBD in HaCat 
cells. (A) Amino acid sequence of IRF6 protein with the residues chosen for site-
directed mutagenesis in bold and the point mutation that cause VWS and PPS shown 
above. The conserved DBD amino acids 13-113 is highlighted in green and IAD amino 
acid 226-394 is highlighted in pink. (B) The graph shows the percentage of cytoplasmic 
(C), cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing EGFP-IRF6 VWS/PPS missense mutant proteins as indicated. Statistically 
significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for C/N and (#) for N 
localization when compared with wildtype EGFP-IRF6. Percentages are representative 
of 100 cell counts each from three independent experiments.  
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Figure 4.3. Subcellular localization of VWS and PPS point mutants in the IRF6-
DBD in HaCat cells. HaCat cells were transiently transfected with constructs 
expressing wildytpe EGFP-IRF6 or EGFP-IRF6 point mutants in the DBD. The selected 
IRF6 point mutants that are found in VWS and PPS patients are indicated above. After 
24 hours post-transfection cells the subcellular localization of EGFP-IRF6 point 
mutants was then determined. A to O: GFP fluorescence (green); A‟ to O‟: The nucleus 
is stained with DAPI fluorescence (blue); A‟‟ to O‟‟ Merged images of GFP and DAPI 
fluorescence. Images were acquired with an Olympus widefield microscope using a 
x100 objective. Scale bar represents 10 µm. 
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Mutations in the IAD of IRF6 mainly lead to VWS (Kondo et al., 2002). In IRFs 
the IAD is involved in protein-protein interaction, as well as homo- and hetero-
dimerization of IRFs (Barnes et al., 2002).  To investigate if missense mutations in the 
IAD of EGFP-IRF6 affect subcellular distribution, eight VWS causing missense 
mutations were selected for analysis. The fluorescent microscopy data revealed that the 
missense mutations in the IAD were predominantly localized in the cytoplasm in a 
similar manner to wildtype EGFP-IRF6 (Fig 4.4). This indicates that there is no 
difference in the subcellular localization of missense mutations in the DBD or the IAD. 
Furthermore, all the selected VWS and PPS missense mutants did not alter the 
subcellular localization of EGFP-IRF6.  
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Figure 4.4. Subcellular localization of VWS missense mutants in the IRF6 IAD in 
HaCaTcells. HaCaT cells were transiently transfected with constructs expressing 
wildytpe EGFP-IRF6 or EGFP-IRF6 point mutants in the IAD. The selected IRF6 point 
mutants that are found in VWS patients are indicated above. After 24 hours post-
transfection the subcellular localization of EGFP-IRF6 point mutants was then 
determined. A to H: GFP fluorescence (green); A‟ to H‟: The nucleus is stained with 
DAPI fluorescence (blue); A‟‟ to H‟‟ Merged images of GFP and DAPI fluorescence. 
Images were acquired with an Olympus widefield microscope using a x100 objective. 
Scale bar represents 10 µm. The graph shows the percentage of cytoplasmic (C), 
cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing EGFP-IRF6 VWS/PPS missense mutant proteins as indicated. Statistically 
significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for C/N and (#) for N 
localization when compared with wildtype EGFP-IRF6. Percentages are representative 
of 100 cell counts each from three independent experiments. 
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4.3. Selected growth factors and mitogens do not affect the subcellular 
localization of IRF6 
The nuclear translocation of a transcription factor may be regulated at many levels. 
Subcellular localization may be regulated by the direct modification of the transcription 
factor or indirectly by regulating the activities of associated factors. The associated 
factors can act as cytoplasmic inhibitors that promote nuclear translocation in response 
to signal transduction or inhibit translocation prior to activation (Whiteside and 
Goodbourn, 1993). EGFP-IRF6 was shown to be predominantly cytoplasmic and the 
activation of specific signalling pathways that induce IRF6 nuclear translocation and 
activation are still unknown. The subsequent studies were conducted to identify 
signalling pathways that may induce nuclear translocation and retention of IRF6.  
Foetal bovine serum (FBS) is added as a supplement in growth medium for cell 
cultures as it contains a broad spectrum of macromolecules essential for cell growth, 
proliferation and maintenance. The macromolecules include trace elements, lipids, 
hormones and growth factors (Gstraunthaler, 2003). To analyze if components in the 
serum affect IRF6 distribution, the subcellular localization of EGFP-IRF6 in serum-
arrested cells and serum-stimulated cells was assessed. HaCaT cells transiently 
expressing EGFP-IRF6 were synchronized by serum starvation to induce growth arrest. 
The localization of EGFP-IRF6 in cells in this quiescence state was predominantly 
cytoplasmic. (Fig 4.5, panel A). The cells were then stimulated by the addition of serum 
for  1 hour, 2 hours, 4 hours and 8 hours, and the subcellular localization of EGFP-IRF6 
was then analyzed (Fig 4.5, panel B-E). The data shows that EGFP-IRF6 remains 
predominantly localized in the cytoplasm after serum stimulation over the time course. 
There was no statistically significant difference observed in the subcellular localization 
at the indicated time points. Therefore stimulation of HaCaT cells with serum does not 
induce nuclear translocation of EGFP-IRF6.  
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Figure 4.5. Effect of serum on the subcellular distribution of EGFP-IRF6 in 
HaCaT cells. HaCaT cells were transiently transfected with EGFP-IRF6 for 24 hours in 
complete growth medium followed by serum starvation (0.5% FBS) for 24 hours. Time 
0 mins represent 24h of serum starvation, subsequent time points indicate a time elapsed 
after serum stimulation (10% FBS).  A to E: GFP fluorescence (green); A‟ to E‟: 
Nucleus is stained with DAPI fluorescence (blue); A‟‟ to E‟‟. Merged images of GFP 
and DAPI fluorescence. Images were acquired with an Olympus widefield microscope 
using a x100 objective. Scale bar represents 10 µm. The graph below shows the 
percentage of cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) 
subcellular localization of cells expressing EGFP-IRF6 after serum stimulation as 
indicated. No statistically significant difference of (P<0.05) was observed for C, C/N 
and N when compared with EGFP-IRF6 untreated control. Percentages are 
representative of 100 cell counts each from three independent experiments. 
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Various stimulants were assessed to delineate potential signalling pathways that may 
regulate IRF6 activity. Treatment with EGF, phorbol-12-myristate-13-acetate (PMA) 
and phytohemagglutinin (PHA) was performed. EGF binds to the EGF receptor which 
subsequently activates several signalling cascades, which include the Ras/mitogen 
activated protein kinase (Ras/MAPK) pathway, Src kinases, JAKs and 
phosphatidylinositol signalling (Jorrisen, 2003). PMA is a natural compound that can 
induce the activation of protein kinase C (PKC). PKC is a family of serine-threonine 
kinases that are involved in various essential cellular processes including proliferation 
and survival (Afrasiabi et al., 2008). Phytohaemagglutinin (PHA) is a lectin known to 
have an effect on cell metabolism by inducing mitogenesis. PHA can bind to complex 
carbohydrates on the cell surface to mimic a natural ligand of a receptor or inhibit 
binding of the natural ligand, thereby eliciting a wide range of local and systemic effects 
(Otte, 2001). In an attempt to activate signalling pathways that may lead to the 
activation of IRF6, HaCaT cells transfected with EGFP-IRF6 were stimulated with EGF 
(Fig 4.6, panel B), PHA (Fig 4.6, panel C) and PMA (Fig 4.6, panel D) and their 
subcellular localization was analysed after 4 hours of stimulation. The data shows that 
the EGFP-IRF6 subcellular distributions changed slightly after stimulation with EGF. 
There was a slight reduction the percentage of cytoplasmic localization of IRF6, but the 
subcellular distribution pattern still remained similar to that of the unstimulated control. 
There was no significant change in the subcellular distribution of EGFP-IRF6 after 
stimulation with PHA and PMA. EGFP-IRF6 still mainly resided in the cytoplasm. The 
percentage of C/N and N distribution resembles that of the unstimulated control, 
indicating that the stimulants did not induce nuclear translocation. These findings 
suggest that pathways activated by EGF, PHA and PMA do not regulate nuclear 
translocation of IRF6.  
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Figure 4.6. Effect of selected growth factors and mitogens on the subcellular 
distribution of EGFP-IRF6 in HaCaT cells. HaCaT cells were transiently transfected 
with EGFP-IRF6 for 24 hours. Panel A represent unstimulated cells at time 0 mins. 
Panel B, C and D shows stimulation with 0.3 ng/ml EGF, 0.4 µg/ml PHA and 0.01 nM 
PMA respectively where the subsequent time points indicate a time elapsed after 
stimulation.  A to D: GFP fluorescence (green); A‟ to D‟: Nucleus is stained with DAPI 
fluorescence (blue); A‟‟ to D‟‟. Merged images of GFP and DAPI fluorescence. Images 
were acquired with an Olympus widefield microscope using a x100 objective. Scale bar 
represents 10 µm. The graph below shows the percentage of cytoplasmic (C), 
cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing EGFP-IRF6 proteins without or with growth factor or mitogen stimulation as 
indicated. Statistically significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for 
C/N and (#) for N localization when compared with EGFP-IRF6 untreated control. 
Percentages are representative of 100 cell counts each from three independent 
experiments. 
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4.4. Toll-like receptor signalling does not induce IRF6 nuclear 
translocation 
Toll-like receptors (TLRs) are essential for the recognition of invading pathogens and 
serve as an important link between innate and adaptive immunity. In response to virus-
derived double-stranded ribonucleic acid (dsRNA), TLR3 recruits the adapter protein, 
Toll/IL-1R domain-containing adaptor-inducing IFN-β (TRIF). TRIF then recruits 
TRAF3 and non-canonical IκB kinases Tank binding kinase 1 (TBK1) and Ikappa B 
kinase (IKK)ε. TBK1 and IKKε subsequently phosphorylates and activates IRF-3 and 
IRF-7, leading to the production of α/β IFNs (Fitzgerald et al., 2003). PolyI:C is a 
dsRNA mimetic that can be recognized by TLR3 and consequently activate multiple 
signalling pathways. PolyI:C activation of TLR3/TLR4 induced IRF3 and NF-κB 
transcriptional regulation of genes involved in primary and secondary immune response, 
such as IFNβ, ISG15, RANTES and IRF7 (Doyle et al., 2002).  To investigate if IRF6 is 
regulated by TLR3 signalling, human mammary epithelial cells (MCF-10A) were 
transfected with EGFP-IRF6 and treated with Poly I:C. MCF-10A cells were used as 
TLR3 expression has been detected in these cells (Bailey and Hendrix, 2008). MCF-
10A transfected with EGFP-IRF6 revealed that EGF-IRF6 is predominantly localized in 
the cytoplasm (Fig 4.7, panel A) suggesting that the cytoplasmic localization may not be 
cell-type specific. Upon treatment with Poly I:C (Fig 4.7, panel B-E), there was no 
visible effect on EGFP-IRF6 subcellular localization. EGFP-IRF6 remained 
predominantly cytoplasmic throughout the experimental time course. The percentage of 
cells that are C, C/N or N may vary slightly in comparison to the untreated cells, but 
there was no significant difference observed. This demonstrates that Poly I:C does not 
have an obvious effect on EGFP-IRF6 nuclear translocation.   
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Figure 4.7. Effects of the activation of TBK and IKKɛ on the subcellular 
distribution of eGFP-IRF6 in MCF-10A cells. MCF-10A cells were transiently 
transfected with EGFP-IRF6 for 24 hours, then stimulated with 10 µg/ml Poly I:C. Time 
0 mins represent unstimulated cells, subsequent time points indicate a time elapsed after 
Poly I:C stimulation. A to E: GFP fluorescence (green); A‟ to E‟: Nucleus is stained 
with DAPI fluorescence (blue); A‟‟ to E‟‟ Merged images of GFP and DAPI 
fluorescence. Images were acquired with an Olympus widefield microscope using a 
x100 objective. Scale bar represents 10 µm. The graph below shows the percentage of 
cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization 
of cells expressing EGFP-IRF6 proteins without or with poly I:C stimulation as 
indicated. No statistically significant difference of (P<0.05) was observed for C, C/N 
and N when compared with EGFP-IRF6 untreated control. Percentages are 
representative of 100 cell counts each from three independent experiments. 
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4.5. Leptomycin B inhibits nuclear export of IRF6 
Previous studies have demonstrated that the nucleocytoplasmic translocation of IRFs 
can be mediated by both NLS and NES signals (Kumar et al., 2000; Barnes et al., 2002). 
The NLS is important in nuclear translocation and retention, while the NES is involved 
in nuclear export (Lin et al., 2005). Therefore we speculated that IRF6 cytoplasmic 
distribution may also be mediated by a NES. Chromosomal region maintenance 1 
(CRM1) is a shuttling receptor known to bind to NESs and function in the export of 
NES-containing proteins from the nucleus to the cytoplasm. The antibiotic leptomycin 
B (LMB) is an unsaturated, branched-chain fatty acid that directly binds to CRM1, 
which prevents CRM1 recognition of NES containing proteins. This inhibits CRM1‟s 
function in mediating nuclear export (Fig 4.8 B) (Kumar et al., 2000). We therefore 
examined the effect of LMB on subcellular localization of IRF6. HaCaT cells 
transiently transfected with EGFP-IRF6 were treated with LMB over a time course of 
up to 4 hours and the subcellular localization was monitored by fluorescent microscopy 
(Fig 4.8 A). HaCaT cells that were not treated with LMB showed that EGFP-IRF6 was 
predominantly cytoplasmic (Fig 4.8 A, panel A). Analysis of the EGFP-IRF6 
distribution after treatment of LMB over a 4 hour time course revealed that the 
percentage of cells with EGFP-IRF6 in the cytoplasm gradually diminished and EGFP-
IRF6 accumulated in the nucleus (Fig 4.9 A, panel B-F). Significant changes in the 
subcellular distribution were observed within 15 minutes of LMB treatment. EGFP-
IRF6 distribution in the cytoplasm is decreased by approximately 0.5 fold, and the 
distribution of C/N and N EGFP-IRF6 increased by approximately 2 fold, in 
comparison to the untreated control. After 30 mins of LMB treatment, EGFP-IRF6 C/N 
distribution and N distribution are at similar levels, which range between 40%-50% of 
the population. Treatment of LMB for 2 hours shows that over time more EGFP-IRF6 
accumulates in the nucleus. EGFP-IRF6 is distinctly retained in the nucleus and the 
localization becomes predominantly nuclear.  This implies that IRF6 can shuttle into the 
nucleus. We can therefore conclude that the cytoplasmic relocalization of EGFP-IRF6 is 
inhibited by LMB treatment. 
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Figure 4.8. Effects of LMB on the subcellular distribution of EGFP-IRF6 in 
HaCaT cells. (A) HaCat cells transiently transfected with EGFP-IRF6 and were 
untreated or treated with 10ng/ml leptomycin B for 15 mins , 30 mins, 1 hour, 2 hours 
and 4 hours. A to F: GFP fluorescence (green); A‟ to F‟: Nucleus is stained with DAPI 
fluorescence (blue); A‟‟ to F‟‟ Merged images of GFP and DAPI fluorescence. Images 
were acquired with an Olympus widefield microscope using a x100 objective. Scale bar 
represents 10 µm. The graph below shows the percentage of cytoplasmic (C), 
cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing EGFP-IRF6 proteins without or with leptomycin B treatment as indicated. 
Statistically significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for C/N and 
(#) for N localization when compared with EGFP-IRF6 untreated control. Percentages 
are representative of 100 cell counts each from three independent experiments. (B) 
Schematic representation of CRM1 mediated export. CRM1 associates to cargo 
containing a NESs in the presence of Ran-GTP. The ternary export complex can 
interacts with nuclear pore proteins that mediate transport through the nuclear pore 
complex. The ternary export complex then dissociates upon Ran-GTP hydrolysis to 
release the cargo in the cytoplasm. The NES-mediated export is prevented by the 
treatment with leptomycin B (red). 
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Co-immunoprecipitation experiments were performed to examine if IRF6 associates 
with CRM1. A plasmid that encodes full-length mouse IRF6 fused to the C-terminus of 
2 FLAG epitopes (FLAG-IRF6) was used to ensure high-level expression and facilitate 
detection in co-immunoprecipitation. Whole extracts of Cos 7 cells expressing FLAG-
IRF6 were immunoprecipitated using anti-FLAG antibody, anti-CRM1 antibody and 
IgG antibody as a negative control. The immunoprecipitates were analyzed by western 
blot and immunoblot. A band was detected at ~60 kDa that corresponds to FLAG-IRF6 
(Fig 4.9, lane 3). The specificity of FLAG-IRF6 enrichment was confirmed by the 
absence of the FLAG-IRF6 band in the IgG control. The FLAG co-immunoprecipitation 
was also immunoblotted for CRM1, whereby a band was detected at ~110 kDa that 
corresponds to endogenous CRM1. Reciprocally, when CRM1 was immunoprecipitated 
with an anti-CRM1 antibody, FLAG-IRF6 was detected (Fig 4.9 B, lane 7). Taken 
together these data suggest that IRF6 contains a CRM1-dependent NES.  
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Figure 4.9. IRF6 interacts with CRM1. Cos 7 cells were transiently transfected with 
constructs expressing wildytpe FLAG tagged-IRF6. After 24 hours of transfection, 
whole cells extracts were prepared and co-immunoprecipitated with anti-FLAG or anti-
CRM1 antibody, with IgG as a negative control. The co-immunoprecipitated complexes 
were resolved on a 8% SDS-PAGE and subsequently immune-blotted with anti-FLAG 
(top panel) and anti-CRM1 (bottom panel).  
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4.6. Mapping the IRF6 nuclear export signal  
Transcription factors depend on the nuclear localization for the access of genetic 
material for transcriptional function. To provide a better understanding of the molecular 
mechanisms that underlies IRF6 steady state subcellular distribution, it was important to 
identify regions within IRF6 that mediate IRF6 localization. Manipulation of this region 
may lead to the generation of an IRF6 protein that is constitutively nuclear. Such a 
mutant might be transcriptionally active and thus allow the effects of disease-causing 
mutants on transcriptional activity to be determined. Thus, it was necessary to delineate 
essential residues that were involved in the nucleocytoplasmic transport of IRF6. EGFP-
IRF6 deletion proteins can help map residues that constitute the nuclear export signal 
(NES) or the nuclear localization (NLS) signals or deduce any autoinhibitory domain 
within IRF6. The regions that determine the subcellular localization of IRF6 were 
therefore determined by generating a series of EGFP-IRF6 C-terminal deletions up to 
amino acid 120 (Fig 4.10 A). All the EGFP-IRF6 C-terminal deletions were generated 
by PCR and incorporated into the EGFP expression vector (pEGFP-C3). The integrity 
of the constructs was confirmed by restriction digest analysis and sequencing. Cos 7 
cells were transiently transfected with plasmids encoding individual EGFP-IRF6 C-
terminal deletion mutants to examine their expression. Whole extracts were collected 
for western blot analysis and immunoblot with anti-GFP antibody for the detection of 
the EGFP fusion proteins (Fig 4.10 B and C). Fig 4.10 B and C, lane 1 shows non-
transfected Cos 7 cells that was used as a negative control. In Fig 4.10 B and C, lane 2 
wildtype EGFP-IRF6 has an apparent molecular weight of ~95 kDa. This is higher than 
the predicted molecular weight of 80.7 kDa of the 711 residue EGFP-IRF6 protein. The 
deviation of the measured molecular weight may be due to several factors such as the 
abundance of proline residues, protein isoelectric point and acidity (Burton 1981). The 
EGFP-IRF6 C-terminal deletion mutants show a gradual stepwise decrease in molecular 
weight that correlates with the progressive removal of C-terminal residues up to amino 
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acid 120 (Fig 4.10 B, lane 3-7 and C, lane 3-8). This verifies expression of EGFP-IRF6 
C-terminal deletions proteins. 
The wildtype EGFP-IRF6 and EGFP-IRF6 C-terminal deletion mutants were 
transfected into HaCaT cells and their subcellular distribution was assessed by 
fluorescent microscopy (Fig 4.11).The deletion of C-terminal residues up to amino acid 
170, showed a similar phenotype to the wildtype EGFP-IRF6, with the exception of 
EGFP-IRF6-225 which showed a slight reduction in the percentage of cells that exhibit 
cytoplasmic localization. It is apparent that they are predominantly cytoplasmic. 
However, there was a notable change in the subcellular localization in the transition 
from IRF6-170 to IRF6-164 from being predominantly cytoplasmic to predominantly 
nuclear. Indeed, all subsequent EGFP-IRF6 C-terminal deletion proteins, from amino 
acid 164 to amino acid 120, were predominantly nuclear. All showed significant 
difference of P values less than 0.0001 for cytoplasmic localization and nuclear 
localization when compared to wildtype EGFP-IRF6. This indicates that the C-terminal 
truncation to amino acid 164 disrupts or removes the region that determines the 
cytoplasmic localization of EGFP-IRF6. Given this, we were prompted to evaluate 
essential residues within this region that contribute to EGFP-IRF6 nuclear export.  
 The CRM1 receptor generally recognizes hydrophobic amino acid-rich 
NES targets (Fukuda et al., 1997), therefore hydrophobic residues were identified in the 
region between amino acids 159 and 170 (
159
IQDTFPFLNING
170
). To assess the 
importance of these hydrophobic residues, they were replaced by alanine residues in 
EGFP-IRF6. The single mutation I159A (EGFP-IRF6 NES 1A), double  mutations 
F163A/F165A and L166A/I168A (EGFP-IRF6 NES 2-1A and EGFP-IRF6 NES 2-2A 
respectively) and quadruple mutations F163A/F165A /L166A/I168A (EGFP-IRF6 NES 
4A) were introduced and their role in the nuclear export of EGFP-IRF6 determined (Fig 
4.12 A). The EGFP-IRF6 NES alanine mutants were transiently expressed in HaCaT 
cells and their subcellular distribution was observed (Fig 4.12 B). Wildtype EGFP-IRF6 
was used as a positive control showing a predominantly cytoplasmic localization.  
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Figure 4.10. Western blot analysis of EGFP-IRF6 C-terminal deletions. (A) A 
Schematic representation of a series of IRF6 C-terminal deletions generated. The DNA 
binding domain and the interferon association domain are indicated. (B and C) Cos 7 
cells transiently transfected with constructs expressing wildytpe EGFP-IRF6 and EGFP-
IRF6 C-terminal deletions. After 24 hours of transfection, whole cell extracts were 
prepared and analysed by SDS-PAGE and western blotting using a polyclonal anti-GFP 
antibody to detect EGFP-IRF6 C-terminal deletions. The blot was also probed with anti- 
β tubulin as a loading control. Predicted sizes of EGFP fusion proteins: wildtype IRF6, 
80.7 kDa; EGFP-IRF6-359, 68.3 kDa; EGFP-IRF6-225, 53.1 kDa; EGFP-IRF6-190, 
49.0 kDa; EGFP-IRF6-180, 48.1 kDa; EGFP-IRF6-170, 47.2 kDa; EGFP-IRF6-164, 
46.5 kDa; EGFP-IRF6-160, 46.1 kDa; EGFP-IRF6-150, 44.9 kDa; EGFP-IRF6-140, 
43.7 kDa; EGFP-IRF6-130, 42.5 kDa; EGFP-IRF6-120, 42.6 kDa.   
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Figure 4.11. Mapping the nuclear export signal of mouse IRF6. HaCaT cells were 
transiently transfected with constructs expressing wildytpe EGFP-IRF6 or EGFP-IRF6 
C-terminal deletion mutants. The subcellular localization was determined 24 hours post-
transfection. A to M: GFP fluorescence (green); A‟ to M‟: The nucleus is stained with 
DAPI fluorescence (blue); A‟‟ to M‟‟ Merged images of GFP and DAPI fluorescence. 
Images were acquired with an Olympus widefield microscope using a x100 objective. 
Scale bar represents 10 µm. The graph below shows the percentage of cytoplasmic (C), 
cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing IRF6 C-terminal deletion proteins as indicated. Statistically significant 
difference of (P<0.05) are denoted as (*) for C, (Ŧ) for C/N and (#) for N localization 
when compared with wildtype EGFP-IRF6. Percentages are representative of 100 cell 
counts each from three independent experiments.. 
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In comparison, the EGFP-IRF6 1A mutant exhibited a different distribution to wildtype 
EGFP-IRF6, with distinct differences seen by the increase of C/N localization and a 
dominant N localization phenotype. The EGFP-IRF6 NES 2-1A and EGFP-IRF6 NES 
2-2A double alanine mutants and the EGFP-IRF6-NES 4A quadruple alanine mutant 
exhibited a more prominent N distribution. The double and quadruple alanine mutants 
exhibited a similar subcellular distribution to each other. This indicates that mutation of 
F163/F165A or L66A/I168A is sufficient to disrupt the nuclear export of IRF6. The 
single I159A mutation also prevented nuclear export, but at a lesser degree to the double 
mutants. These observations demonstrate that the hydrophobic resides between 159 and 
168 are responsible for the nuclear export of IRF6. Thus this region can be defined as a 
NES. 
The identification of a functional NES, and the subsequent mutation of this NES 
enabled the generation of a full-length EGFP-IRF6 that accumulates in the nucleus. We 
subsequently determined whether the accumulation EGFP-IRF6 containing a mutated 
NES was transcriptionally active. Luciferase assays were carried out using the 
constitutively nuclear EGFP-IRF6 NES mutants to test their ability to transactivate the 
luciferase reporter gene that is under the regulation of a multimerized IRF6 consensus 
sequence (Fig 4.13). As controls, Cos 7 cells were co-transfected with the pGL3P-
5IRF6S reporter and IRF6-DBD, VP16AD or VP16AD-IRF6-DBD expression plasmids. 
The VP16AD-IRF6-DBD was transcriptionally active showing approximately 6 fold 
increase in luciferase activity compared to the VP16AD, IRF6-DBD and wildtype 
EGFP-IRF6 (Fig 4.13, Lane 1-3 add lane number). However, the EGFP-IRF6 NES 2-
1A and EGFP-IRF6 NES 2-2A mutants were also inactive (Fig 4.13, Lane 6 and 7). 
These findings suggest that nuclear accumulation alone is not sufficient for IRF6 to 
regulate transcription.  
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Figure 4.12. Identification of important residues in IRF6 nuclear export signal. (A)  
Schematic representation of IRF6 NES alanine mutants generated to assess the 
importance of hydrophobic residues between amino acids 159-168. (B) The subcellular 
localization of the EGFP-IRF6 IRF6 NES alanine mutants in HaCaT cells. HaCaT cells 
were transiently transfected with constructs expressing wildytpe EGFP-IRF6 or EGFP-
IRF6 NES alanine mutants for 24 hours. The subcellular localization of EGFP-IRF6 
NES alanine mutants was then determined. A to E: GFP fluorescence (green); A‟ to E‟: 
The nucleus is stained with DAPI fluorescence (blue); A‟‟ to E‟‟ Merged images of 
GFP and DAPI fluorescence. Images were acquired with an Olympus widefield 
microscope using a x100 objective. Scale bar represents 10 µm. The graph below shows 
the percentage of cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) 
subcellular localization of cells expressing EGFP-IRF6 NES alanine mutant proteins as 
indicated. Statistically significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for 
C/N and (#) for N localization when compared with wildtype EGFP-IRF6. Percentages 
are representative of 100 cell counts each from three independent experiments. 
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Figure 4.13. Transcriptional activity of wildtype EGFP-IRF6 and EGFP-IRF6 
NES mutant EGFP-IRF6 in the IRF6 reporter. Luciferase assays to assess the 
activation of the pGL3P-5IRF6S reporter by EGFP-IRF6 NES mutants as indicated. 
Cos 7 cells were co-transfected with 0.4 µg of
 
pGL3P-5IRF6S reporter with 3.5µg of 
empty vector or IRF6 expression plasmids as indicated. To control the transfection 
efficiency cells were additionally transfected with 0.1 µg ß-galactosidase plasmid pSV-
ßGal. Cells were analyzed for luciferase and ß-galactosidase activities 24 h after 
transfection. The columns show the luciferase relative light units fold increase 
normalized to the ß-galactosidase activity. Luciferase assays were performed in 
triplicate. Error bars represent standard error. Asterisks (*) indicates a statistically 
significant difference determined by ANOVA (P<0.05) when compared with VP16AD 
and EGFP-IRF6 control. 
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4.7. Identification of the IRF6 nuclear localization signal  
The NLSs identified in IRF family members share an enriched basic amino acid 
sequence; however they show considerable diversity throughout the IRF family. All the 
IRFs contain an NLS at the N-terminal region. The deletion of C-terminal residues to 
amino acid 113 lead to the nuclear retention of EGFP-IRF6, suggesting that IRF6 
contains an N-terminal NLS. To determine where the NLS is located within the first 113 
amino acids, further EGFP-IRF6 N- and C-terminal deletion proteins were generated in 
order to map the IRF6 NLS (Fig 4.14 A). The expression of the EGFP-IRF6 C-terminal 
deletion and EGFP-IRF6 N- and C-terminal deletion mutants were confirmed by 
western blot analysis using anti-GFP antibody (Fig 4.14 B). In Fig 4.14 B and C, non-
transfected Cos 7 cells was used as a negative control (lane 1) and EGFP-IRF6 was used 
as a positive reference (lane 2). The EGFP-IRF6 C-terminal deletion mutants show a 
gradual stepwise decrease in molecular weight that correlates with the progressive 
removal of C-terminal residues from amino acids 113 to 60 (Fig 4.14 B, lane 3-8). The 
EGFP-IRF6 N- and C-terminal deletion mutants correspond to their relative truncation 
(Fig 4.14 C, lane 3-9). This verifies expression of EGFP-IRF6 N- and C-terminal 
deletion fusion proteins. 
The plasmids expressing wildtype EGFP-IRF6, EGFP-IRF6 deletion mutants 
were transfected into HaCaT cells and their subcellular distribution were assessed by 
fluorescent microscopy (Fig 4.15). The subcellular localization of EGFP-IRF6 C-
terminal deletions of residues from amino acid 113 up to amino acid 60 were 
predominantly nuclear, similar to C-terminal deletions EGFP-IRF6-164 to EGFP-IRF6-
120. However, EGFP-IRF6 N-and C-terminal deletions showed a change in the cellular 
distribution where it is mainly diffuse in both the cytoplasm and nucleus. The one 
exception was EGFP-IRF6 11-467 that has a similar phenotype to wildtype EGFP-IRF6, 
which is due to the presence of the NES. Statistical analysis revealed a significant 
difference of P values less than 0.0001 for C/N localization of EGFP-IRF6 N-and C-
terminal deletion mutants when compared to wildtype EGFP-IRF6. This suggested that 
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the N-terminal deletion up to the first 11 amino acids may have removed or disrupted 
the NLS. Sequence analysis of the first 11 amino acids of IRF6 reveals a potential NLS 
of 
5
PRRVRLK
11 
that is
 
identical to the IRF5 NLS. 
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Figure 4.14. Western blot analysis of EGFP-IRF6-DBD c-terminal and N-terminal 
deletions. (A) Schematic representation of a series of IRF6-DBD C-terminal and N-
terminal deletions generated. The DNA binding domain and the interferon association 
domain are indicated. (B and C) Cos 7 cells transiently transfected with constructs 
expressing wildytpe EGFP-IRF6 and EGFP-IRF6 C-terminal deletions. After 24 hours 
of transfection, whole cell extracts were prepared and analyzed by SDS-PAGE and 
western blotting using a polyclonal anti-GFP antibody to detect EGFP-IRF6 c-terminal 
deletions. The blot was also probed with anti- β tubulin as a loading control. Predicted 
sizes of EGFP fusion proteins: wildtype IRF6, 80.7 kDa; EGFP-IRF6-113, 40.9 kDa; 
EGFP-IRF6-100, 39.3 kDa; EGFP-IRF6-90, 38.1 kDa; EGFP-IRF6-80, 37.0 kDa; 
EGFP-IRF6-70, 35.7 kDa; EGFP-IRF6-60, 34.8 kDa; EGFP-IRF6-16-113, 39 kDa; 
EGFP-IRF6-16-60, 32.9 kDa; EGFP-IRF6-12-113, 39.5 kDa; EGFP-IRF6-12-60, 33.4 
kDa; EGFP-IRF6-11-467, 79.6 kDa; EGFP-IRF6-11-113, 39.6 kDa; EGFP-IRF6-11-60, 
33.6 kDa. 
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Figure 4.15. Mapping the nuclear localization signal of mouse IRF6. The subcellular 
localization of the EGFP-IRF6 deletion mutants in HaCat cells. HaCat cells were 
transiently transfected with constructs expressing wildytpe EGFP-IRF6 or EGFP-IRF6 
deletion mutants. The subcellular localization was determined 24 hours post-
transfection. A to L: GFP fluorescence (green); A‟ to L‟: The nucleus is stained with 
DAPI fluorescence (blue); A‟‟ to L‟‟ Merged images of GFP and DAPI fluorescence. 
Images were acquired with an Olympus widefield microscope using a x100 objective. 
Scale bar represents 10 µm. The percentage of cells expressing EGFP-IRF6 deletion 
proteins that are localized in the cytoplasm, nucleus or both is summarized on the right. 
The graph below shows the percentage of cytoplasmic (C), cytoplasmic and nuclear 
(C/N) and nuclear (N) subcellular localization of cells expressing IRF6 C-terminal and 
N-terminal deletion proteins as indicated. Statistically significant difference of (P<0.05) 
are denoted as (*) for C, (Ŧ) for C/N and (#) for N localization when compared with 
wildtype EGFP-IRF6. Percentages are representative of 100 cell counts each from three 
independent experiments. 
  - 152 - 
4.8. Discussion  
There is a diverse array of mechanisms involved in the regulation of transcription factor 
activity.  One of these regulation events is the control of the subcellular localization. 
The subcellular localization of members of the IRF family influences their function. 
There are several mechanisms that are involved in regulating the nucleocytoplasmic 
transport of IRF members. Members of the IRF family have been shown to be 
phosphorylated at multiple sites and the combination of phosphorylated sites leads to 
conformational change, nuclear translocation and functional activation (Lin et al., 1998; 
Servant et al., 2002). Wildtype IRF6 was shown to be autoinhibited; therefore it was 
necessary to identify mechanisms involved in its activation and nuclear translocation. In 
this chapter the subcellular localization of IRF6 was first investigated to determine if 
VWS and PPS mutations affect its subcellular localization. An array of different stimuli 
was assessed to see if they affect IRF6 subcellular distribution and functional activation. 
Finally, internal signals that may be responsible for IRF6 nucleocytoplasmic shuttling 
were mapped. 
4.8.1. IRF6 and IRF6 VWS and PPS missense mutants are 
predominantly localized in the cytoplasm 
The nucleocytoplasmic transport is an important process for transcription factors as 
nuclear compartmentalization creates a physical barrier to restrict the accessibility of 
DNA (Strambio-De-Castillia et al., 2010). Fluorescent microscopy data demonstrated 
that EGFP-IRF6 was predominantly localized in the cytoplasm although traces are 
present in the nucleus in HaCaT cells (Fig 4.1 A). Western blot analysis of endogenous 
IRF6 was only detected in the cytoplasmic extract and not in the nuclear extract of 
HaCaT cells (Fig 4.1 B). A possible explanation of the presence of the EGFP-IRF6 in 
the nucleus may be due to the abundance of EGFP-IRF6, driven by the over-expression 
of EGFP-IRF6 proteins. This may indicate that the export of IRF6 is the prevailing 
mechanism leading to accumulation of IRF6 in the cytoplasm. This is also observed in 
other IRF family members, namely IRF3, IRF5 and IRF7. In uninfected
 
cells, IRF3 is 
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also located in the cytoplasm in a closed conformation (Weaver et al., 1998; Sato et al., 
2000). Similarly, IRF6 may exist in an inactive closed conformation. We have 
demonstrated the C-terminal region autoinhibits the DNA-binding ability of IRF6, as 
the full-length IRF6 was not able to bind DNA. However, the C-terminal deletion of 
IRF6 up to residue 113, containing the isolated IRF6-DBD, was able to bind DNA 
avidly (Fig 3.10).  
Mutations in the IRF6 have functional consequences that lead to the 
development of VWS and PPS (Kondo et al., 2002). The majority of IRF6 mutations 
are missense mutations (about 90%) (Ye et al., 2005). Thus missense mutations may 
provide an understanding of the relationship of the structure and function of IRF6. We 
have selected 22 missense mutations that have been mapped in the IRF6 gene in patients 
with VWS and PPS to investigate if they have any influence on IRF6 subcellular 
localization (Fig 4.2). The preliminary examination shows that these 22 missense 
mutations in the DBD and the IAD do not affect IRF6 subcellular localization (Fig 4.3 
and 4.4). The subcellular localization of these missense mutations do not distinguish 
between VWS and PPS mutations as they are all predominantly cytoplasmic,  similar to 
the wildtype. Therefore, the selected VWS and PPS mutation do not appear to disrupt 
the internal signal involved in the export of IRF6 to the cytoplasm. As the VWS and 
PPS mutations do not lead to nuclear accumulation, protein transport dysregulation may 
not be the consequential effect of these missense mutations.  It could be possible that 
intramolecular interaction within IRF6 still prevents functional activation, and that these 
mutations do not lie in regions that are involved in relieving autoinhibition of IRF6. 
4.8.2. Effects of serum starvation, EGF, PHA and PMA and Poly I:C on 
subcellular localization of IRF6  
To elucidate how IRF6 activity is positively regulated is beneficial for understanding 
how IRF6 functions as a transcription factor. Regulatory proteins that are located in the 
cytoplasm can be activated by specific signals that trigger IRF6 nuclear accumulation. 
We then evaluated potential stimulants that may relieve autoinhibition and lead to the 
trafficking of IRF6 into the nucleus. The stimulation of growth by the addition of serum 
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did not affect subcellular distribution as EGFP-IRF6 still remained spatially confined in 
the cytoplasm (Fig 4.5). It is possible that FBS serum stimulation does not affect the 
subcellular localization of EGFP-IRF6 as IRF6 regulation may not play an essential role 
in cell growth. Bailey et al. used immunohistochemistry to compare the levels of IRF6 
expression during pregnancy and lactation in mice that characterize proliferation and 
differentiation respectively. Weak IRF6 expression was observed during pregnancy, in 
contrast to the increased levels of IRF6 expression during lactation. This implies a 
functionally active role for IRF6 in promoting differentiation rather than in proliferation 
(Bailey et al., 2008).  EGFR plays a role in normal palate development during the 
degeneration of the MES. Egfr
-/-
 mice have a high incidence of cleft palate and show 
residual MEE in the midline. EGFR is highly expressed in degenerating MEE during 
palate fusion (Miettinen et al., 1999). Similarly, IRF6 is also highly expressed in the 
MEE and in the fusion zone (Knight et al., 2006). In this study, EGF stimulation was 
not able to efficiently induce IRF6 translocation (Fig 4.6), suggesting that EGFR-
mediated signalling may not be involved in IRF6 activation.  
PHA and PMA stimulation has been shown to elicit IRF expression and function. 
For example, in rainbow trout splenocytes PHA stimulation induced a significant 
increase in IRF8 expression. While, in rainbow trout PMA treatment also induced a 
significant increase in IRF4 expression. PMA was suggested to activate PKC isotypes 
which in effect regulates IRF4 (Holland et al., 2010). Another study showed that in 
resting T lymphocytes IRF4 is tightly regulated and its expression can be inducible by 
PMA treatment. PMA treatment induced IRF4 transactivation of IL-12 promoter. IL-12 
plays a role in T cell growth and differentiation (Chen et al., 2008a). However, 
mitogenic activation by PHA and PMA stimulation did not elicit IRF6 nuclear 
translocation (Fig 4.6). Possible reasons for the lack of IRF6 activation and nuclear 
retention may be that PHA and PMA did not activate upstream signalling pathways or 
kinases that target IRF6 or the absence of ligand or protein required for the activation of 
IRF6 in HaCaT cells. 
TLR3 signal-dependent phosphorylation has been shown to activate members of 
the IRF family (Taniguchi et al., 2001). TLR3 activation by Poly I:C has been shown to 
  - 155 - 
activate IRF3 and IRF7 through TBK and IKKε (Fitzgerald et al., 2003). Poly I:C 
stimulation did not have an impact on the cytoplasmic localization of IRF6 (Fig 4.7). 
TLR3 signalling may not be involved in the regulation of IRF6 translocation. Activation 
of IRFs via TLR-dependent signalling has been shown to be involved in the induction 
of proinflammatory genes and type1 IFNs genes. However, it is unknown if IRF6 has 
any biological significance in relation to the immune response.  
4.8.3. IRF6 contains internal NES and NLS sequences  
The precise localization of a transcription factor in cellular compartments is 
fundamental for transcriptional activation.  Rapid and selective transport of proteins 
between the cytoplasm and the nucleus is facilitated by an active transport mechanism 
(Mattaj and Englmeier, 1998). The control of the balance of nuclear import and export 
is important for IRFs, particularly with IRF3, IRF5 and IRF7.  At a steady state, IRF6 
appears to be predominantly cytoplasmic. Unraveling the mechanisms involved in the 
subcellular localization of IRF6 would be beneficial for assessing IRF6 transcriptional 
activity. Treatment of EGFP-IRF6 transfected cells with LMB, an inhibitor of the 
CRM1-mediated export, lead to immediate nuclear sequestration of EGFP-IRF6 (Fig 
4.8). This signifies that IRF6 is able to enter the nuclear compartment but is exported to 
the cytoplasm. Furthermore, IRF6 nuclear export is via a signal-mediated export 
pathway that is sensitive to LMB. Therefore, IRF6 may contain an intrinsic NES 
sequence and that the CRM1/exportin-dependent nuclear exporting mechanism may be 
the pathway involved in the nuclear export of IRF6.  Immunoprecipitation of FLAG-
IRF6 provides evidence that IRF6 interacts with the export receptor CRM1 (Fig 4.9). 
The most well characterized NESs are those that contain a loosely conserved motif 
containing a stretch of three to four hydrophobic
 
amino acids (Pemberton and Paschal, 
2005). The other member of the IRF family IRF3, IRF5 and IRF7 were found to reside 
predominantly in the cytoplasm, and upon virus-induced phosphorylation at the serine 
rich region, they translocate to the nucleus (Lin et al., 1998; Lin et al., 1999; Lin et al., 
2000b). The three all have been shown to exhibit leucine-rich sequences of 
139
ILDELLGNMVL
149 
(Kumar et al., 2000), 
150
LQRMLPSLSLT
160
 (Lin et al., 2005) 
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and 
448
LVLVKLEPWLCRVHL
462 
(Lin et al., 2000b), that are recognized as functional 
NESs respectively (Lin et al., 2005).  
Protein sequence alignment of IRF members for their NES signals showed that 
they were not conserved in IRF6, thus it was necessary to map the regions within IRF6 
involved in the export of IRF6. The IRF6 NES was initially defined by C-terminal 
deletions. The C-terminal deletion mutant EGFP-IRF6-164 displayed a nuclear 
localization, implicating that residues near residues 164 have an important function in 
IRF6 export (Fig 4.11). Evaluation of the importance of individual residues within 
residues 159 to 170 in the context of NES alanine mutations shows that the hydrophobic 
residues abrogate the export of IRF6 from the nucleus. The single I159, double 
mutations F163A/F165A and L66A/I168A were sufficient to inactivate the NES (Fig 
4.12). These results provide evidence that the hydrophobic residues in 
159
IQDTFPFLNI
168
 are critical for efficient nuclear export and function as a NES. Like 
IRF3 and IRF5, the IRF6 NES is located between the DBD and the IAD. Furthermore 
the predominant cytoplasmic localization of IRF6 signifies that the NES is 
constitutively active and nuclear export is normally dominant. 
Luciferase assays revealed that neither the EGFP-IRF6 2-1A nor EGFP-IRF6 2-
2A NES mutants were able to mediate changes in transcriptional activity. This 
demonstrates that the EGFP-IRF6 2-1A and 2-2A NES mutants are not recruited to the 
promoter of the luciferase reporter. The redistribution of IRF6 from the cytoplasm to the 
nucleus was therefore not indicative of IRF6 transcriptional activation. The introduction 
of the NES mutations may distort the NES signal to allow nuclear accumulation, 
however it does not induce transcriptional activation. The NES mutations may not alter 
the conformation to overcome the C-terminal inhibitory effect and the DBD may remain 
in an orientation that is not favourable for DNA interaction. Therefore the cytoplasmic 
localization may not be the only limiting factor for full activation of IRF6. 
In these luciferase studies 5 complete IRF6 consensus sequences were inserted 
upstream of the luciferase gene. This may not be representative of genuine binding sites 
as IRF binding sites can have overlapping dimeric sites.  Thus the full length EGFP-
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IRF6 NES mutants may not have preferential binding to the multimerized monomeric 
IRF6 consensus sequences. In addition, the N-terminal EGFP tagged protein may also 
interfere with DBD:DNA interaction.  
Furthermore, the EGFP-IRF6 NES mutants would rely on the IAD functional 
activation for transactivation to occur. The transactivation by IRFs can be mediated 
through interactions with other nuclear proteins that function as co-factors such as 
CBP/p300 (Yoneyama et al., 1998). Previous studies show that IRF6 expression is 
spatial and temporal during palatal development. It is therefore possible that IRF6 
requires a co-activator that is cell-type specific and is absent in HaCaT cells or Cos 7 
cells.  
Previous studies show that the IRFs contain an intrinsic NLS located within or 
close to the DBD. The exposure of the NLS contributes to nuclear translocation. The 
EGFP-IRF6-113 C-terminal deletion was predominantly cytoplasmic indicating that the 
NLS is located in the first 113 residues (Fig 4.11). Analysis of the first 113 amino acids 
of IRF6 was necessary to identify the NLS (Fig 4.15). C-terminal deletion of the IRF6-
DBD revealed that the NLS was not found between residues 60 to 113, as they remained 
predominantly nuclear. In contrast, deletion of the first N-terminal 15 residues leads to 
dispersed cytoplasmic and nuclear distribution of IRF6. A putative IRF6 NLS of 
5
PRRVRLK
11
 was identified to be located N-terminal of the DBD. Sequence alignment 
of IRF6 with IRF5 revealed that the IRF6 putative NLS bears resemblance the IRF5 N-
terminal NLS. The IRF5 N-terminal NLS 
46
PRRVRLK
52
 is sufficient for nuclear 
localization and retention, however it is masked by intramolecular or protein interaction 
in uninfected cells (Barnes et al., 2002). This 
5
PRRVRLK
11 
monopartite IRF6 NLS may 
facilitate IRF6 translocation into the nucleus.  
Although we have identified the internal sequences within IRF6 responsible for 
its nucleocytoplasmic transport, the mechanism that leads to IRF6 nuclear retention is 
still elusive. Other essential steps in transcriptional activation such as protein 
interactions or structural modifications are yet to be addressed.  
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Chapter 5 
Investigating the role of phosphorylation on the regulation of IRF6 
activity 
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5. Introduction 
In IRFs there are multiple activation processes for specific and optimal activation, 
which include relieving autoinhibition, dimerization, nuclear translocation, protein 
interactions, DNA interaction and transcriptional activation. Phosphorylation events can 
be rate-limiting steps that regulate some of these activation processes (Servant et al., 
2001). The activation by viral infection, DNA damaging agents, stress inducers, 
cytokines, growth factors and several kinases have been implicated in the regulation of 
IRF activity via direct phosphorylation or phosphorylation through distinct signalling 
pathways (Servant et al., 2001; Panne et al., 2007b). For example, IRF3 exists in the 
cytoplasm in a latent closed conformation, where it is believed to form intramolecular 
interactions between the C-terminal and N-terminal region. The C-terminal 
autoinhibition can be relieved by virus- and dsRNA-induced phosphorylation of IRF3 at 
specific serine/threonine residues in the 396 to 406 cluster (Lin et al., 1998; Lin et al., 
1999; Lin et al., 2000a). IRF3 phosphorylation leads to the formation of homodimers 
(Dragan et al., 2007) or heterodimers with IRF7 which can translocate to the nucleus to 
regulate transcription (Paun and Pitha, 2007). Phosphorylation of IRF3 can also lead to 
nuclear sequestration through interaction with CBP/p300 (Kumar et al., 2000). 
Furthermore, virus-induced phosphorylation by DNA-PK at T135 is involved in the 
downregulation of IRF3 degradation as a result of nuclear retention (Karpova et al., 
2002). In Chapter 3, EMSA studies demonstrated that IRF6 DNA-binding activity was 
autoinhibited by the C-terminal region. However, the mechanism in which the 
autoinhibition is relieved is still unknown. The role of phosphorylation in the regulation 
of IRF6 remains to be elucidated. To provide an insight into IRF6 phosphorylation, the 
direct phosphorylation of conserved phosphorylation sites was initially examined using 
phosphomimetic and alanine mutants to determine their effects on nuclear translocation. 
Mass spectrometry (MS) was then used to map phosphorylation sites and the role of 
phosphorylation at the identified sites with regards to IRF6 nuclear retention and DNA 
binding was further investigated.  
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5.1. IRF6 is constitutively phosphorylated. 
An intriguing observation in the western blot analysis of endogenous IRF6 in HaCaT 
cells is the detection of a second band showing a reduced mobility of the IRF6 protein 
(Fig 4.1 B). We needed to distinguish if the presence of the two bands were attributable 
to two isoforms of IRF6 or the post translational modification of IRF6. As IRFs have 
been shown to be directly phosphorylated through distinct signalling pathways to 
regulate their activity (Panne et al., 2007b), further investigations were carried out to 
examine if IRF6 was phosphorylated. To address the question of whether IRF6 is 
directly phosphorylated, cells were treated with lamda alkaline phosphatase (λPP) to 
remove phosphate groups from serine, threonine or tyrosine residues. A plasmid 
encoding the full-length mouse IRF6 fused to the C-terminus of 2x flag tag (FLAG-
IRF6). The flag epitope (DYKDDDDK) was used to facilitate fusion protein detection 
using antibodies. Whole cell extracts of Cos 7 cells transiently transfected with plasmids 
expressing FLAG-IRF6 were treated with or without λPP in the absence or presence of 
phosphatases inhibitors (Fig 5.1). Treatment of λPP in the absence of phosphatase 
inhibitors caused the slower migrating form of IRF6 to disappear to give a more intense 
single band (Fig 5.1, Lane 2). To confirm that the disappearance of the slower migrating 
form of IRF6 is due to λPP activity, the inclusion of phosphatase inhibitors prevented 
the dephosphorylation of IRF6 (Fig 5.1, Lane 4). This provides supporting evidence that 
the different mobilities of the IRF6 proteins are due to its phosphorylation.  
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Figure 5.1 Western blot analysis of the dephosphorylation of FLAG-IRF6. Whole 
cell extracts (WE) of Cos 7 cells transiently transfected with FLAG-IRF6 were treated 
without (-) or with (+) commercially obtained lambda protein phosphatase in the 
absence (-) or presence (+) of phosphatase inhibitors for 30 mins as indicated. Whole 
cell extracts were then analyzed by SDS-PAGE and western blotting using a 
monoclonal anti-FLAG antibody to detect FLAG-IRF6. The blot was also probed with 
anti- β tubulin as a loading control. 
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5.2. Combinatorial Phosphorylation at the serine/threonine rich region 
induces IRF6 nuclear retention  
Phosphorylation at the serine/threonine (S/T) rich region  plays a critical role in 
inducing dimerization, nuclear translocation and transcriptional activation of IRF family 
members (Chen et al., 2008b). IRF3, IRF5 and IRF7 are found to reside predominantly 
in the cytoplasm, and virus-induced phosphorylation in the S/T rich region induces 
nuclear translocation and transactivation. Substitution of the S/T residues at multiple 
sites with phosphomimetic aspartic acid (D)  residues, generated constitutively active 
forms of IRF3 (Servant et al., 2003), IRF5 (Cheng et al., 2006) and IRF7 (Lin et al., 
2000b). Sequence alignment showed that there were six potential phosphorylation sites 
found within the S/T rich region of IRF6 that were conserved in other IRF family 
members (Fig 5.2). These potential phosphorylation sites are S407, T411, S413, S416, 
S418 and S424. To examine the functional
 
effects of phosphorylation at these selected 
sites, phosphomimetic mutants were generated. Aspartic acid residues were substituted 
at
 
the putative phosphoacceptor sites individually (Fig 5.3 A). All the phosphomimetic 
mutants and alanine mutants were generated by site-directed mutagenesis in EGFP-
IRF6 and confirmed by sequencing. HaCaT cells were transfected with wildtype EGFP-
IRF6 or EGFP-IRF6 phosphomimetic mutants, and the effects attributable to the 
introduction of negative charges at these sites on subcellular localization were 
monitored (Fig 5.3 B). The EGFP-IRF6 phosphomimetic mutants all exhibit a high 
percentage of cells (>65%) that have cytoplasmic localization which is similar to the 
wildtype. The overall distribution showed the same trend. In general, the subcellular 
localization of all the single phosphomimetic mutants was essentially indistinguishable 
from the wildtype EGFP-IRF6. This suggests that mimicking the phosphorylation at 
individual sites in the S/T rich region was not sufficient to induce nuclear accumulation 
and retention. 
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Figure 5.2. Sequence alignment of potential IRF6 phosphorylation sites within the 
serine/threonine rich region. Sequence alignment of the conserved S/T rich region in 
members of the mouse IRF family as indicated. The serine and threonine residues are 
highlighted in red.  
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Figure 5.3. Subcellular localization of IRF6 phosphomimetic mutant within the 
serine/threonine rich region in HaCaT cells. (A) Schematic representation of IRF6 
phosphomimetic mutants generated to assess the importance of potential 
phosphorylation sites in the S/T rich region. (B) HaCaT cells were transiently 
transfected with constructs expressing wildtype EGFP-IRF6 or EGFP-IRF6 S/T 
phosphomimetic mutants indicated above. After 24 hours post-transfection the 
subcellular localization of EGFP-IRF6 point mutants was then determined. A to G: GFP 
fluorescence (green); A‟ to G‟: The nucleus is stained with DAPI fluorescence (blue); 
A‟‟ to G‟‟ Merged images of EGFP and DAPI fluorescence. Images were acquired with 
an Olympus widefield microscope using a x100 objective. Scale bar represents 10 µm. 
The graph below shows the percentage of cytoplasmic (C), cytoplasmic and nuclear 
(C/N) and nuclear (N) subcellular localization of cells expressing EGFP-IRF6 proteins 
as indicated. Statistically significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) 
for C/N and (#) for N localization when compared with wildtype EGFP-IRF6. 
Percentages are representative of 100 cell counts each from three independent 
experiments. 
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 Virus-induced activation of IRF3 involves the hyperphosphorylation of the C-
terminal region. The substitution of S/T residues at multiple sites in the C-terminal 
region with aspartic acid residues can give rise to constitutively active IRFs. For 
example IRF3 5D with 5 phosphomimetic mutations at serine residues S396, S398, 
S402, S404 and S405 could interact with CBP and activate gene transcription in the 
absence of virus infection (Lin et al., 1998). Similarly, IRF5/4D phosphomimetic 
mutations at serine residues S451, S453, S456, and S462 gave rise to a constitutively 
active form of IRF5
 
(Cheng et al., 2006). Therefore the combinatorial phosphorylation 
at the S/T rich region of EGFP-IRF6 was examined. Additional phosphomimetic 
mutants were generated containing 2, 4, 5 or 6 aspartic acid substitutions within the S/T 
rich region (Fig 5.4 A). HaCaT cells were transfected with wildtype EGFP-IRF6 or 
EGFP-IRF6 multiple phosphomimetic mutants to assess whether multiple 
phosphorylation at the S/T rich region affects IRF6 subcellular localization (Fig 5.4 B). 
Like wildtype EGFP-IRF6, the EGFP-IRF6 T411D/S413D and S416D/S418D double 
mutants had a predominantly cytoplasmic localization. Similarly, the EGFP-IRF6 4D 
with four aspartic acid substitutions between 
411
T-S
418
 also shared a similar distribution 
to that of the wildtype. A significant change was observed with EGFP-IRF6 5D (
407
S-
S
418
), although it was still predominately cytoplasmic, there was a ~13% decrease in the 
cytoplasmic localization and a ~15% increase in the nuclear localization in the 
percentage of cells that express EGFP-IRF6 5D. In contrast, the EGFP-IRF6 6D (
407
S-
S
424
) exhibited a remarkable change in its subcellular distribution. There were 
significant differences observed in the C, C/N and N localization. The nuclear 
distribution is the most predominant phenotype that showed a ~6 fold increase in the N 
localization and a ~2 fold increase in the C/N localization. There was less than 3.7% 
with a C localization. The EGFP-IRF6 5D results show that the summation of 
phosphorylation between (
407
S-S
418
) was not sufficient for EGFP-IRF6 retention. 
However, the phosphorylation at all six serine and threonine residues (
407
S-S
424
) in the 
S/T rich region can induce nuclear retention. Although phosphorylation at S424, alone 
does not induce nuclear accumulation, S424 is important for the combinatorial  
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Figure 5.4. Subcellular localization of IRF6 phosphomimetic mutant within the 
serine/threonine rich region in HaCaT cells. (A) Schematic representation of IRF6 
phosphomimetic mutants generated to assess the importance of potential 
phosphorylation sites in the S/T rich region. (B) HaCaT cells were transiently 
transfected with constructs expressing wildtype EGFP-IRF6 or EGFP-IRF6 S/T 
phosphomimetic mutants indicated above. After 24 hours post-transfection the 
subcellular localization of EGFP-IRF6 point mutants was then determined. A to F: GFP 
fluorescence (green); A‟ to F‟: The nucleus is stained with DAPI fluorescence (blue); 
A‟‟ to F‟‟ Merged images of EGFP and DAPI fluorescence. Images were acquired with 
an Olympus widefield microscope using a x100 objective. Scale bar represents 10 µm. 
The graph below shows the percentage of cytoplasmic (C), cytoplasmic and nuclear 
(C/N) and nuclear (N) subcellular localization of cells expressing EGFP-IRF6 proteins 
as indicated. Statistically significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) 
for C/N and (#) for N localization when compared with wildtype EGFP-IRF6. 
Percentages are representative of 100 cell counts each from three independent 
experiments. 
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phosphorylation at the S/T rich region for nuclear retention. Therefore the multiple 
phosphorylations at the S/T rich region influence EGFP-IRF6 subcellular distribution 
and may play a role in nuclear retention. 
 Experiments were subsequently performed to determine if the removal of 
phosphorylation at the S/T rich region affects the subcellular distribution of EGFP-IRF6. 
EGFP-IRF6 alanine mutants containing single or multiple alanine substitutions at S/T 
residues were generated. In addition, treatment with leptomycin B would help determine 
if phosphorylation at the S/T region alone is necessary and sufficient for nuclear 
translocation. The single and multiple alanine mutants include substitutions at 1, 2, 4, 5 
and 6 of the S407, T411, S413, S416, S418 and S424 residues to provide a complete 
coverage of the conserved S/T rich region. All constructs were generated by site-
directed mutagenesis in EGFP-IRF6 and confirmed by sequencing (Fig 5.5A). HaCaT 
cells were transfected with wildtype EGFP-IRF6 or EGFP-IRF6 S/T alanine mutants 
and treated with or without 10 ng/ml leptomycin B for 2 hours and their subcellular 
localization was monitored. The localization of all 5 of the EGFP-IRF6 S/T alanine 
mutants resembled the subcellular distribution of the wildtype EGFP-IRF6 (Fig 5.5B). 
Therefore, in the absence of phosphorylation at the S/T rich region IRF6 still remains 
cytoplasmic. EGFP-IRF6 can shuttle in and out of the nucleus, whereby nuclear export 
has a prevailing effect, which results in a predominantly cytoplasmic steady state. Upon 
LMB treatment there is a dramatic change in the subcellular distribution of wildtype 
EGFP-IRF6 (Fig 5.6). LMB treatment inhibits the nuclear export of EGFP-IRF6, which 
consequently leads to its nuclear accumulation. When HaCaT cells expressing the 
EGFP-IRF6 S/T alanine mutants were treated with LMB, all the EGFP-IRF6 S/T 
alanine mutants were retained in the nucleus as previously observed with the wildtype 
EGFP-IRF6 treated with LMB. When comparing subcellular distribution of EGFP-IRF6 
S/T alanine mutant untreated against LMB treated, a significant difference was observed 
for both C and N. This indicates that EGFP-IRF6 can still shuttle in and out of the 
nucleus even in the absence of phosphorylation at the S/T rich region.  
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Figure 5.5. Subcellular localization of EGFP-IRF6 S/T alanine mutants in the 
serine/threonine rich region. (A) Schematic representation of EGFP-IRF6 S/T alanine 
mutants in the S/T rich region generated. The DNA-binding domain and the interferon 
association domain and the serine/threonine region are indicated. (B) HaCaT cells 
transiently transfected with constructs expressing wildtype EGFP-IRF6 and EGFP-IRF6 
alanine mutants. After 24 hours of transfection the subcellular localization of EGFP-
IRF6 S/T alanine mutants was then determined. A to F: GFP fluorescence (green); A‟ to 
F‟: The nucleus is stained with DAPI fluorescence (blue); A‟‟ to F‟‟ Merged images of 
EGFP and DAPI fluorescence. Images were acquired with an Olympus widefield 
microscope using a x100 objective. Scale bar represents 10 µm. The graph below shows 
the percentage of cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) 
subcellular localization of cells expressing EGFP-IRF6 S/T alanine mutant proteins as 
indicated. No statistically significant difference of (P<0.05) was observed for C, C/N 
and N when compared with wildtype EGFP-IRF6. Percentages are representative of 100 
cell counts each from three independent experiments. 
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Figure 5.6. Subcellular localization of EGFP-IRF6 alanine mutants in the 
serine/threonine rich region with leptomycin B treatment. HaCaT cells transiently 
transfected with EGFP-IRF6 and EGFP-IRF6 S/T alanine mutants and were treated with 
10ng/ml leptomycin B for 2 hours. A to F: GFP fluorescence (green); A‟ to F‟: Nucleus 
is stained with DAPI fluorescence (blue); A‟‟ to F‟‟ Merged images of GFP and DAPI 
fluorescence. Images were acquired with an Olympus widefield microscope using a 
x100 objective. Scale bar represents 10 µm. The graph below shows the percentage of 
cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization 
of cells expressing EGFP-IRF6 S/T alanine mutant proteins without or with leptomycin 
B treatment as indicated. Statistically significant difference of (P<0.05) are denoted as 
(*) for C, (Ŧ) for C/N and (#) for N localization when compared with wildtype EGFP-
IRF6 treated with leptomycin B control. Percentages are representative of 100 cell 
counts each from three independent experiments. 
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Therefore, although multiple phosphorylation at the S/T rich region can induce nuclear 
accumulation, there are other mechanisms that can also induce nuclear translocation.  
The cytoplasmic localization became almost undetectable relative to the nuclear signal, 
and a dramatic increase in the nuclear localization was seen for the mutants treated with 
LMB. This demonstrates that all the S/T alanine mutants still have the ability to shuttle 
into the nucleus and LMB also inhibits their nuclear export. Thus, phosphorylation of 
these sites is not entirely responsible for nuclear translocation, suggesting that if 
phosphorylation events are involved in nuclear translocation then other residues aside 
from the S/T region must also be modified.  
IRF6 exists in a non-phosphorylated form (lower band) and phosphorylated 
form (upper band) (Fig 5.1). Further investigations were carried out to determine 
whether the phosphorylation of serine or threonine residues within the S/T rich region 
were the only residues that gave rise to the phosphorylated form of IRF6. Western blot 
analysis of EGFP-IRF6 S/T alanine mutants would show if residues within the S/T rich 
region are the only phosphorylation sites. The replacement of the S/T residue to alanine 
would prevent the addition of the phosphate group and would result in the 
disappearance of the upper band. Therefore Cos 7 cells were transfected with plasmids 
expressing EGFP-IRF6 S/T alanine mutants and whole cell extracts were collected 24 
hours post-transfection (Fig 5.7). The extracts were analyzed by immunoblotting with 
anti-GFP antibody for the detection of the EGFP-IRF6 S/T alanine mutant. Fig 5.7, lane 
1 shows non-transfected Cos 7 cells as a negative control. In Fig 5.7, lane 2 and 8 
wildtype EGFP-IRF6 is detected at ~95 kDa as two distinct bands. The upper band with 
a reduced mobility indicates the existence of phosphorylated forms of IRF6. All the 
EGFP-IRF6 S/T alanine mutants in Fig 5.7, lanes 3-7 exhibited two distinct bands, 
reflecting the presence of both the non-phosphorylated and phosphorylated forms. This 
indicated that phosphorylation at the S/T rich region is not the only contributing factor 
to the increase in molecular weight. This also implies that there are other 
phosphorylation sites that are not within the S/T rich region that are phosphorylated.  
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Figure 5.7. Western blot analysis of alanine mutants in the serine/threonine rich 
region. HaCaT cells transiently transfected with constructs expressing wildtype EGFP-
IRF6 and EGFP-IRF6 alanine mutants. After 24 hours of transfection, whole cell 
extracts were prepared and analyzed by SDS-PAGE and western blotting using a 
polyclonal anti-GFP antibody to detect EGFP-IRF6 alanine mutants. The ponceau S red 
stained blot is shown as a loading control. Non-phosphorylated (np) and phosphorylated 
(p) forms of EGFP-IRF6 and EGFP-IRF6 alanine mutants are indicated by the arrows. 
The molecular weight marker (in kDa) is shown. 
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5.3. Phosphorylation at non-conserved serine/threonine residues in the 
C-terminal region does not alter IRF6 subcellular distribution 
The phosphorylation profile may be specific for individual IRFs for their regulation and 
non-conserved S/T residues can still be targeted for phosphorylation.  Thus, for a 
complete coverage of other potential C-terminal phosphorylation sites, four residues 
T425, T445, S448 and S457 located C-terminal to the S/T rich region were also 
assessed. Aspartic acid residues were substituted at
 
individual putative phosphoacceptor 
sites located at the C-terminal region (Fig 5.8 A). HaCaT cells were transfected with 
wildtype EGFP-IRF6 or EGFP-IRF6 C-terminal phosphomimetic mutants for 24 hours 
and their subcellular localization was observed. The subcellular localization of the four 
EGFP-IRF6 C-terminal phosphomimetic mutants T425D, T445D, S448D and S457D 
were markedly similar to the wildtype IRF6 (Fig 5.8 B). The proximity of the S/T 
residues in relation to the S/T rich region did not have an influence on their subcellular 
distribution. Therefore, mimicking phosphorylation at the individual S/T residues 
located in the C-terminal region does not affect IRF6 subcellular distribution. 
Unfortunately, the generation of phosphomimetic mutant at non-conserved S/T 
residues did not provide any conclusive discoveries with regards to the identification of 
phosphorylation sites that may be required for nuclear translocation. On the contrary, 
more questions were raised regarding the locations of the other phosphorylation sites in 
IRF6. Furthermore, if IRF6 is phosphorylated at multiple sites, then what are the 
functional consequences of the phosphorylation at those specific sites? To address this, 
a systematic approach was necessary for the mapping of IRF6 phosphorylation sites by 
mass spectrometry. 
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Figure 5.8. Subcellular localization of IRF6 phosphomimetic mutant within the C-
terminal region in HaCaT cells. (A) Schematic representation of EGFP-IRF6 
phosphomimetic mutants in the C-terminal region generated. The DNA-binding domain 
and the interferon association domain and the serine/threonine region are indicated. (B) 
HaCaT cells were transiently transfected with constructs expressing wildtype EGFP-
IRF6 or EGFP-IRF6 phosphomimetic mutants in the C-terminal region indicated above. 
After 24 hours post-transfection the subcellular localization of EGFP-IRF6 point 
mutants was then determined. A to E: GFP fluorescence (green); A‟ to E‟: The nucleus 
is stained with DAPI fluorescence (blue); A‟‟ to E‟‟ Merged images of EGFP and DAPI 
fluorescence. Images were acquired with an Olympus widefield microscope using a 
x100 objective. Scale bar represents 10 µm. The graph below shows the percentage of 
cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization 
of cells expressing EGFP-IRF6 phosphomimetic mutant proteins as indicated. No 
statistically significant difference of (P<0.05) was observed for C, C/N and N when 
compared with wildtype EGFP-IRF6. Percentages are representative of 100 cell counts 
each from three independent experiments. 
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5.4. Characterization of IRF6 phosphorylation by Mass spectrometry  
IRFs can have multiple phosphorylation sites with varying stoichiometry. The λPP 
assay indicates that IRF6 is constitutively phosphorylated. Liquid 
chromatography/tandem mass spectrometry (LC/MS/MS) analysis was employed for 
the comprehensive mapping of IRF6 phosphorylation sites. The advantage of 
LC/MS/MS is that it can determine if phosphopeptides possess single or multiple 
phosphorylations as there may be a combination of different phosphorylation sites that 
exist.  
 For the isolation and enrichment of IRF6, Cos 7 cells were tranfected with 
FLAG-IRF6 expression vector for 24 hours. Whole cell extracts were then collected for 
immunoprecipitation (Fig 5.9 A, lane 1). Extracts were immunoprecipitated with IgG as 
a non-specific control (Fig 5.9 A, lane 2) and FLAG-IRF6 was immunoprecipitated with 
an anti-FLAG antibody (Fig 5.9 A, lane 3). The immunoprecipitation was resolved by 
SDS-PAGE and analyzed by immunoblotting with anti-FLAG antibody to detect 
FLAG-IRF6. The results show that FLAG-IRF6 was enriched and isolated and two 
bands were detected at ~60 kDa indicating both unphosphorylated and phosphorylated 
forms of FLAG-IRF6 had been precipitated. FLAG-IRF6 has a predicted molecular 
weight of ~55.1 kDa. For LS/MS/MS analysis, the immunoprecipitated FLAG-IRF6 
was resolved by SDS-PAGE and stained with colloidal coomassie blue to visualize 
protein bands. The non-phosphorylated (np) and phosphorylated (p) forms of FLAG-
IRF6 can be seen at ~60 kDa (Fig 5.9 B).  
 The enriched FLAG-IRF6 was enzymatically digested with trypsin alone, AspN 
+ trypsin or GluC + trypsin. Trypsin is a serine protease that cleaves C-terminally to 
arginine or lysine residues (Olsen et al., 2004). The protease GluC cleaves the carboxyl 
side of glutamic acid and the protease AspN cleaves the amino side of aspartic acid. The 
FLAG-IRF6 peptide mixture was then analyzed by LC/MS/MS and sequence data 
collected to help identify the exact phosphoacceptor sites of FLAG-IRF6. 
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Figure 5.9. Immunoprecipitation for the isolation and enrichment of FLAG-IRF6. 
Cos 7 cells were transiently transfected with constructs expressing wildytpe FLAG-
IRF6. After 24 hours of transfection, whole cells extracts were prepared and 
immunoprecipitated with anti-FLAG antibody, with IgG as a negative control. (A) The 
immunoprecipitation were resolved on a 10% SDS-PAGE and subsequently analyzed 
by western blot using a monoclonal anti-FLAG to detect FLAG-IRF6. (B) The 
immunoprecipitation were resolved on a 10% SDS-PAGE and stained with coomassie. 
The proteins with a size that corresponds to the molecular weight of ~60 kDa 
confirming presence of non-phosphorylated (np) and phosphorylated (p) forms of 
FLAG-IRF6. The molecular weight markers (in kDa) are shown. 
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The LC/MS/MS data confirmed the identity of FLAG-IRF6, indicating that IP 
successfully isolated and enriched the non-phosphorylated and phosphorylated forms of 
FLAG-IRF6. The overall protein sequence coverage values showing the percentage of 
protein sequence identified for the respective proteases were: 58% coverage for trypsin, 
53% coverage for GluC + trypsin, and 60% coverage for AspN + trypsin. This gave a 
total of 79% sequence coverage of IRF6 which is highlighted in yellow shown in Fig 
5.10 A.  This indicates that 21% of IRF6 was not covered. Thus, a number of serine 
residues within the 21% were not detected for phosphorylation, specifically residues 
S33, S171, S177, S182, S187, S190 and S292. A complete list of IRF6 phosphopeptides 
identified by LC/MS/MS is provided in the appendix.  
Mass spectrometry can detect phosphorylated sites by measuring accurate 
molecular weights of peptides. The MS/MS spectra of mono-phosphorylated peptides 
have a difference of 98 m/z (phosphoric acid, H3PO4) or (dephosphorylation, HPO3) 80 
m/z compared to the non-phosphorylated counterpart as a result of the phosphate group. 
From the analyses, five novel phosphorylation sites in IRF6 were mapped (Fig 5.10 B). 
The different proteolytic digestions lead to the generation of specific peptide sequences 
that enabled the identification of unique phosphorylation sites within IRF6. The 
phosphorylation site pS47 was identified by trypsin digestion, pS47, pS131 and pS153 
by AspN + trypsin digestion and pS424 and pT425 by GluC + trypsin digestion. All of 
the phosphopeptides were mono-phosphorylated peptides as they show an 80 Da shift 
due to phosphate incorporation. Fig 5.11 shows the product ion spectra for each site of 
phosphorylation.  The peptide sequences (above) were determined by fragmentation. 
The breakage of the backbone at the amide bond CO-NH gives rise to two species, one 
with a neutral charge and the other with a charge. Only the charged species is monitored 
by MS. The fragment ions labeled as b ions refers to the species that have the charge 
retained on the N-terminal fragment. The b series ions are indicated in red and extend 
from the N-terminus. The fragment ions labeled as y ions refers to the species that have 
the charge retained on the C-terminal fragment. The y series ions are indicated in blue 
and extend from the C-terminus.  
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         Total coverage:  370/467 amino acids (79% coverage) 
 
MALHPRRVRLKPWLVAQVDSGLYPGLIWLHRDSKRFQIPWKHATRHSPQQEEENTIFKAW 60 
AVETGKYQEGVDDPDPAKWKAQLRCALNKSREFNLMYDGTKEVPMNPVKIYQVCDIPQTQ 120 
GSVINPGSTGSAPWDEKDNDVDEDEEEDELEQSQHHVPIQDTFPFLNINGSPMAPASVGN 180 
CSVGNCSPESVWPKTEPLEMEVPQAPIQPFYSSPELWISSLPMTDLDIKFQYRGKEYGQT 240 
MTVSNPQGCRLFYGDLGPMPDQEELFGPVSLEQVKFPGPEHITNEKQKLFTSKLLDVMDR 300 
GLILEVSGHAIYAIRLCQCKVYWSGPCAPSLAAPNLIERQKKVKLFCLETFLSELIAHQK 360 
GQIEKQPPFEIYLCFGEEWPDGKPLERKLILVQVIPVVARMIYEMFSGDFTRSFDSGSVR 420 
LQISTPDIKDNIVAQLKQLYRILQTQESWQPMQPAPSMQLPQALPAQ  467 
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MALHPRRVRLKPWLVAQVDSGLYPGLIWLHRDSKRFQIPWKHATRHSPQQEEENTIFKAW 60 
AVETGKYQEGVDDPDPAKWKAQLRCALNKSREFNLMYDGTKEVPMNPVKIYQVCDIPQPQ 120 
GSIINPGSTGSAPWDEKDNDVDEEDEEDELDQSQHHVPIQDTFPFLNINGSPMAPASVGN 180 
CSVGNCSPEAVWPKTEPLEMEVPQAPIQPFYSSPELWISSLPMTDLDIKFQYRGKEYGQT 240 
MTVSNPQGCRLFYGDLGPMPDQEELFGPVSLEQVKFPGPEHITNEKQKLFTSKLLDVMDR 300 
GLILEVSGHAIYAIRLCQCKVYWSGPCAPSLVAPNLIERQKKVKLFCLETFLSDLIAHQK 360 
GQIEKQPPFEIYLCFGEEWPDGKPLERKLILVQVIPVVARMIYEMFSGDFTRSFDSGSVR 420 
LQISTPDIKDNIVAQLKQLYRILQTQESWQPMQPTPSMQLPPALPPQ  467 
 
 
 
 
Figure 5.10. Sequence coverage and phosphorylation sites identified by LC/MS/MS 
of sequencing of IRF6. (A) The IRF6 amino acid sequence showing 79% sequence 
coverage in yellow from trypsin, GluC+trypsin and AspN+trypsin digests. (B) The IRF6 
amino acid sequence showing the identified phosphorylation sites in blue. The IRF6 
functional domains are highlighted, the DBD (green), the IAD (pink) and the NLS and 
NES (grey). The penta-tryptophan residues are highlighted in red and the S/T rich 
region is underlined. 
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Figure 5.11. Mass spectrometric characterization of IRF6 phosphopeptides. IRF6 
peptides digested with trypsin, AspN+trypsin or GluC+trypsin were analyzed by 
LC/MS/MS. Five serine/threonine phosphopeptides were identified and the peptide 
sequence is shown with the phosphorylated residues in lowercase. The representative 
MS/MS spectra of the phosphopeptides are shown on the right. The b and y ions are 
coloured in red and blue respectively and are indicated on the corresponding spectrum 
peak. The green peaks indicate the removal of a phosphoric acid (H2PO4-98) from the 
peptide. 
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The peptide sequences were delineated by calculating the mass difference between two 
adjacent b or y ion peaks to identify the individual amino acids. For all the 
phosphopeptides a green peak was detected that is indicative of the removal of a 
phosphoric acid (H2PO
4
-98) from the peptide.  
Separate trypsin digests of the upper (phosphorylated) and lower (non-
phosphorylated) band revealed the existence of pS47 phosphopeptides in both bands. In 
the lower band two pS47 phosphopeptides were identified and in the upper band six 
pS47 phosphopeptides were identified. This shows that there may be a mixture of low 
level phosphorylation in the lower band, whereby the increase in molecular weight is 
not sufficient to see a distinct band that is visible by western blot. 
 A closer inspection of the 5 identified phosphorylation sites in relation to the 
functional domains of IRF6 revealed that the sites are located throughout IRF6 (Fig 5.10 
B). As initially predicted, the S/T rich region is indeed phosphorylated. However, only 
one of the six predicted S/T sites was shown to be phosphorylated - at S424. 
Interestingly, the C-terminal residue S424 and T425, that were previously investigated 
individually in phosphomimetic studies, are genuine phosphorylation sites. The S131 
and S153 phosphorylation sites were found between the DBD and the IAD. Finally, and 
most surprisingly, the S47 phosphorylation site is located in the DBD. Although five 
IRF6 phosphorylation sites have been assigned, their functional relevance is still 
unknown. The significance of the identified phosphorylation sites with regards to IRF6 
function are still unknown.  
5.5. Dual phosphorylation at C-terminal residues S424 and T425 
To assess the effects of phosphorylation at the individual phosphorylation sites 
phosphomimetic mutants and alanine mutants were subsequently generated. All the 
mutants were generated by site-directed mutagenesis and confirmed by sequencing. C-
terminal phosphorylation of other IRFs mainly occurs in the S/T rich region. The MS 
data identified T425 as a phosphorylation site, a site that is not within the S/T rich 
region. The effects of single phosphomimetic mutations at S424 and T425 on IRF6 
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subcellular localization were previously investigated. The results demonstrated that 
phosphorylation at the single sites S424 and T425 did not have an effect on the 
subcellular distribution of IRF6. However, S424 is required for multiple 
phosphorylations at the S/T rich region to induce nuclear translocation (Fig 5.4). It is 
possible that the dual phosphorylation at S424 and T425 may be involved in 
combinatorial activation of IRF6. To further investigate this, additional phosphomimetic 
and alanine mutants were generated at residues S424 and T425. (Fig 5.12 A). The 
fluorescent microscopy data reveals that there was no difference in the subcellular 
distribution between wildtype EGFP-IRF6, S424D/T425D and S424A/T425A mutants, 
as all of them were predominantly cytoplasmic. This suggests that the dual 
phosphorylation at S424/T425 is not sufficient to induce nuclear accumulation and 
retention. Due to the variation in the homology at the C-terminal region between 
individual members of the IRF family, each IRF has a unique combinatorial 
phosphorylation. We cannot exclude the possibility that the dual phosphorylation at 
S424 and T425 is required but not sufficient for nuclear retention. T425 was not 
included in the initial assessment of multiple phosphorylations at the S/T rich region, as 
T425 was not a highly conserved residue among IRFs. It is possible that T425 is also 
involved in the combinatorial phosphorylation of the C-terminal region. Sequence 
alignment of mouse IRF6 
424
ST
425
 with other IRF revealed that the two phosphoacceptor 
sites correspond to mouse IRF7 
437
SS
438
 phosphoacceptor sites. Caillaud et al showed 
that there are two groups of serine residues that are important in the virus-induced 
phosphorylation of IRF7, which are 
425
SS
426
 and 
437
SS
438
 that contributes to the maximal 
activity of IRF7. 
 
Furthermore, alanine mutants of 
425
SS
426
 and 
437
SS
438
 abrogated the 
virus-induced transactivation of IRF7 (Caillaud et al., 2005). 
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Figure 5.12. Subcellular localization of IRF6 phosphomimetic and alanine mutant 
at S424 and T425 in HaCaT cells. (A) Schematic representation of EGFP-IRF6 
phosphomimetic and alanine mutants at residues S424 and T425 generated. The DNA-
binding domain and the interferon association domain and the serine/threonine region 
are indicated. (B) HaCaT cells were transiently transfected with constructs expressing 
wildtype EGFP-IRF6 or EGFP-IRF6 phosphomimetic mutants indicated above. After 
24 hours post-transfection the subcellular localization of EGFP-IRF6 point mutants was 
then determined. A to C: GFP fluorescence (green); A‟ to C‟: The nucleus is stained 
with DAPI fluorescence (blue); A‟‟ to C‟‟ Merged images of EGFP and DAPI 
fluorescence. Images were acquired with an Olympus widefield microscope using a 
x100 objective. Scale bar represents 10 µm. The graph below shows the percentage of 
cytoplasmic (C), cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization 
of cells expressing EGFP-IRF6 phosphomimetic and alanine mutant proteins as 
indicated. No statistically significant difference of (P<0.05) was observed for C, C/N 
and N when compared with wildtype EGFP-IRF6. Percentages are representative of 100 
cell counts each from three independent experiments. 
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5.6. IRF6 N-terminal phosphorylation  
IRF3 is phosphorylated by DNA-PK at T135 which is located near the NES. The 
phosphorylation at 
135
TQ
136
 was suggested to inhibit the nuclear export of IRF3 
(Karpova et al., 2002). MS data confirms that IRF6 is subject to N-terminal 
phosphorylation at S131 and S153. In chapter 4, the IRF6 NES was mapped to residues 
159
IQDTFPFLNI
168
. 
153
SQ
154
 is found proximal to the IRF6 NES 
159
IQDTFPFLNI
168
. In 
addition, IRF3 has been shown to be phosphorylated at S173 by the TAK-JNK pathway, 
which leads to the regulation of IRF3 transcriptional activity and dimerization (Zhang et 
al., 2009). IRF3 residue S173 corresponds to IRF6 residue S187, which were not 
covered by MS. Therefore, the two serine residues S171 and S187, also found proximal 
to the IRF6 NES, were selected for phosphomimetic mutational analysis. To investigate 
the physiological significance of IRF6 phosphorylation at N-terminal sites and sites 
proximal to the NES, aspartic acid residues (Fig 5.13 A) and alanine residues (Fig 5.14 
A) were substituted at
 
these individual putative phosphoacceptor sites in EGFP-IRF6. 
HaCaT cells were transfected with wildtype EGFP-IRF6 or EGFP-IRF6 N-terminal 
phosphomimetic (Fig 5.13 B) and alanine mutants (Fig 5.14 B) for 24 hours and their 
subcellular localization was observed. The subcellular localization of the S171 
phosphomimetic and alanine mutants were also similar to the wildtype IRF6. No 
significant different was seen in the subcellular distribution when compared to the 
wildtype. This indicates that the phosphorylation at residue S171 located immediately 
C-terminal to the NES does not modulate IRF6 nuclear retention. Similarly, the 
substitution of either aspartic acid or alanine at S131 and S153, located N-terminally to 
the IRF6 NES, did not significantly change the subcellular distribution in comparison to 
the wildtype EGFP-IRF6. Both EGFP-IRF6 S131D and S153D mutants exhibited a 
predominantly cytoplasmic localization. The EGFP-IRF6 S131A and S153A mutant 
also exhibited a predominantly cytoplasmic localization, similar to the wildtype. 
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Figure 5.13. Subcellular localization of IRF6 N-terminal phosphomimetic mutants 
in HaCaT cells. (A) Schematic representation of EGFP-IRF6 phosphomimetic mutants 
in the N-terminal region generated. The DNA-binding domain and the interferon 
association domain and the NES are indicated. (B) HaCaT cells were transiently 
transfected with constructs expressing wildytpe EGFP-IRF6 or EGFP-IRF6 N-terminal 
phosphomimetic mutants indicated above. After 24 hours post-transfection the 
subcellular localization of EGFP-IRF6 N-terminal phosphomimetic mutants was then 
determined. A to E: GFP fluorescence (green); A‟ to E‟: The nucleus is stained with 
DAPI fluorescence (blue); A‟‟ to E‟‟ Merged images of GFP and DAPI fluorescence. 
Images were acquired with an Olympus widefield microscope using a x100 objective. 
Scale bar represents 10 µm. The graph below shows the percentage of cytoplasmic (C), 
cytoplasmic and nuclear (C/N) and nuclear (N) subcellular localization of cells 
expressing EGFP-IRF6 proteins as indicated. Statistically significant difference of 
(P<0.05) are denoted as (*) for C, (Ŧ) for C/N and (#) for N localization. Percentages are 
representative of 100 cell counts each from three independent experiments.  
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Figure 5.14. Subcellular localization of IRF6 N-terminal alanine mutants in 
HaCaT cells. (A) Schematic representation of EGFP-IRF6 alanine mutants in the N-
terminal region generated. The DNA-binding domain and the interferon association 
domain and the NES are indicated. (B) HaCaT cells were transiently transfected with 
constructs expressing wildytpe EGFP-IRF6 or EGFP-IRF6 N-terminal alanine mutants 
indicated above. After 24 hours post-transfection the subcellular localization of EGFP-
IRF6 N-terminal alanine mutants was then determined. A to E: GFP fluorescence 
(green); A‟ to E‟: The nucleus is stained with DAPI fluorescence (blue); A‟‟ to E‟‟ 
Merged images of GFP and DAPI fluorescence. Images were acquired with an Olympus 
widefield microscope using a x100 objective. Scale bar represents 10 µm. The graph 
below shows the percentage of cytoplasmic (C), cytoplasmic and nuclear (C/N) and 
nuclear (N) subcellular localization of cells expressing EGFP-IRF6 proteins as indicated. 
No statistically significant difference of (P<0.05) was observed for C, C/N and N when 
compared with the wildtype EGFP-IRF6 control. Percentages are representative of 100 
cell counts each from three independent experiments. 
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Comparison of the non-phosphorylated and phosphorylated state of the S131 and S153 
in relation to their subcellular distribution shows no distinct variation between the two 
states. This implies that the direct phosphorylation of IRF6 at N-terminal residues S131 
and S153 does not affect the integrity of the NES. S153 is located 6 residues away from 
the identified IRF6 NES 
159
IQDTFPFLNI
168
, while residue S131 is comparatively more 
distal than S153 from the predicted NES. Therefore the phosphorylation at S131 and 
S153 may be too remote to impair the recognition of the NES by export proteins. 
Alanine substitutions within the predicted NES were adequate in disrupting the nuclear 
export of IRF6 (Fig 4.11). Given that the S153A alanine mutation did not affect IRF6 
subcellular distribution, the S153 residue is therefore not necessary for recognition 
and/or interaction by other proteins that are involved in IRF6 nuclear export. The 
phosphorylation at S131 and S153 may affect other functional activities of IRF6 such as 
transactivation. The degree of phosphorylation of IRF6 may correlate to its functional 
activation. The collective phosphorylation at all N-terminal residues S131 and S153 and 
C-terminal S424 and T425 could affect the net activity of IRF6, which is yet to be 
assessed. More phosphomimetic mutants should be generated to assess the cumulative 
effect of the phosphorylation at the N-terminal and C-terminal sites.  
The EGFP-IRF6 S187D mutant exhibited a 3% increase in cytoplasmic 
localization which was considered statistically significant difference to the wildtype. 
However, this increase did not drastically alter the predominantly cytoplasmic 
distribution of IRF6. The EGFP-IRF6 S187A mutant also showed a predominantly 
cytoplasmic localization similar to the wildtype. Comparison of the phosphomimetic 
and alanine mutants reveals that the N-terminal phosphorylation at the conserved S187 
does not appear to be directly linked to IRF6 nuclear translocation and retention. 
Although IRF3 phosphorylation at S173 was associated with the transcriptional 
activation and dimerization (Zhang et al., 2009), phosphorylation at the homologous 
residue S187 in IRF6 may not regulate IRF6 in a similar manner. 
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5.7. Phosphorylation in the IRF6-DBD affects its DNA-binding ability 
Residue S47 lies in the DBD of IRF6 and was assigned as a phosphorylation site by 
LC/MS/MS.  The IRF6-DBD is located in amino acids 13-113 and has an α/β 
architecture (α1-α3 and β1-β4) linked by 3 distinctive loops (L1-L3). The residue S47 is 
located in loop L1 which links β2-α2. To assess the functional effects of S47 
phosphorylation, EGFP-IRF6 S47D phosphomimetic and S47A alanine mutants were 
generated (Fig 5.15 A). HaCaT cells were transfected with wildtype EGFP-IRF6, S47D 
or S47A mutants, and their subcellular localization were monitored (Fig 5.15 B). The 
subcellular localization of the EGFP-IRF6 S47D and S47A mutants does not appear to 
be fundamentally different to that of wildtype EGFP-IRF6, suggesting that 
phosphorylation at S47 does not induce nuclear retention of IRF6.  
In chapter 3, the IRF6-DBD was shown to interact with DNA in a sequence 
specific manner. As the S47 residue is located within the DBD, EMSA studies were 
carried out to assess the effects of phosphorylation at S47 on IRF6 DNA-binding 
activity. IRF6-DBD phosphomimetic (IRF6-DBD S47D) and alanine (IRF6-DBD 
S47A) mutants were generated by site-directed mutagenesis and confirmed by 
sequencing.  EMSA studies were performed using in vitro translated wildtype IRF6-
DBD, IRF6-DBD S47D and IRF6-DBD S47A to assess their DNA-binding ability to an 
IRF6 consensus sequence (Fig 5.16 A). The IRF6-DBD containing the amino acids 1-
113 was able to bind DNA avidly (Fig 5.16 A, lane 3). Interestingly, mimicking 
phosphorylation at S47D ablates IRF6-DBD interaction with DNA (Fig 5.16 A, lane 4). 
However, mutating the S47 residue to alanine (IRF6-DBD S47A) did not affect the 
DNA-binding activity of IRF6-DBD (Fig 5.16 A, lane 5). This confirms that the 
inhibition of DNA-binding is due to the phosphomimetic mutation and not alterations in 
the primary sequence that may consequently affect the DBD tertiary conformation. This 
implies that phosphorylation at S47 abrogates IRF6 DNA-binding activity. To establish 
the location of the S47 residue in the tertiary structure of the DBD with DNA 
interaction, protein modelling analyses was undertaken using Pymol. 
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Figure 5.15. Subcellular localization of IRF6 S47 phosphomimetic and alanine 
mutant in HaCaT cells. (A) Schematic representation of EGFP-IRF6 phosphomimetic 
and alanine mutants at residue S47 generated. The DNA-binding domain and the 
interferon association domain are indicated. (B) HaCaT cells were transiently 
transfected with constructs expressing wildytpe EGFP-IRF6, EGFP-IRF6 S47D or 
S47A mutants indicated above. After 24 hours post-transfection the subcellular 
localization of EGFP-IRF6 point mutants was then determined. A to C: GFP 
fluorescence (green); A‟ to C‟: The nucleus is stained with DAPI fluorescence (blue); 
A‟‟ to C‟‟ Merged images of EGFP and DAPI fluorescence. Images were acquired with 
an Olympus widefield microscope using a x100 objective. Scale bar represents 10 µm. 
The graph below shows the percentage of cytoplasmic (C), cytoplasmic and nuclear 
(C/N) and nuclear (N) subcellular localization of cells expressing EGFP-IRF6 proteins 
as indicated. No statistically significant difference of (P<0.05) was observed for C, C/N 
and N when compared with wildtype EGFP-IRF6. Percentages are representative of 100 
cell counts each from three independent experiments. 
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Figure 5.16 Phosphorylation at S47 in the IRF6-DBD inhibits DNA interaction. (A) 
EMSA showing the DNA-binding activity exhibited by in vitro translated IRF6-DBD, 
IRF6-DBD S47D and IRF6-DBD S47A binding affinity to 
32
P radiolabeled dsDNA 
(AGACAATAATTTAGACCGAAACCAGA) containing an IRF6 consensus sequence. 
The lower mobility band corresponds to the IRF6DBD:DNA complexes, as shown by 
the arrow. The higher mobility band corresponds to the free DNA probe. (B) Homology 
model of IRF6-DBD interaction with DNA. The IRF6-DBD is shown in green cartoon 
representation and the DNA in orange. The recognition helix (α3) is tilted in the major 
groove of DNA and the loop 1 (L1) contacts the DNA sugar phosphate backbone. The 
right panel shows the position of serine 47 in red, the middle panel shows the S47D 
phosphomimetic mutation in red and the left panel shows the S47A alanine mutation in 
red. The recognition helix (α3) and the loop 1 (L1) are indicated. 
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The structure of the IRF3-DBD was used for homology modelling of IRF6-DBD (Panne 
et al., 2007a). The IRF6 S47 residue was introduced to the corresponding residue and 
the S47D phosphomimetic mutant was inserted for comparison which are shown in red 
(Fig 5.16 B). The ribbon representation shows IRF-DBD (green) interaction with DNA 
(orange). The recognition helix (α3) is tilted in the major groove with its axis almost 
parallel to the DNA sugar-phosphate backbone. The loop L1 extends into the minor 
groove. The serine residue at position 47 (red) on loop L1 does not directly reach into 
the minor groove. However, the adjacent residues are in close proximity for direct 
interaction with DNA. The introduction of the aspartic acid residue shows the projection 
of the residue is almost parallel to the DNA. This shows that the introduction of the 
phosphate group may bring the residue S47D in close proximity to the DNA phosphate 
backbone. In contrast, replacement of S47 with an alanine residue shows minimal 
protrusion of the side chain. 
5.8. Mitogen-activated protein kinases do not induce IRF6 nuclear 
retention 
Mitogen-activated protein kinases (MAPK) comprise of a family of S/T kinases, which 
participate in signal transduction pathways that mediate many intracellular events 
including cell growth, cell differentiation and development and apoptosis (Fig 5.17 A). 
MAPK are categorized into a three tier linear architecture in the MAPK cascades 
(Pearson et al., 2001). The MAPK signalling pathways have been implicated in the 
regulation of individual IRFs.  For example, in C6 astrocytoma cells, taxol stimulation 
was shown to up-regulate IRF1 expression in a p38 MAPK activation dependent 
manner to induce transcription of inducible nitric oxide synthase (iNOS) for nitric oxide 
production (Cvetkovic et al., 2004).  Studies in human monocytic cells showed that c-
Jun-NH2-terminal kinase (JNK) MAPK activation of IRF7 was required for the 
transcriptional regulation of the co-stimulatory molecule B7.1 in response to 
lipopolysaccharide (LPS) (Lim et al., 2005). In IRF3 the N-terminal phosphorylation by 
mitogen-activated protein kinase kinase kinase (MKKK) was mapped to amino acids 
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186-198 of IRF3 (Servant et al., 2001). As IRF6 was shown to be phosphorylated at the 
N-terminus, investigations were therefore undertaken to examine if IRF6 is activated by 
MAPKs phosphorylation cascades. Cos 7 cells were transiently co-transfected with 
EGFP-IRF6 and constitutively active MAPK expression plasmids mitogen-activated 
protein kinase kinase (MEK) 1, MEK kinase (MEKK) 1, p38α and MEKK6 
individually or in different combinations for 24 hours and analyzed by fluorescent 
microscopy (Fig 5.18). MAPK-induced changes in EGFP-IRF6 subcellular localization 
were then assessed. The co-transfection of EGFP-IRF6 with individual constitutively 
active MAPKs showed that the activation of MEK1, MEKK1, p38α and MEKK6 
signalling pathways alone did not significantly affect IRF6 distribution. Similarly, the 
co-transfection of EGFP-IRF6 with different combinations of 2, 3 or 4 MAPKs that lead 
to the activation of several distinct MAPK cascades did not have a notable influence on 
IRF6 distribution where it still remained predominantly cytoplasmic. In general, there 
was >80% of the cells expressing EGFP-IRF6 showing cytoplasmic localization. This 
may indicate that IRF6 is not a direct target of MAPK signalling or the activation of 
these MAPK signalling pathways alone may not be effective inducers of IRF6 
regulation.  
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Figure 5.17. Effect of selected mitogen-activated kinases on the subcellular 
distribution of EGFP-IRF6 HaCaT cells. The mitogen activated protein kinase 
cascade are a family of serine/threonine kinases that are organized in a three-tiered 
signalling modules that regulate various biological processes.(B) The graph shows the 
percentage of cytoplasmic (C), cytoplamic and nuclear (C/N) and nuclear (N) 
subcellular localization of cells co-expressing EGFP-IRF6 and MAPK proteins as 
indicated. Statistically significant difference of (P<0.05) are denoted as (*) for C, (Ŧ) for 
C/N and (#) for N localization when compared with wildtype EGFP-IRF6. Percentages 
are representative of 100 cell counts each from three independent experiments. 
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Figure 5.18. Effect of selected mitogen-activated kinases on the subcellular 
distribution of EGFP-IRF6 in Cos 7 cells. Cos 7 cells were transiently co-transfected 
with constructs expressing wildytpe EGFP-IRF6 and mitogen-activated protein kinases, 
as indicated above, for 24 hours. The subcellular localization of EGFP-IRF6 point 
mutants was then determined. A to P: GFP fluorescence (green); A‟ to P‟: The nucleus 
is stained with DAPI fluorescence (blue); A‟‟ to P‟‟ Merged images of EGFP and DAPI 
fluorescence. Images were acquired with an Olympus widefield microscope using a 
x100 objective. Scale bar represents 10 µm.  
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5.9. Discussion 
The activation of multiple signal transduction pathways are orchestrated for the 
maximal activation of IRFs. Phosphorylation events have been shown to play a key role 
in activation of IRFs by modulating several processes including dimerization, nuclear 
translocation, protein interactions, and transcriptional activation (Servant et al., 2001).  
However, little is known about the role of phosphorylation in the regulation of IRF6 
function.  
5.9.1. IRF6 is phosphorylated 
Western blot analysis of IRF6 demonstrates that there are two bands with distinct 
molecular weight which implicates that there are two isoforms of IRF6. This could be 
due to expression of another IRF6 isoforms or post translational modifications. Other 
members of the IRF family are known to express alternatively spliced isoforms. For 
example isoform IRF-3a differs from IRF3 in that it lacks half of the DBD and 
consequently its ability to bind DNA containing the IRF consensus sequence (Karpova 
et al., 2001). IRFs are also subject to post translational modifications such as 
phosphorylation (Panne et al., 2007b), acetylation (Ozato et al., 2007) and 
ubiquitination (Higgs and Jefferies, 2008) for stringent regulation. Phosphorylation is 
the most studied post translational modification of IRFs. To determine if the presence of 
the second form of IRF6 is due to the phosphoryation of IRF6, whole cell extracts of 
Cos 7 cells transfected with FLAG-IRF6 were treated with λPP. The identity of the 
phosphorylated IRF6 form was verified by the collapse of the slower migrating form 
(upper band) to the faster migrating form (lower band) upon λPP  treatment (Fig 5.1). 
Treatment with λPP in the presence of a cocktail of phosphatase inhibitors prevented the 
de-phosphorylation and thus the slower migrating form was still present. This validates 
that λPP activity was accountable for the de-phosphorylation of IRF6. This result 
indicated that IRF6 is a target for phosphorylation.  
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5.9.2. Combinatorial phosphorylation of IRF6 at the Serine/Threonine 
rich regions can induce nuclear accumulation and transactivation 
Phosphorylation in IRF family members is known to frequently induce their 
transcriptional activation. Members of the IRF family share a conserved S/T rich region 
and phosphomimetic mutations in this region generate constitutively active IRFs. The 
IRF5/4D phosphomimetic mutant, where serine residues at S451, S453, S456, and S462 
were substituted with aspartic acid (IRF5/4D), functioned as a constitutively active
 
molecule and significantly induced gene expression in the absence
 
of IKKε activation. 
(Cheng et al., 2006). In IRF7, the phosphomimetic mutation of residues S477D and 
S479D generated a constitutively active form of IRF7 (Lin et al., 2000b). As the 
substitution of serine residues with aspartic residues gave rise to constitutively active 
IRFs, we have explored this approach with IRF6.  Given this prominent role of 
phosphorylation in the regulation of IRFs, we sought to determine whether mimicking 
phosphorylation on IRF6 affects nuclear retention. Six potential phosphorylation sites 
within IRF6 were identified by sequence alignment of known phosphorylation sites in 
IRF family members. The generation of phosphomimetic and alanine mutation at these 
potential sites were designed to examine which phosphorylations are responsible for 
changes in subcellular distribution. The IRF6 phosphomimetic mutations of all the 
single mutants and the double, 4D and 5D mutants that encompass residues 
407
S-S
418
 
remained restricted to the cytoplasm. Interestingly mono-phosphorylation at S424 did 
not induce nuclear retention; however S424 is required for multiple phosphorylations at 
the S/T rich region to induce nuclear accumulation and retention. In addition, treatment 
of EGFP-IRF6 S/T alanine mutants with LMB lead to nuclear accumulation, this 
indicated IRF6 was still able to shuttle in and out of the nucleus. Therefore, the 
phosphorylation at the S/T rich region is not required for nuclear translocation. Thus 
combinatorial phosphorylation at the S/T rich region of IRF6 may act as a regulatory 
switch for nuclear retention. In IRF3 there are seven C-terminal potential 
phosphorylation sites that are suggested to have functional consequences. Of the seven 
phosphorylation sites in IRF3 only two are conserved in IRF6. Residues S386 and S396 
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in IRF3 are equivalent to S413 and S424 in IRF6, respectively. The IRF3 is 
autoinhibited as the C-terminal transactivation domain contains a N- and C-terminal 
autoinhibitory segment that interact to mask the hydrophobic surface of the IAD (Qin et 
al., 2003). S386 is easily accessible as it is located in a loop that is exposed and its 
phosphorylation has been implicated in controlling phosphorylation at adjacent S/T sites 
(Lin et al., 1999). Whilst, S396 is located in a loop that has direct interaction with the 
N-terminal autoinhibitory segment. S396 phosphorylation is suggested to disrupt the 
autoinhibitory structures owing to charge repulsion. The results indicated that 
phosphorylation at IRF6 S424 in combination with other residues in the S/T region was 
necessary for nuclear sequestration. This confirms that full activation of IRF6 requires 
the phosphorylation at specific sites. If the phosphorylation of S413 and S424 in IRF6 
has a similar consequence to that of IRF3, the autoinhibitory region would therefore be 
destabilized. The additional phosphorylation of residues in the hydrophobic core of 
IRF3, namely S402, T404 and S405, induced structural rearrangement and exposure of 
the hydrophobic surface for protein-protein interaction (Qin et al., 2003). These residues 
were not conserved in IRF6 and thus it is possible the unfolding of the IAD may be 
stabilized in a slightly different manner.  
We cannot, however, exclude the possibility that the phosphomimetic mutations 
at the S/T rich region may impact other processes, such as protein interaction. The 
crystal structure data of IRF5 show that phosphoactivation of IRF5 cause dramatic 
structural transformation of the C-terminal autoinhibitory/dimerization region. This 
leads to the formation of an extended conformation that enables IRF5 dimerization and 
exposure of protein interaction sites (Chen 2008). The IRF5 (222-467) transactivation 
domain containing potential phosphorylation sites S425, S427, S430 and S436 were 
suggested to have biological significance. The phosphomimetic mutants S425D, S427D, 
S430D, S436D were shown to increase CREB binding protein (CBP) interaction. These 
residues correspond to residues T411, S413, S416, and S424 in IRF6 respectively. 
Crystallographic analysis of IRF5 (222-467) S430D implicates that phosphorylation at 
S425, S427 and S430 would contribute to unfolding of the autoinhibitory conformation. 
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The S430D phosphomimetic mutant revealed an extended conformation, which 
facilitates dimerization and exposes the CBP/p300 binding site. Furthermore, the IRF5 
(222-467) S430D formed stable homodimers, while in the presence of CBP formed 
IRF52CBP2 complexes. This provided evidence that CBP binding and IRF5 
dimerization are coupled. Whilst the phosphorylation at S436 may be involved in 
stabilizing IRF5 homodimer interaction (Chen et al., 2008b). The interaction with 
CBP/p300 occurs in the nucleus and this interaction may play a role in IRF5 nuclear 
retention and DNA-binding. It could be possible that IRF6 nuclear retention may 
involve intermolecular interaction with other co-factors. We must also take into 
consideration that, in situ hybridization sections of mice during palatal development 
indicate that IRF6 has a precise spatial and temporal expression profile that is cell 
specific (Knight et al., 2006). The nuclear accumulation IRF6 may also depend on the 
orchestration of a network of appropriate co-factors and partner proteins. These 
interacting proteins may be subject to availability or require simultaneous activation. 
One caveat to this study is the constitutively present aspartic acid phosphomimetic 
substitution. The aspartic acid substitution may confer no phosphomimetic effect or for 
functional relevance it requires the recognition of phosphoserine/phosphotheronine as 
part of the interaction interface. Another option for mimicking phosphorylation is the 
use of glutamic acid. 
5.9.3. Identification of phosphorylation sites by Mass spectrometry 
Western blot analysis of alanine mutants of all the serine and threonine resides in the 
S/T rich region show that there were two bands suggesting that IRF6 is still 
hyperphosphorylated (Fig 5.7). This provided evidence that phosphorylation events in 
IRF6 are not restricted to the S/T rich region. Due to the hierarchal levels of 
phosphorylation exhibited by other members of the IRF family it was plausible that 
IRF6 is subject to multiple phosphorylation. This was later confirmed by LC/MS/MS 
studies. In this study, LC/MS/MS analysis was used to map in vivo phosphorylation 
sites. For the first time, genuine IRF6 phosphorylation sites have been identified. The 
LC/MS/MS data provides evidence of phosphorylation at multiple distinct sites across 
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IRF6. The residues S47, S131, S153, S424 and S425 were revealed as 
phosphoacceptors. This showed that IRF6 was phosphorylated in the C-terminal and the 
N-terminal at conserved and non-conserved residues in the IRF family. Western blot 
analyses of IRF6 showed the existence of two bands (Fig 5.9 A). LC/MS/MS analyses 
of the two bands separately detected the presence of phospho-proteins in both bands. It 
is possible that there is a co-existence of multiple species with different degrees of 
phosphorylation. To be precise, IRF6 may exist in a non-phosphorylated, low level 
phosphorylation and hyper-phosphorylated forms.  
 Although there was a 78% coverage of IRF6 by mass spectrometry, there may 
still be some sites within the covered residues that were not detected. There are several 
factors that influence the detectability of phosphopeptides. The abundance of 
phosphopeptides relies on the efficiency of the affinity chromatography. In addition, the 
low phosphorylation stochiometry would result in the under-representation of the 
phosphopeptide in the mixture of peptides. Furthermore, the method of phosphatase 
treatment is important to maintain the phosphorylation. This would lead to insufficient 
levels that would be undetected (Steen et al., 2006).   
 There was still 22% of IRF6 sequence that was not covered by LC/MS/MS. It is 
possible that digests with trypsin, GluC and AspN could have yielded fragments that are 
too small and out of range of the detection limit. Unfortunately there was no 
phosphorylation sites identified in the IAD in this study. This may have revealed 
residues that are involve in direct protein:protein interaction. For example, IRF3 is also 
phosphorylated in the IAD at S339 and its phosphorylation is associated with 
dimerization, CBP interaction and destabilization (Clement et al., 2008). In normal 
mammary epithelial cells, IRF6 was shown to directly interact with maspin. Bailey et al. 
showed by co-immunoprecipitation studies that IRF6 dephosphorylation with λ 
phosphatase reduced its ability to interact with maspin. Furthermore yeast two hybrid 
studies using truncated forms of IRF6 revealed that the isolated IRF6 IAD was 
sufficient and necessary for the maspin-IRF6 interaction, whereby the C-terminal region 
plays a role in modulating this interaction. However, the mechanism that underlies the 
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reduction in interaction was not resolve (Bailey et al., 2005). The identification of 
phosphorylation sites in the IRF6 IAD would be ideal to provide a better understanding 
of key residues involved in protein interaction interface.  
 LC/MS/MS analysis showed that both pS424 and pT425 phosphopeptides were 
co-eluted at the same time by LC indicating that they shared similar properties. 
However, enzymatic digestion of IRF6 produced peptides that did not include both 
S424 and T425 residues within the same peptide. The phosphopeptides identified were 
all mono phosphorylated and phosphopeptides that possessed dual phosphorylation at 
424
ST
425 
were not detected. Furthermore, out of the six S/T residues in the S/T rich 
region only S424 was detected as a phosphoacceptor. It is possible that the other sites 
are not phosphoacceptors or that multiple phosphorylated peptides were not detected by 
LC/MS/MS. Phosphorylation can alter the proteolysis kinetics of cleavage sites that are 
located near phosphorylation sites. Furthermore multiple phosphorylated peptides 
increase the hydrophilicity of the peptide which can be problematic as it can lead to 
reduced retention in LC (Steen et al., 2006). Further analysis using alternative 
proteolysis may lead to the generation of different peptide fragments and consequently 
the detection of different phosphorylation sites.  For improved coverage of IRF6 other 
protease combinations may be considered such as LysC or non-specific proteases such 
as elastase, proteinase K and thermolysin that have been used to detect phosphopeptides 
(Schlosser et al., 2001; Kim et al., 2007).  
5.9.4. Dual phosphorylation at S424 and T425 is not sufficient for 
nuclear retention 
Phosphomimetic studies of the S/T rich region indicated that residue S424 was 
important for nuclear accumulation of IRF6. MS data revealed that S424 and T425 were 
indeed phosphoacceptor sites. Sequence alignment of IRF6 
424
ST
425
 with other members 
of the IRF family revealed that IRF7 is also phosphorylated at the conserved residues 
437
SS
438
. Previous studies by Caillaud et al show that in mice there are two groups of 
serine residues that are important in the virus-induced phosphorylation of IRF7, which 
are 
425
SS
426
 and 
437
SS
438
. Two dimensional gel analysis of phosphomimetic mutations of 
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the two groups showed that 
437
SS
438 
is the primary site of phosphorylation. Whereas 
425
SS
426
 may be secondarily phosphorylated, to ensure the correct folding of the C-
terminal transactivation domain, this consequently contributes to the maximal 
phosphorylation-dependent activity of IRF7. 
 
Furthermore, luciferase assay analysis of 
alanine mutants of 
425
SS
426
 and 
437
SS
438
 abrogated the virus-induced transactivation of 
IRF7 (Caillaud et al., 2005).  The second group 
437
SS
438
 corresponded to the two 
phosphoacceptor sites 
424
ST
425 
detected by LC/MS/MS. The first group in IRF7 
425
SS
426 
was not an identical match to IRF6 as the corresponding sequence was 
412
RS
413
 which 
only possesses one potential phosphoacceptor. It would be interesting to see whether 
phosphorylation at both S
413 
and 
424
ST
425 
may partially contribute to or be sufficient 
enough for maximal IRF6 activation In IRF7 
429
SSS
431
 and S
441
 may not be primary 
targets for kinase phosphorylation, however hyper-phosphorylation at these sites does 
enhance transactivation and/or distal phosphorylation (Caillaud et al., 2005). The dual 
phosphorylation at 
424
ST
425 
was not sufficient for nuclear sequestration. Thus 
combinatorial phosphorylation at 
424
ST
425 
with additional phosphorylation at the S/T 
rich region will be necessary for nuclear retention and functional activation.  
5.9.5. N-terminal phosphorylation at S131 and S153 does not disrupt the 
nuclear export signal  
IRF3 phosphorylation by DNA-PK at T135 is associated with nuclear retention and 
delayed proteolysis. T135 is located immediately proximal to the NES and its 
phosphorylation was suggested to inhibit the IRF3 nuclear export by CRM1. Retention 
of IRF3 in the nucleus would result in reduced levels of IRF3 in the cytoplasm targeted 
for degradation by the ubiquitin-proteasome pathway. As DNA-PK mainly resides in 
the nucleus, IRF3 must translocate into the nucleus for T135 phosphorylation by DNA-
PK to occur (Karpova et al., 2002). The phosphomimetic mutants S131D, S153D and 
S171D located N-terminally and C-terminally to the IRF6 NES 
159
IQDTFPFLNI
168 
all 
exhibited predominantly cytoplasmic localization (Fig 5.13). Despite the similarities of 
IRF6 S153 to IRF3 T135 in that they are both located N-terminal to their respective 
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NESs and have an S/TQ motif, their phosphorylation have different consequential 
effects. In this study we have demonstrated that phosphorylation at residues proximal to 
the IRF6 NES is not associated with nuclear retention by the disruption of the NES. 
Other regulatory mechanism may therefore be associated with IRF6 nuclear retention, 
such as the association with nuclear proteins. EMSA studies using C-terminal deletions 
of IRF6 showed that only the IRF6 1-113 containing the DBD was able to bind DNA 
avidly (Fig 3.10). The IRF6 1-152 deletion protein was not able to bind DNA, 
indicating that residues 114 to 152 still has an inhibitory effect on DNA-binding. This 
may reveal the importance of residues between 114 to 152. The identification of 
phosphorylation sites, namely S131 and S153 within this region in IRF6 is intriguing. 
Although the phosphorylation at S131 and S153 is not directly associated with nuclear 
retention through the disruption of the NES, we cannot exclude their involvement in 
other regulatory mechanisms such as transactivation or autoinhibition. If the IRF6 
functional regulation is dependent on the degree of phosphorylation a combination of N-
terminal phosphorylation and C-terminal phosphorylation at S424/T425 can be assessed 
to examine if they have a complementary role in IRF6 activation. 
Fluorescent microscopy was not sufficient to provide answers concerning the 
functionality of the phosphorylation at residues S131 and S153. More studies will be 
required to investigate role of phosphorylation in the regulation of other functions of 
IRF6 such as protein stability, protein interaction and dimerization.  
5.9.6. Phosphorylation at S47 inhibits IRF6 DNA-binding ability 
 
There is currently no data relating to changes in the phosphorylation state within the 
DBD of IRFs that affect their DNA-binding function, aside from the data presented here. 
The LC/MS/MS data provided evidence of IRF6 being phosphorylated in Loop 1 
40
WKHATRHSPQQEEENT
55
 at S47. EMSA studies revealed that mimicking the 
phosphorylation at S47, by phosphomimetic mutations, abrogated IRF6-DBD 
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interaction with DNA (Fig 5.16 A). This finding demonstrates that phosphorylation of 
IRF6 in the DBD consequently alters its DNA-binding ability. There is a general 
importance of loop L1 in IRFs in light of the observation that residues in loop L1 
interact with the AA 5‟flanking sequence at the minor groove in a similar fashion. In 
IRF1 loop L1 and loop L3 interact with the DNA phosphate backbone as far as six 
nucleotides upstream of the GAAA core sequence. The residues that interact with the 
minor groove of DNA and phosphate backbone in loop L1 are H40,  K43 and H44, and 
in loop L3 are R99 and N100 (Escalante et al., 1998). In IRF3, H40 projects into the 
minor groove to interact with the bases. In addition, several residues flanking H40, 
including W38 and G41, interact with the sugar phosphate backbone to stabilize the 
interaction. It was also shown that L42 can also protrude deeper than H40 by contacting 
the base and the minor groove edge in certain instances. Similar to IRF1, the IRF3 loop 
L1 also interacted with bases upstream of the 5‟ AA flanking region. The main chain 
amide of Q44 in loop L1 donates a hydrogen bond to the sugar phosphate backbone of 
an upstream cytosine of a G:C base pair (TAGGAAAACTGAAA), (Escalante et al., 
2007). The IRF1 
44
HG
45 
and the IRF3 
44
QD
45 
residues correspond to 
46
HS
47 
in IRF6, 
indicating that it is likely that H46 in IRF6 may interact with the sugar phosphate 
backbone. As S47 is adjacent to the H46 residue, phosphorylation events occurring at 
S47 may directly impair the H46 interaction with DNA and consequently disrupting its 
stabilization. It is also possible that the addition of the phosphate group may introduce a 
new interaction with the phosphate backbone and alter the position of adjacent residues, 
thus hampering the loop L1 insertion into the DNA minor groove (Fig 5.11). In addition 
the loop L1 sequence is not highly conserved in IRFs, which may influence the 
flexibility and structure of the loop L1 in individual IRFs. The S47 residue in IRF6 is 
not conserved among other IRFs and may therefore be unique to IRF6 specificity. 
Alternatively, loop L3 also interacts with the phosphate backbone at the same position 
as loop L1. Therefore phosphorylation at S47 may weaken or hinder the loop L3 
interaction.  Due to the flexibility of loops L1 and L3, intra-molecular interaction could 
possibly occur thus distorting the tertiary structure of the DBD.  The residue S47 is 
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specific to IRF6 as it is not conserved in other IRFs. The direct phosphorylation S47 in 
the DBD and may serve as a potential mechanism for regulating IRF6 activity.  
5.9.7. MAP Kinase signalling is not sufficient to activate IRF6  
MAPKs play important roles in pathways controlling several biological processes, 
including differentiation, proliferation and apoptosis (Pearson et al., 2001). Distinct 
MAPK pathways have been identified to signal upstream of individual IRFs. For 
example, MEKK1-JNK pathway can induce nuclear translocation and transcriptional 
activity of IRF3 (Kim et al., 2000a). Another study demonstrated that IRF7 is activated 
by the MKK4-JNK pathway in response to DNA-damaging agents.  The ectopic 
expression of MKK4 enhanced the transcriptional activity of IRF7. Furthermore, 
fluorescent microscopy data showed that GFP-IRF7 was mainly localized in the 
cytoplasm. Interestingly, the co-transfection of MKK4 with GFP-IRF7 expression 
plasmids lead to nuclear translocation of GFP-IRF7 (Kim et al., 2000b). Fluorescent 
microscopy was used to explore if MAPK signalling played a role in the activation and 
nuclear translocation of IRF6. Cos 7 cells co-transfected with EGFP-IRF6 and MAPKs 
(MEK1, MEKK1, p38α and MEKK6) showed that EGFP-IRF6 remained localized in 
the cytoplasm (Fig 5.2 B). This indicated that the activation of these MAPK cascades 
alone does not stimulate IRF6 nuclear translocation. The TAK-JNK cascade was shown 
to stimulate the phosphorylation of IRF3 that lead to positive regulation of downstream 
gene expression, in response to LPS and PolyI:C. In addition, the MAPK signalling and 
TBK1/IKKβ signalling cooperates to synergistically regulate IRF3 activity. Here, N-
terminal phosphorylation by JNK serves in collaboration with C-terminal 
phosphorylation by TBK1 in IRF3 activation, as JNK phosphorylation was implicated 
in the dimerization of IRF3. Furthermore, the transcriptional activity of constitutively 
active IRF3 (5D) was inhibited by a JNK specific inhibitor. The JNK phosphorylation 
site was mapped to S173 and was further confirmed by assessing the S173A alanine 
mutant (Zhang et al., 2009).  The S173 in IRF3 is equivalent to S187 in IRF6. 
Fluorescent microscopy analysis of IRF6 phosphorylation at S187 using the EGFP-
IRF6 S187D phosphomimetic mutant revealed that it was predominantly localized in 
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the cytoplasm. Similarly, a study by Servant et al. showed that the activation of the 
MAPKKK-related pathway that causes N-terminal phosphorylation between residues 
186-198 of IRF3 does not alter its nuclear translocation, CBP interaction, DNA-binding 
activity or transcriptional activity (Servant et al., 2001). Triggering distinct pathways 
can result in different effects on IRF activation. It could be possible that MAPK 
signalling alone does not have a significant impact on the activation of IRF6.  Like IRF3, 
MAPK signalling may require the cross-talk and the convergence of other signalling 
transduction pathways to modulate IRF6 activity.  
Interestingly, the IRF7 serine clusters in the S/T rich region all precede or are 
followed by leucine residues. 
425
SS
426
 is associated with leucine 
425
SSL
427
 as mutation 
of the L427A abrogated virus-induced phosphorylation. These motifs are necessary for 
distinct recognition by kinases specific for IRF7 (Caillaud et al., 2005). Analysis of the 
identified IRF6 phosphorylation sites and their surrounding residues may help identify 
putative kinase sequence patterns (acceptor motifs) to provide an insight into possible 
upstream kinases (Blom et al., 2004). Sequence analysis using NetPhospoK that 
predicts kinase specific eukaryotic protein phosphorylation sites set at a threshold of 0.5 
was able to identify kinases PKA for S47, DNA-PK and ATM for S153 and p38 MAPK 
for T425. 
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Chapter 6 
General Discussion
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6.1. Project aims 
 VWS is the most common syndromic form of cleft lip and cleft palate accounting for 
2% of all cases (Schutte et al., 2000). Individuals with PPS share a similar orofacial 
phenotype to VWS and have additional features.  Linkage analysis was initially used to 
identify the 1q32-q41 locus as the critical region for VWS and PPS (Bocian and Walker, 
1987). Sequence analysis of genes within the critical region in VWS and PPS 
individuals was fundamental in the discovery of IRF6 as the causative gene of VWS and 
PPS (Kondo et al., 2002). Extensive studies have since been carried out to identify 
inherited and de novo mutations in the IRF6 gene that contribute to VWS and PPS in 
diverse populations worldwide.  Mutations that lead to VWS and PPS are not randomly 
distributed in the IRF6 gene with a higher frequency of mutations in the DBD and the 
IAD (de Lima et al., 2009). Through the genotype-phenotype correlations of IRF6 
mutations in individuals with VWS or PPS, Kondo et al. speculated that missense 
mutations could result in the complete loss of IRF6 function and dysfunction of the 
DBD and IAD. However, biochemical evidence was still required to establish the 
consequential effect of missense mutations on the functional role of IRF6 that leads to 
VWS and PPS. It was first necessary to define the molecular function of IRF6 and 
determine mechanisms involved in IRF6 regulation. An important function of a 
transcription factor is the ability to bind DNA and activate or repress transcription of 
target genes. Initial characterization of the IRF6 consensus sequence was required to 
establish how the disease causing mutations affect IRF6 DNA-binding. There are 
several mechanisms involved in the regulation of transcription factors. Since IRF6 
exists in an inactive form, it was essential to identify the mechanism involved in the 
nuclear translocation and activation of IRF6.   
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6.2. IRF6 DNA binding activity is disrupted by VWS and PPS missense 
mutations in the DBD 
Data presented in this thesis demonstrates that the IRF6 consensus sequence 
selected by the IRF6-DBD monomer was AACCGAAAC
C
/T (Fig 3.5 B). The IRF6 
consensus sequence is consistent with the IRF family DNA binding motifs 
(AANNGAAA), this is due to the extensive sequence homology among their DBDs 
(Tanaka et al., 1993). The subtle difference in the consensus sequence may indicate the 
specificity of IRF6 compared to other members of the family. Crystal structure of IRF4 
reveals that the residue K103 directly interacts with the cytosine in the GAAAC 
extended core sequence. This lysine residue is conserved in four other members of the 
IRF family, including IRF6 (Escalante et al., 2002). Interestingly, IRF6 showed 
recognition of the GAAAC extended core sequence in all the selected sites. Identification 
of the IRF6 consensus sequence shows the rigidity of IRF6 recognition as variations in 
the recognition sequence in the CC spacer and GAAA core sequence disrupts DNA 
binding (Fig 3.6). A surprising finding was revealed as IRF6 showed the ability to 
recognize a variation of the GAAA core sequence that is GATA.  Determining the 
distinct binding specificities of IRF6 can provide a gateway to delineating the network of 
genes regulated by IRF6 in palate development. In mice, Irf6 has a temporal and spatial 
expression pattern during primary and secondary palate development (Knight et al., 
2006). Examining the co-expression of IRF6 and other factors may reveal IRF6 
responsive genes. The understanding of IRF6 DNA-binding specificity can help predict 
putative genetic interactions. A study by Moretti et al. revealed a genetic link between 
human IRF6 and p63 after identifying two p63-like consensus binding sequences in the 
upstream promoter region of the IRF6 gene. ChIP assays were used to confirm that IRF6 
is a direct p63 target in keratinocytes. p63 is involved in the initial transactivation of 
IRF6 gene expression. Immunohistochemistry data revealed that elevated levels of IRF6 
resulted in reduced levels of p63. There is a negative feedback loop, whereby IRF6 
downregulates the ΔNp63 isoform by targeting ΔNp63 for proteasome-dependent protein 
degradation (Moretti et al., 2010). Knowledge of the IRF6 consensus sequence provides 
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the foundation to identify natural sites in known upstream promoter regions to identify 
putative downstream targets. ChIP on chip or ChIP-sequencing assays may be carried out 
to verify candidate IRF6 target genes identified by sequence analysis. Identification of 
genes that are modulated by IRF6 may provide a clearer understanding of the importance 
of the role IRF6 plays in palate development and uncover novel functions of IRF6.  
Missense mutations provide an understanding of the relationship of the structure 
and function of the IRF6 gene product. In PPS there is a high prevalence of missense 
mutations in the DBD (de Lima et al., 2009). In contrast, missense mutations in VWS 
are evenly distributed between the DBD, IAD and C-terminal region (Kondo et al., 
2002). Luciferase assays using the multimerized IRF6 consensus sequences upstream of 
the reporter gene, show that VWS missense mutations and PPS missense mutations 
introduced in the IRF6-DBD equally affected IRF6 DNA-binding by reducing 
transcriptional activity in vivo. However, the results here with regards to the PPS 
phenotypic consequence do not have a strong correlation with their relative levels of 
impaired transactivation. The same missense mutation can cause either VWS or PPS, 
such as R84C, R84H and L98E (de Lima et al., 2009). In addition, different missense 
mutation of the same residue can cause VWS or PPS.  For example W60C and W60G 
were found in a patient diagnosed with VWS and PPS respectively, signifying that they 
are not mutually exclusive (de Lima et al., 2009). Furthermore, there is the interplay of 
genetic factors and environmental factors that underlie the diverse variations of disease 
progression in individuals (Stanier and Moore, 2004). 
6.3. IRF6 contains internal signals that modulate its subcellular 
localization  
Subcellular compartmentalization can be a regulatory mechanism for transcription 
factors to restrict access to DNA. Internal signals can modulate dynamic
 
shuttling 
between the cytoplasm and the nucleus. The results presented here provide an insight 
into the mechanisms that regulate IRF6 subcellular localization. The IRF6 NES was 
mapped to 
159
IQDTFPFLNI
168 
which is
 
located between the DBD and the IAD.  The 
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predominant cytoplasmic localization of IRF6 implies that the NES is constitutively 
active and nuclear export is more dominant than nuclear import. The N-terminal region 
can be associated with nuclear export in individual IRFs as NES sequences 
139
ILDELLGNMVL
149    in IRF3 and 
150
LQRMLPSLSLT
161
 IRF5 are also located in this 
region. Both IRF3 and IRF5 nuclear export were shown to involve the CRM1-
dependent pathway and their interaction with CRM1 was shown by in vitro binding 
assays and Co-IP respectively (Kumar et al., 2000) (Lin et al., 2005). In contrast,  IRF7 
NES is located in the C-terminal region at 
448
LVLVKLEPWLCRVHL
462 
(Lin et al., 
2000b). However the nuclear export of IRF7 does not involve the CRM1-dependent 
pathway as treatment with LMB did not induce nuclear accumulation (Marie et al., 
2000). The IRF3, IRF5 and IRF7 exhibit a leucine-rich NES sequence, whereas the 
IRF6 is composed of mainly hydrophobic residues. 
The molecular dissection of IRF6 by generating C-terminal and N-terminal 
deletions uncovered a potential IRF6 NLS of 
5
PRRVRLK
11
. IRF1, IRF2, IRF4, IRF8 
and IRF9 all contain bipartite consensus NLSs (Schaper et al., 1998). The NLS of IRFs 
are generally contained within or flank the DBD. IRF3 has a unique NLS with only two 
basic residues of 
77
RK
78 
and its nuclear transport may be mediated by a subset of 
importin-α receptors (Kumar et al., 2000). Interestingly, the IRF5 contains two 
monopartite consensus NLS, an N-terminal NLS of 
46
PRRVRLK
52
 and a C-terminal 
NLS of 
448
PREKKLI
454
. The IRF5 N-terminal NLS 
46
PRRVRLK
52
 is sufficient for 
nuclear localization and retention, but is autoinhibited or masked in uninfected cells 
(Barnes et al., 2002). The IRF6 monopartite
 
NLS
 5
PRRVRLK
11 
is identical to the IRF5 
N-terminal NLS and may facilitate IRF6 nuclear translocation in a similar manner. The 
22 VWS and PPS missense mutations assessed in this study did not alter the nuclear 
export of IRF6. Interestingly, mutations within the IRF6 NLS were identified in VWS 
families, but not in PPS families. The VWS associated missense and truncation 
mutations were mapped to 
6
R in 5 individuals and 
9
R in 2 individuals (de Lima et al., 
2009). These mutations may possibly interfere with the regulation of IRF6 subcellular 
localization, as a result of deficient nuclear import. In IRF3, high levels of IRF3 in the 
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cytoplasm are preferential for signal reception via infection or modification. However, 
constant shuttling into the nucleus is still necessary for activated IRF3 to interact with 
CBP/p300 for nuclear accumulation and retention for gene expression  (Kumar et al., 
2000). Similarly, IRF6 is continuously shuttling in and out of the nucleus and may 
possibly require interactions with other factors or post translational modifications for 
nuclear sequestration. 
6.4. Combinatorial phosphorylation at the C-terminal of IRF6 induces 
nuclear translocation 
Phosphorylation is an established mechanism that regulates several processes involved 
in maximal activation of IRF transcriptional activity. Virus-induced phosphorylation of 
IRF3 is required for nuclear translocation, interaction with CBP/p300 and 
transcriptional activation. Phosphorylation is also involved in proteasome-dependent 
degradation of IRF3 (Servant et al., 2001).  The DNA-binding activity of full-length 
IRF6 is autoinhibited and may require phosphorylation-dependent structural 
rearrangement for the exposure of functional domains.  Phosphorylation has also been 
implicated in the regulation of IRF6. The interaction between maspin and IRF6 is 
dependent on the phosphorylation state of IRF6, as de-phosphorylation of IRF6 was 
shown to prevent the C-terminal interaction with maspin (Bailey et al., 2005).  
Phosphorylation of IRF6 can target it for ubiquitination and consequently proteasome-
dependent degradation or lead to cytoplasmic sequestration via maspin interaction 
(Bailey et al., 2008). However, the mechanistic role of phosphorylation in the regulation 
of IRF6 function was still elusive.  
LC/MS/MS data presented in this thesis show that five novel phosphorylation 
sites were identified at S47, S131, S153, S424 and S425 which are located in different 
regions of the IRF6 protein.  
Phosphomimetic studies showed that phosphorylation at S424 was necessary for 
multiple phosphorylations at the S/T rich region for IRF6 nuclear accumulation. 
However, phosphorylation at the 
424
ST
425 
alone did not induce nuclear retention. In 
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IRF6, 
424
ST
425 
may be the primary target phosphorylation sites, even in unstimulated 
cells, and additional phosphorylation within the S/T rich region can augment 
transactivation. Previous studies by Caillaud et al show that 
425
SS
426
 and 
437
SS
438 
are 
important in the virus-induced phosphorylation of IRF7. 
437
SS
438 
was identified as the 
primary site of phosphorylation, whereas, 
425
SS
426
 could be secondarily phosphorylated 
enabling the correct exposure of the C-terminal transactivation domain necessary for 
maximal activation of IRF7. In addition, the hyper-phosphorylation of adjacent residues 
increases transcriptional activation (Caillaud et al., 2005).  In TBK1 and IKKε 
activation of IRF3 involves phosphorylation at two distinct sites that have different roles. 
The phosphorylation at site 2 
396
S-S
405 
is the primary target required for relieving 
autoinhibition to enable CBP interaction and facilitates subsequent phosphorylation at 
site 1 
385
SS
386
. Phosphorylation at site 1 plays a role in dimerization (Panne et al., 
2007b). Alanine mutational analysis of human FLAG-IRF5 at putative phosphorylation 
sites revealed that full activation of IRF5 requires phosphorylation at multiple distinct 
sites. It was shown that phosphorylation at S475 is not essential for virus-induced 
activation. In contrast, single mutants S477A and S480A showed a two- to threefold 
reduction in activity and the triple mutant IRF5 3SA (S475A/S477A/S480A) was not 
responsive to virus-induced activation. This indicates that in virus-induced activation of 
IRF5, residues S477 and S480 may be targeted for phosphorylation. As the IRF5 3SA 
did not completely abolish its transcriptional activity, other serine residues may also be 
phosphorylated (Barnes et al., 2002). Human IRF5 residues S475, S477 and S480 
correspond to mouse IRF6 residues T411, S413 and S424 respectively. Interestingly the 
IRF6 S424 residue is conserved in IRF3, IRF5 and IRF7 and their respective serine 
residues were all identified as phosphorylation sites that contribute to functional 
activation. 
The minimal phosphoacceptor sites required for the full activation of IRF6 is yet 
to be identified. The precise combination of multiple phosphorylations at specific sites 
imposes different functional consequences, with regards to dimerization, nuclear 
translocation, protein interaction or transcriptional activation. For example, size 
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exclusion chromatography of phosphomimetic mutants of IRF3 demonstrates that 
S396D mutation leads to IRF3 interaction with CBP. It was reported that IRF3 S386D 
strengthened the IRF3 S396D interaction with CBP. In contrast, IRF3 S385D weakens 
the interaction, suggesting antagonistic functions in the regulation of IRF-3 
phosphoactivation (Chen et al., 2008c). The hetero-dimerization between the C-terminal 
regions of IRF3 and IRF7 is dependent on phosphorylation. This dimerization plays an 
essential role in the activation of gene transcription. However, the C-terminal 
phosphorylation at IRF3 and IRF7 has different consequences. IRF3 phosphorylation 
leads to a conformational change that is favorable for dimerization and activation. In 
contrast, IRF7 exists as homodimers in uninfected cells, upon phosphorylation the 
regulatory inhibitory domain on the transactivation domain is relieved for hetero-
dimerization (Lin et al., 2000b). Similarly, tyrosine phosphorylation is important for 
IRF8 C-terminal dimerization with either IRF1 or IRF2 (Sharf et al., 1997).  
Servant et al. showed the existence of multiple forms of IRF3 phosphoproteins 
in both unstimulated and virus-infected cells (Servant et al., 2001). LC/MS/MS is an 
ideal tool to analyze IRF phosphorylation. Recently LC/MS/MS was used in IRF3 
studies to identify residues that are directly phosphorylated by IKK. The active/inactive 
status of IRF3 was analyzed by co-expressing IRF3 189-427 with IKK. Three 
phosphorylation forms were identified with mono or di-phosphorylation at S386, S396 
and S402 (Fujii et al., 2010). Although LC/MS/MS identified IRF6 phosphorylation 
sites, the correct phosphorylation profile necessary for functional activation of IRF6 was 
not revealed. Further LC/MS/MS experiments should be performed with particular 
emphasis on the C-terminal region using different parameters to enhance detection of 
multiple phosphorylations. 
6.5. N-terminal phosphorylation of IRF6  
N-terminal phosphorylation is not uncommon to IRFs. For example, Lin et al. mapped 
casein kinase II phosphorylation sites on IRF1 by using in vitro protein phosphorylation 
assays with C-terminal deletions of IRF1. Two clusters were identified, one in the N-
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terminal region between residues 138-150 and the other in the C-terminal region 
between residues 219-231. Mutational analysis revealed that the C-terminal cluster 
modulated transcriptional activity. Unfortunately, the functional consequence of 
phosphorylation between residues 138-150 was not assigned (Lin and Hiscott, 1999). 
IRF3 was shown to be phosphorylated at the N-terminal region between residues 186-
198 upon activation of the MAPKKK-related pathway. However, this phosphorylation 
was not associated with IRF3 nuclear translocation, CBP interaction, DNA-binding 
activity or transcriptional activity (Servant et al., 2001). Another IRF3 N-terminal 
phosphorylation site was found at T135 immediately proximal to the NES. 
Phosphorylation by DNA-PK at T135 leads to nuclear retention and delayed proteolysis 
(Karpova et al., 2002). Two phosphorylation sites were identified in the N-terminal 
region of IRF6, namely S131 and S153, that are located in close proximity to the 
identified IRF6 NES. The phosphorylation of these two sites does not appear to disrupt 
the nuclear export of IRF6. The functional consequence of S131 and S153 N-terminal 
phosphorylation is yet to be determined. The N-terminal region can also be associated 
with other functions. For example, in differentiated myeloid cells, the complex 
formation of PU.1/IRF2 and IRF8 is dependent on the phosphorylation of PU.1 at S148, 
and N-terminal phosphorylation of IRF2 at Y109 and IRF8 at Y95 for transcriptional 
activation (Huang et al., 2007). A study by Marie et al. was carried out to map 
functional domains and their organization in IRF7. A series of IRF7-Gal4 DBD fusion 
protein were generated and their transcriptional activity was examined using a luciferase 
reporter with a Gal4-binding site promoter. The data revealed that the transactivation 
domain exists at the extreme C-terminal region (residues 411-457) and the fusion 
protein containing this isolated region alone exhibits high levels of transcriptional 
activity. In addition, the IRF7 fusion protein containing residues 132-237 also activated 
transcription in the absence of the extreme C-terminal transactivation domain. This 
revealed a second internal transactivation domain at residues 132-237. The comparison 
of transcriptional activity of the internal and C-terminal transactivation domain 
individually and in combination revealed that both of the transactivation domains are 
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essential for maximal transcriptional activity. The residues 238-410 were shown to act 
as an autoinhibitory region that silences the two flanking transactivation domains 
(Marie et al., 2000). Little et al. identified the IRF6 transactivation domain by 
generating GAL4-IRF6 N-terminal deletion fusion protein. The study showed that 
GAL4-IRF6 113-467 was able to induce a 4-fold increase in transcriptional activation. 
This was relatively lower than GAL4-IRF6 226-467, that contained the isolated IAD 
and C-terminal region, which induced a 5-fold increase in transcriptional activation. 
Whether residues 113-226 had a direct impact on transactivation was not determined 
(Little et al., 2009). Due to the complexity of activation by phosphorylation, a 
combination of N-terminal phosphorylation and C-terminal phosphorylation still needs 
to be investigated. The cooperation of multiple phosphorylation sites may consequently 
maximize IRF6 activation. 
Phosphorylation of IRF6 in the DBD acts as a negative mechanism of regulation. 
The phosphorylation at S47 interferes with IRF6 DNA-binding ability by potentially 
disrupting the IRF6-DBD Loop L1 interaction with the DNA phosphate backbone at the 
minor groove. Phosphorylation as a mechanism of regulating DNA binding ability was 
also observed in IRF8. EMSA studies using in vitro translated IRF8 that were incubated 
in the absence or presence of alkaline phosphatase or tyrosine phosphorylation 
inhibitors revealed that the DNA-binding affinity of dephosphorylated IRF8 increased. 
Tyrosine phosphorylation negatively regulates IRF8 by inhibiting its ability to bind 
DNA and subsequently preventing IRF8 from binding to target genes (Sharf et al., 
1997).    
 Collectively, the findings presented in this thesis have contributed to knowledge 
regarding the molecular effects of VWS and PPS mutations on IRF6 function. In 
addition, the research has partially revealed mechanisms involved in the regulation of 
IRF6 activity.  
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APPENDIX 1-List of IRF6 phosphopeptides identified by LC/MS/MS 
 
 
Sequence Modifications Observed 
Actual 
Mass Charge 
Delta 
AMU 
Delta 
PPM Start Stop 
Trypsin digest         
         
Lower band         
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 711.3075 2,130.90 3 -0.04783 -22.44 42 58 
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 711.3593 2,131.06 3 0.1076 50.45 42 58 
         
Upper band         
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 533.8415 2,131.34 4 0.3884 182.1 42 58 
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 711.1813 2,130.52 3 -0.4264 -200.1 42 58 
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 711.2482 2,130.72 3 -0.2257 -105.9 42 58 
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 711.5773 2,131.71 3 0.7616 -113.1 42 58 
(K)HATRHsPQQEEENTIFK(A) Phospho (+80) 711.7543 2,132.24 3 1.293 135.9 42 58 
(R)HsPQQEEENTIFK(A) Phospho (+80) 833.712 1,665.41 2 -0.2943 -176.6 46 58 
         
GluC and trypsin digest         
         
(R)LQIsTPDIKDNIVAQLK(Q) Phospho (+80) 659.4473 1,975.32 3 0.2806 142 421 437 
(R)LQIStPDIKDNIVAQLK(Q) Phospho (+80) 988.5326 1,975.05 2 0.01115 5.641 421 437 
(R)LQIsTPDIKDNIVAQLK(Q) Phospho (+80) 988.5525 1,975.09 2 0.05095 25.78 421 437 
(R)LQIsTPDIKDNIVAQLK(Q) Phospho (+80) 988.5825 1,975.15 2 0.1109 56.14 421 437 
(R)LQIsTPDIKDNIVAQLK(Q) Phospho (+80) 988.5825 1,975.15 2 0.1109 56.14 421 437 
(R)LQIsTPDIKDNIVAQLK(Q) Phospho (+80) 989.0591 1,976.10 2 1.064 31.06 421 437 
(R)LQIStPDIKDNIVAQLK(Q) Phospho (+80) 989.0717 1,976.13 2 1.089 43.81 421 437 
(R)LQIStPDIKDNIVAQLK(Q) Phospho (+80) 989.1022 1,976.19 2 1.15 74.66 421 437 
         
AspN and trypsin digest         
         
(R)HsPQQEEENTIFK(A) Phospho (+80) 556.3469 1,666.02 3 0.3152 189.1 46 58 
(R)HsPQQEEENTIFK(A) Phospho (+80) 833.9305 1,665.85 2 0.1427 85.64 46 58 
(R)HsPQQEEENTIFK(A) Phospho (+80) 834.4091 1,666.80 2 1.1 58.29 46 58 
         
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.38 2,086.75 2 -0.189 -90.51 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.49 2,086.96 2 0.02505 12 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.49 2,086.97 2 0.03705 17.74 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.51 2,087.00 2 0.05905 28.28 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.51 2,087.00 2 0.06705 32.11 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.51 2,087.01 2 0.07705 36.9 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.52 2,087.02 2 0.07905 37.86 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.52 2,087.03 2 0.09305 44.56 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.52 2,087.03 2 0.09305 44.56 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.52 2,087.03 2 0.09505 45.52 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.53 2,087.05 2 0.109 52.22 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.53 2,087.05 2 0.111 53.18 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.54 2,087.07 2 0.135 64.68 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.55 2,087.09 2 0.153 73.29 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.56 2,087.11 2 0.175 83.83 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.57 2,087.13 2 0.191 91.49 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.58 2,087.14 2 0.203 97.24 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.58 2,087.15 2 0.217 103.9 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.97 2,087.92 2 0.983 -9.422 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,044.99 2,087.96 2 1.023 9.726 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.01 2,088.01 2 1.069 31.75 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.03 2,088.04 2 1.105 48.98 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.04 2,088.07 2 1.137 64.3 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.06 2,088.11 2 1.177 83.44 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.07 2,088.13 2 1.189 89.18 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.08 2,088.15 2 1.215 101.6 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.09 2,088.16 2 1.219 103.5 115 134 
(C)DIPQPQGSVINPGSTGsAPW(D) Phospho (+80) 1,045.09 2,088.16 2 1.225 106.4 115 134 
         
(E)DELEQsQHHVPIQ(D) Phospho (+80) 820.3815 1,638.75 2 0.04435 27.04 148 160 
(E)DELEQsQHHVPIQ(D) Phospho (+80) 820.3815 1,638.75 2 0.04435 27.04 148 160 
(E)DELEQsQHHVPIQ(D) Phospho (+80) 820.4193 1,638.82 2 0.1199 73.15 148 160 
(E)DELEQsQHHVPIQ(D) Phospho (+80) 820.4198 1,638.83 2 0.1209 73.76 148 160 
(E)DELEQsQHHVPIQ(D) Phospho (+80) 820.4209 1,638.83 2 0.1231 75.1 148 160 
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